On this page
Quick Reference
Overview and Recommendations
Background
- •Hepatitis C virus (HCV) is a positive-sense, single-stranded RNA virus of the Flaviviridae family that infects hepatocytes via CD81, SR-BI, and tight-junction proteins. An estimated 71.1 million people are chronically infected worldwide, with 1.75 million new infections annually. Genotype 1 predominates globally (44%), followed by genotype 3 (25%) and genotype 4 (15%). Percutaneous exposure, chiefly injection drug use (60-80% seroprevalence in people who inject drugs) and unscreened blood transfusions before 1998, drives transmission.
- •The virus evades innate immunity by cleaving MAVS and TRIF via NS3-4A protease, blunting interferon induction. Adaptive immune failure results from weak and short-lived CD4+ T-cell responses, exhausted CD8+ T cells with upregulated PD-1, and expanded regulatory T cells. This leads to persistent infection in 70-80% of acutely infected individuals, with chronic necroinflammation activating hepatic stellate cells and driving progressive fibrosis.
- •Chronic HCV is a leading cause of cirrhosis (27% of cases worldwide) and HCC (25% of cases). Untreated, the annual rates of decompensation, HCC, and liver-related death in compensated cirrhosis are 6.37%, 3.36%, and 4.58%, respectively. Extrahepatic manifestations include mixed cryoglobulinemia vasculitis (7.4% gastrointestinal involvement), B-cell non-Hodgkin lymphoma (OR 2.19), insulin resistance, and porphyria cutanea tarda.
- •The treatment paradigm has evolved from interferon monotherapy (SVR <10%) to pegylated interferon plus ribavirin (SVR 40-80%) and now to all-oral pangenotypic DAAs such as glecaprevir/pibrentasvir and sofosbuvir/velpatasvir, which achieve SVR >95% in 8-12 weeks. This revolution represents one of the most dramatic therapeutic advances in modern medicine, but residual HCC risk persists after cure in patients with advanced fibrosis.
Evaluation
- •Suspect HCV in any patient with elevated liver enzymes, unexplained fatigue, or risk factors such as injection drug use (even remote), blood transfusion before 1998, hemodialysis, or HIV coinfection. Extrahepatic clues, palpable purpura, arthralgias, peripheral neuropathy, or blistering skin lesions (porphyria cutanea tarda), should prompt testing.
- •Screen with anti-HCV antibody; a positive result must be confirmed by quantitative HCV RNA (nucleic acid amplification testing) to diagnose active infection. Reflexive testing (automatic HCV RNA on antibody-positive samples) is now standard. HCV core antigen is a less expensive alternative but less sensitive early in therapy.
- •Assess genotype only if pangenotypic DAAs are unavailable or if retreatment is needed after virologic failure; genotype determination is no longer mandatory with first-line pangenotypic regimens.
- •Stage liver fibrosis using noninvasive tools: calculate FIB-4 (age × AST / platelet × √ALT). A FIB-4 ≤1.45 rules out advanced fibrosis (F3-F4) with high sensitivity; >3.25 rules in advanced fibrosis. For indeterminate results, perform transient elastography (FibroScan). A liver stiffness measurement (LSM) ≥12.5 kPa confirms cirrhosis; LSM ≥25 kPa rules in clinically significant portal hypertension (CSPH).
- •In patients with cirrhosis or compensated advanced chronic liver disease (cACLD), apply Baveno VII criteria (LSM ≤15 kPa plus platelets ≥150 × 10⁹/L) to identify those with <5% risk of high-risk varices, allowing safe deferral of screening esophagogastroduodenoscopy (EGD). Otherwise, perform EGD to screen for varices.
- •Initiate hepatocellular carcinoma (HCC) surveillance with semiannual ultrasound plus α-fetoprotein (AFP) in all patients with cirrhosis (F4) or advanced fibrosis (F3). Lowering the AFP threshold to ≥10 ng/mL increases sensitivity without sacrificing specificity. Surveillance should continue indefinitely after SVR, as HCC risk remains above the cost-effectiveness threshold for at least 6 years.
- •Also consider screening for extrahepatic manifestations: check for cryoglobulins if vasculitic symptoms are present, assess for diabetes with oral glucose tolerance test if insulin resistance is suspected, and evaluate for B-cell lymphoma if unexplained lymphadenopathy or cytopenias occur.
Management
- •Initiate direct-acting antiviral (DAA) therapy for all patients with chronic HCV (detectable HCV RNA >6 months), regardless of fibrosis stage, unless life expectancy is limited. Treatment is urgent in acute hepatitis C and decompensated cirrhosis.
- •First-line pangenotypic regimen: glecaprevir/pibrentasvir 300 mg/120 mg (3 tablets) once daily for 8 weeks in non-cirrhotic, treatment-naïve patients; extend to 12 weeks for compensated cirrhosis. Alternative: sofosbuvir/velpatasvir 400 mg/100 mg once daily for 12 weeks for all genotypes and stages.
- •For decompensated cirrhosis (Child-Pugh B/C), use sofosbuvir/velpatasvir 400 mg/100 mg once daily plus ribavirin (weight-based: 1000-1200 mg/day divided BID) for 12 weeks. This achieves SVR12 of 94% and improves Child-Pugh class in 49% of patients by 3 years.
- •Monitor HCV RNA at baseline, week 4, end of treatment, and 12 weeks post-treatment (SVR12). SVR12 is considered cure. For ribavirin-containing regimens, check hemoglobin weekly for the first month, then monthly.
- •After SVR, patients with F3/F4 fibrosis require lifelong HCC surveillance with ultrasound plus AFP every 6 months. Recompensation occurs in ~25% of decompensated patients, but HCC risk persists (2.9% de novo rate). Continue variceal screening if cirrhosis persists.
- •Avoid interferon-based regimens in decompensated cirrhosis or severe psychiatric illness. Do not co-administer amiodarone with sofosbuvir-containing regimens (risk of life-threatening bradycardia). Avoid glecaprevir/pibrentasvir in Child-Pugh C cirrhosis. Do not use ribavirin in pregnancy (teratogenic) or in patients with hemoglobin <10 g/dL without erythropoiesis support.
- •For virologic failure (relapse or breakthrough), check for resistance-associated substitutions (RASs) and retreat with sofosbuvir/velpatasvir/voxilaprevir 400 mg/100 mg/100 mg once daily for 12 weeks (SVR 88.6% after prior DAA failure).
- •In special populations: HIV coinfection, use standard DAA regimens; check drug-drug interactions with antiretrovirals. Chronic kidney disease (eGFR <30), glecaprevir/pibrentasvir is preferred (no dose adjustment). Post-liver transplant, individualize DAA regimen; monitor calcineurin inhibitor levels. Pediatrics, DAAs approved for age ≥3 years, weight-based dosing.
- •Consider chemoprevention: aspirin ≤160 mg daily reduces HCC incidence (HR 0.69) in patients with cirrhosis, with a small increase in gastrointestinal bleeding risk (10-year risk 7.8% vs 6.9%). Coffee consumption is associated with a 40% reduction in HCC risk.
Board Review — High Yield
- •Sustained virologic response (SVR12), undetectable HCV RNA 12 weeks after treatment completion; defines cure.
- •Pangenotypic DAA regimens, glecaprevir/pibrentasvir and sofosbuvir/velpatasvir cover all genotypes 1-6 without need for genotype testing.
- •Baveno VII criteria, LSM ≤15 kPa + platelets ≥150 × 10⁹/L rules out CSPH, allowing safe deferral of EGD.
- •FIB-4 >3.25, rules in advanced fibrosis (F3-F4); associated with increased HCC risk after SVR.
- •Decompensated cirrhosis, treat with sofosbuvir/velpatasvir + ribavirin for 12 weeks; recompensation occurs in ~25%.
- •HCC surveillance, semiannual ultrasound + AFP indefinitely in F3/F4; AFP threshold ≥10 ng/mL improves sensitivity.
- •Aspirin chemoprevention, ≤160 mg daily reduces HCC risk by 31% in cirrhosis; small increase in GI bleeding.
- •Extrahepatic manifestations, mixed cryoglobulinemia (7.4% GI vasculitis), B-cell NHL (OR 2.19), porphyria cutanea tarda.
- •HIV coinfection, DAA regimens are safe and effective; check ART interactions (e.g., efavirenz reduces ledipasvir levels).
- •Chronic kidney disease, glecaprevir/pibrentasvir is preferred for eGFR <30; no dose adjustment needed.
Deep Dive — Evidence Details
Definition, Classification & Nomenclature
- ▸Hepatitis C progresses from acute (first 6 months) to chronic infection in >40% of cases; chronic HCV is a major driver of cirrhosis and HCC.
- ▸HCV is classified into 7 genotypes, with genotype 1 most common globally and genotype 3 associated with faster fibrosis progression.
- ▸Occult HCV infection (positive PBMC RNA with negative serum RNA) occurs in up to 12% of antibody-positive patients and may be missed by standard testing.
Hepatitis C is a systemic infection caused by the hepatitis C virus (HCV), a single-stranded RNA virus that preferentially replicates in hepatocytes and establishes persistent infection in the majority of exposed individuals. The infection evolves through distinct phases: acute hepatitis C (first 6 months after exposure) [4]D5, followed by chronic hepatitis C (persistent viremia beyond 6 months) [46]A1a. Approximately 40% to 95% of untreated acute infections progress to chronicity, and chronic HCV is a leading cause of cirrhosis, decompensated liver disease, and hepatocellular carcinoma (HCC) worldwide [4]D5[40]D5.
Also Called / Synonyms
- HCV (hepatitis C virus)
- Chronic hepatitis C (CHC)
- Acute hepatitis C
- Occult hepatitis C infection (OCI) - defined as detectable HCV RNA in peripheral blood mononuclear cells (PBMCs) with undetectable serum HCV RNA [50]B2b
- Late relapse (RCI) - reappearance of serum HCV RNA in a patient with a prior sustained virologic response (SVR) without reinfection [54]B2b
Classification of HCV Infection Phases and Stages
Phases of infection
- Acute hepatitis C: first 6 months after infection; may be asymptomatic or symptomatic; spontaneous clearance occurs in a minority [4]D5
- Chronic hepatitis C: persistent HCV RNA beyond 6 months; most patients develop chronic infection [46]A1a
- Compensated cirrhosis: cirrhosis (histologic or noninvasive) without decompensation ( , variceal hemorrhage, encephalopathy, jaundice) [1]A1c
- Decompensated cirrhosis: cirrhosis complicated by one or more of ascites, variceal bleeding, , or jaundice [1]A1c
Occult HCV infection: positive HCV RNA in PBMCs with negative serum HCV RNA; prevalence 11.7% in HCV antibody-positive patients and 5.6% in antibody-negative patients [50]B2b
Late relapse: HCV RNA reappearance ≥3 months after SVR without reinfection; occurs in 0.19% of patients over 18 years in one cohort [54]B2b
Genotype Classification
HCV is classified into 7 major genotypes (1-7) and numerous subtypes. Genotype distribution varies geographically and influences treatment regimen selection [9]B2a.
| Genotype | Global Prevalence | Key Features |
|---|---|---|
| 1 | Most common globally (≈46%) | Historically more difficult to treat with interferon-based regimens; now highly curable with DAAs |
| 2 | ≈13% | Generally favorable response to therapy |
| 3 | ≈22% | Associated with more rapid fibrosis progression, steatosis, and higher risk of cirrhosis [8]B2b |
| 4 | ≈13% | Most common in Middle East and Africa |
| 5 | Rare (<2%) | Predominantly in South Africa |
| 6 | ≈5% | Common in Southeast Asia; often misclassified as genotype 1 by older assays [9]B2a |
| 7 | Very rare | Recently described, limited data |
Fibrosis Staging Systems
Liver fibrosis is staged histologically using the Metavir (F0-F4) or Ishak (0-6) scoring systems. Noninvasive tools (FibroScan, FibroMeter, FIB-4, APRI) are increasingly used to estimate fibrosis stage without biopsy [3]B2b. A FIB-4 score ≥5.88 has high specificity for cirrhosis [8]B2b.
Clinical Significance
HCV is a leading cause of chronic liver disease worldwide, responsible for approximately 27% of cirrhosis cases and 25% of HCC cases. Liver-related mortality from HCV is underestimated: when using a broader definition including hepatobiliary cancers and viral hepatitis, mortality rates double compared with traditional ICD-9 codes [15]B2c. The annualized total cost of care for a patient with hepatitis C is $107,007, the highest among all digestive diseases [30]B2c.
Pearl: In any patient with HCV antibody positivity and unexplained liver enzyme elevation, consider occult HCV infection (OCI) by testing PBMC HCV RNA, especially if the antibody titer exceeds 53.2 ng/mL [50]B2b.
Pathophysiology & Mechanism
- ▸HCV evades innate immunity by cleaving MAVS and TRIF via NS3-4A, and adaptively by inducing T-cell exhaustion and NK cell dysfunction.
- ▸Insulin resistance and steatosis, mediated by genotype-specific PPAR downregulation and adipocytokine imbalance, accelerate fibrosis and reduce treatment response.
- ▸Extrahepatic lymphoproliferation arises from chronic B-cell stimulation with increased risk of diffuse large B-cell lymphoma (OR 2.19).
From the initial classification of hepatitis C virus (HCV) as a positive-sense, single-stranded RNA virus of the Flaviviridae family, the mechanistic cascade that drives chronic infection, progressive fibrosis, and extrahepatic disease can be traced through discrete molecular steps. Six major genotypes (1-6) and over 80 subtypes exist, with genotype 1 predominating in the United States and Europe [76]D5.
Viral Entry, Replication, and Hepatocyte Injury
HCV gains entry into hepatocytes via a multistep process involving the tetraspanin CD81, the scavenger receptor class B type I (SR-BI), and the tight-junction proteins claudin-1 and occludin [64]D5. Following receptor-mediated endocytosis and uncoating, the viral RNA genome is translated into a single polyprotein that is cleaved by host and viral proteases (NS2-3, NS3-4A) into structural (core, E1, E2) and nonstructural (NS3, NS4A, NS4B, NS5A, NS5B) proteins. The NS5B RNA-dependent RNA polymerase replicates the viral genome with high error rate, generating a quasispecies swarm that facilitates immune evasion [72]D5. Directly cytopathic effects are modest; instead, hepatocyte injury is driven by the host immune response.
Immune Evasion and Chronicity
In approximately 70-80% of acutely infected individuals, HCV establishes persistence. The virus deploys multiple strategies to subvert innate and adaptive immunity. The NS3-4A protease cleaves the adaptor molecules MAVS and TRIF, disrupting RIG-I and TLR3 signaling and thereby blunting interferon (IFN) induction [59]D5. HCV also induces the expression of the phosphatidylinositol 4-kinase III alpha (PI4KIIIα), which remodels host membranes and promotes viral replication; elevated PI4KIIIα activity correlates with hepatocellular carcinoma (HCC) invasion via cytoskeletal reorganization [60]D5.
Adaptive immune failure is multifactorial. HCV-specific CD4⁺ T-cell responses are weak and short-lived in patients who progress to chronicity, and CD8⁺ T cells become exhausted with upregulated PD-1 expression [66]D5. Regulatory T cells (FOXP3⁺) are expanded in chronic hepatitis C but do not correlate directly with viral persistence at the single-cell level [13]B3b. Natural killer (NK) cells show reduced expression of natural cytotoxicity receptors (NKp30, NKp46) and increased inhibitory receptor NKG2A, impairing cytolytic function [71]B3b.
Hepatic Fibrosis and Cirrhosis
Chronic necroinflammation activates hepatic stellate cells (HSCs) via paracrine signals from injured hepatocytes, Kupffer cells, and sinusoidal endothelial cells. Chemokines such as CCL5 and CXCL10 orchestrate the recruitment of inflammatory cells, while thrombin signaling through protease-activated receptors (PARs) on HSCs promotes their proliferation and collagen deposition [59]D5[68]D5. Insulin resistance (IR), common in HCV infection, drives fibrosis by expanding the ductular reaction (DR) and inducing epithelial-mesenchymal transition (EMT) in reactive ductular cells (RDCs), as evidenced by nuclear Snail expression, E-cadherin downregulation, and vimentin upregulation [69]B2b. IR is associated with higher low-density apolipoprotein B-associated lipoviral particles (LVP), which may enhance hepatocyte reinfection and accelerate disease [70]C4.
Metabolic Dysregulation
HCV directly perturbs host metabolism. The core protein, particularly genotype 3, downregulates peroxisome proliferator-activated receptor (PPAR)-α and -γ, promoting steatosis [88]B3b. Serum adiponectin is reduced and TNF-α elevated in patients with steatosis, contributing to IR [90]B3b. HCV also suppresses hepcidin, leading to iron overload and oxidative stress; even after sustained virologic response (SVR), iron-mediated damage may persist [96]D5. The virus upregulates hexokinase domain-containing protein 1 (HKDC1), driving glycolytic reprogramming that supports viral replication and may predispose to HCC [97]D5.
Extrahepatic Manifestations: Lymphoproliferation and Beyond
HCV is a lymphotropic virus. Chronic antigenic stimulation of B cells leads to oligoclonal expansion and production of IgM rheumatoid factor, forming mixed cryoglobulins (type II) that deposit in small vessels, causing vasculitis [77]D5. The risk of B-cell non-Hodgkin lymphoma, particularly , is increased (OR 2.19) [56]B3b. Multiple mechanisms, chronic antigenic stimulation, direct B-cell infection, and viral protein-mediated oncogenic signaling, are implicated [101]D5.
Microbial translocation from the gut lumen is enhanced in chronic HCV, with elevated levels of lipopolysaccharide (LPS) and soluble CD14 that correlate with liver disease progression [63]B2b. Direct-acting antiviral therapy reduces surrogate markers of microbial translocation and T-cell activation [87]B2b. The tryptophan-kynurenine pathway is upregulated in the portal circulation, indicating a gut-liver inflammatory axis [100]B2b.
Epigenetic Reprogramming and Hepatocarcinogenesis
Chronic HCV infection induces epigenetic alterations, marked by changes in H3K27ac and transcription, that persist after viral cure and confer a residual HCC risk [67]C4. These modifications can be targeted therapeutically; bromodomain 4 inhibitors have shown chemopreventive potential in preclinical models [67]C4.
Pearl: The chronic inflammation and immune dysregulation of HCV extend beyond the liver to drive metabolic syndrome, lymphoproliferation, and epigenetic changes that persist after SVR, mandating continued surveillance for HCC in patients with advanced fibrosis even after cure.
| Step | Molecular Event | Clinical Consequence |
|---|---|---|
| Viral entry | CD81, SR-BI, claudin-1, occludin [64]D5 | Hepatocyte infection |
| Innate evasion | NS3-4A cleaves MAVS/TRIF [59]D5 | Impaired IFN induction |
| Metabolic reprogramming | HKDC1 upregulation [97]D5 | Glycolytic shift, HCC risk |
| Fibrosis | HSC activation, EMT in RDCs [69]B2b | Cirrhosis progression |
| Lymphoproliferation | Chronic B-cell stimulation [56]B3b | Mixed cryoglobulinemia, DLBCL |
| Epigenetic memory | H3K27ac alterations [67]C4 | Residual HCC risk after SVR |
Epidemiology, Etiology & Risk Factors
- ▸Global HCV prevalence is 71.1 million, with incidence 23.7 per 100,000; genotype 1 predominates (44%).
- ▸Injection drug use is the dominant transmission route in high-income countries, with 60-80% anti-HCV prevalence among PWID.
- ▸Healthcare-associated transmission (pre-1998 transfusion OR 3.77) and co-infections (HIV, TB) amplify risk in vulnerable populations.
From the viral lifecycle that hijacks hepatocyte lipid metabolism, the global burden of HCV emerges through well-defined transmission routes. An estimated 71.1 million individuals are chronically infected worldwide, with 1.75 million new infections in 2015 and a global incidence of 23.7 cases per 100,000 population [154]D5. In the United States, prevalence has declined nearly twofold from 1.6% (1988-1994) to 0.9% (2013-2016), driven by blood screening and antiviral therapy [140]B2c. Genotype 1 accounts for 44% of cases globally, followed by genotype 3 (25%) and genotype 4 (15%) [154]D5.
Risk Factors
Percutaneous exposure to blood drives transmission. Injection drug use (IDU) is the dominant route in high-income countries: 60-80% of people who inject drugs (PWID) have anti-HCV in 25 countries, and an estimated 10.0 million PWID worldwide are anti-HCV positive [124]B2c. Among incarcerated populations, seroprevalence is markedly elevated due to IDU, tattooing, and high-risk sexual activity [145]D5. Healthcare-associated transmission persists where infection control is suboptimal; blood transfusion before 1998 carries an odds ratio of 3.77 for HCV infection [128]B2a. Other invasive procedures also increase risk: surgery (OR 3.22 for transplantation), endoscopy (OR 1.46 for dental procedures), and hemodialysis [128]B2a[163]B2a.
| Risk Factor | Odds Ratio / Hazard Ratio | Evidence Level |
|---|---|---|
| Injection drug use (anti-HCV prevalence) | 60-80% in 25 countries | 2c [124]B2c |
| Diabetes mellitus (HCV prevalence in Africa) | 11.34% pooled prevalence | 1a [155]A1a |
Special Populations
Refugees, asylum seekers, and internally displaced persons in Africa have a pooled HCV seroprevalence of 3.63% (95% CI 0.54-9.16), with rates reaching 10.03% in those from Northern Africa [156]A1a. Co-infection with HIV accelerates fibrosis progression; among HIV-positive PWID, HCV incidence remains high at 6.47 per 100 person-years in Montreal [169]B2b. In India, HCV co-infection occurs in 6% of tuberculosis patients [167]A1a. These epidemiologic patterns directly shape the clinical presentation, which ranges from asymptomatic infection to decompensated cirrhosis.
Pearl: In any patient with unexplained liver enzyme elevation, ask about injection drug use, even remote, because 60-80% of PWID in endemic regions carry anti-HCV, and spontaneous clearance occurs in only 15-25% [124]B2c[4]D5.
Clinical Presentation
- ▸Most acute HCV infections are asymptomatic; jaundice is more common in IL28B CC genotype and predicts spontaneous clearance only in non-CC patients.
- ▸Extrahepatic manifestations, particularly mixed cryoglobulinemia, porphyria cutanea tarda, and diabetes, often dominate the clinical picture and may be the presenting complaint.
- ▸Cirrhosis at first presentation occurs in nearly 20% of patients, underscoring the need for early detection and surveillance.
The transition from exposure to clinical disease is highly variable; most acute infections are asymptomatic, yet a subset present with jaundice and flu-like illness, and the majority progress to chronic infection with insidious onset of fatigue and extrahepatic manifestations.
Presenting Symptoms
Acute hepatitis C is symptomatic in approximately 80% of cases, with jaundice occurring in 40% [187]C4. Symptoms typically appear 2 to 12 weeks after exposure and include malaise, anorexia, right upper quadrant discomfort, and dark urine. Aminotransferase levels and HCV RNA fluctuate markedly; 18% of patients are intermittently HCV RNA negative during the acute phase [187]C4. Spontaneous clearance occurs in only 20% of patients and is strongly associated with the IL28B CC genotype (64% clearance vs 24% for CT and 6% for TT) [173]B2b. Jaundice during acute infection is more common in CC patients (32.7% vs 16.1%) but predicts clearance only in non-CC patients (42.9% with jaundice vs 13.7% without) [173]B2b. In young children, acute HCV is often asymptomatic but can cause histologic liver injury even with mild ALT elevation [193]C4.
Chronic hepatitis C is typically asymptomatic for decades. When symptoms emerge, fatigue is the most common complaint, followed by arthralgias, myalgias, and right upper quadrant pain. Extrahepatic manifestations often dominate the clinical picture. Mixed cryoglobulinemia presents with palpable purpura, arthralgias, and ; vasculitis occurs in 7.4% of patients with HCV-related systemic vasculitis and consistently presents with abdominal pain, with half developing surgical abdomen or intestinal bleeding [172]B3b. Porphyria cutanea tarda (PCT) is present in 69% of HCV-infected patients, characterized by blistering skin lesions on sun-exposed areas [36]C4. Metabolic comorbidities are common: diabetes in 17.9%, obesity in 20.9%, and chronic kidney disease in a substantial proportion [183]B2b. HCV genotype 3 is associated with hepatic steatosis, particularly in patients with the MTTP -493G/T dominant T allele (OR 11.57) [184]B3a.
Cirrhosis and hepatocellular carcinoma may be the first presentation. In a population-based study, 18% of patients with newly diagnosed chronic liver disease had cirrhosis at presentation [179]B2c. Among Swedish patients with cirrhosis, occurred in 43%, variceal bleeding in 6%, and overt encephalopathy in 4% at diagnosis [185]B2b. Alcohol-associated HCC presents at more advanced ( ) stage (OR 0.7 for stage 0/A) and has lower curative treatment rates (24.5% vs 33.9%) compared with HCV-related HCC [121]B2a. Post-DAA HCC may exhibit a more aggressive phenotype with larger infiltrative tumors and higher portal vein thrombosis rates [192]B2b. Regional variation is marked: surveillance rates range from 59.5% to 100%, and median tumor diameter from 1.8 to 5.0 cm across global sites [180]B2b.
Physical Examination Findings
| System | Finding | Associated Condition |
|---|---|---|
| Skin | Palpable purpura, livedo reticularis | Mixed cryoglobulinemia |
| Skin | Blistering lesions, skin fragility, hypertrichosis | Porphyria cutanea tarda |
| Abdomen | Hepatomegaly, splenomegaly, ascites | Cirrhosis, |
| Neurologic | Peripheral neuropathy (sensory > motor), mononeuritis multiplex | Cryoglobulinemic vasculitis |
| Vascular | Spider angiomata, palmar erythema, caput medusae | Chronic liver disease |
| Musculoskeletal | Arthralgias, arthritis (non-erosive) | Cryoglobulinemia, autoimmune overlap |
Red Flags
- HBV reactivation during DAA therapy: monitor HBV DNA; 5% of HBsAg-positive patients develop ALT >2× ULN with HBV DNA rise, and some require HBV treatment [170]C4.
- Acute HCV mimicking : HCV RNA testing is essential in suspected DILI, as acute HCV was the final diagnosis in 4 of 9 unlikely DILI cases [171]C4.
- GI vasculitis: acute abdominal pain with surgical abdomen or gastrointestinal bleeding in a patient with HCV and cryoglobulinemia requires urgent evaluation [172]B3b.
- Decompensated cirrhosis: new-onset ascites, variceal hemorrhage, or signals advanced disease and mandates immediate referral.
Atypical Presentations
- overlap: 6.3% of women with type I AIH had onset during pregnancy; HCV serology should be checked in all patients with acute hepatitis [188]B2b.
- Amebic colitis coinfection: in men who have sex with men, amebic colitis can present with segmental colonic ulcers and may be mistaken for inflammatory bowel disease; HCV coinfection is a recognized association [194]C4.
- Acute-on-chronic liver disease in older patients: older adults with HCV have higher rates of cirrhosis, hepatic encephalopathy, and infection at presentation compared with younger patients [190]B2b.
Pearl: In any patient with unexplained fatigue, palpable purpura, or blistering skin lesions, check HCV serology, extrahepatic manifestations may precede liver-related symptoms by years and are often the key to early diagnosis.
| Manifestation | Frequency in HCV | Key Features |
|---|---|---|
| Mixed cryoglobulinemia | 10-30% | Palpable purpura, arthralgias, peripheral neuropathy, glomerulonephritis |
| Porphyria cutanea tarda | 69% [36]C4 | Blistering skin lesions on sun-exposed areas, skin fragility |
| Diabetes mellitus | 17.9% [183]B2b | Type 2 diabetes, associated with insulin resistance |
| Obesity | 20.9% [183]B2b | BMI ≥30 kg/m², worsens steatosis and fibrosis |
| Chronic kidney disease | Variable | Membranoproliferative glomerulonephritis, cryoglobulinemic nephropathy |
| Gastrointestinal vasculitis | 7.4% [172]B3b | Abdominal pain, surgical abdomen, intestinal bleeding |
| Hepatic steatosis | 40-80% | Genotype 3 associated; MTTP polymorphism increases risk [184]B3a |
| B-cell non-Hodgkin lymphoma | 0.5-1% | Marginal zone lymphoma, diffuse large B-cell lymphoma |
Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
- ▸HCV RNA (NAT) is the gold standard for confirming active infection; core antigen is a reliable alternative for end-of-treatment and SVR assessment.
- ▸Non-invasive fibrosis staging (FIB-4, APRI, transient elastography, MRE) has largely replaced liver biopsy; MRE has the highest accuracy for cirrhosis.
- ▸In cirrhotic patients, Baveno VII criteria (LSM ≤15 kPa + platelets ≥150,000/mm³) identify a low-risk group in whom diagnostic EGD can be avoided.
- ▸HCC surveillance with semiannual ultrasound and AFP (threshold ≥10 ng/mL) is cost-effective in HCV-cured cirrhosis; LI-RADS standardizes diagnostic imaging.
From clinical suspicion, the diagnostic pathway proceeds through serologic confirmation, fibrosis staging, and screening for complications. The workup is anchored by laboratory detection of active infection, non-invasive assessment of liver fibrosis, and targeted endoscopic and imaging surveillance in patients with advanced disease.
Laboratory Studies
Anti-HCV antibody is the initial screening test. It has a sensitivity exceeding 99% in immunocompetent individuals but can yield false-positive results in low-prevalence populations; a positive result must be confirmed by detection of HCV RNA. HCV RNA (by nucleic acid amplification testing, NAT) is the gold standard for diagnosing active infection. It confirms viremia, establishes the need for treatment, and is used to monitor virologic response. Quantitative HCV RNA is measured at baseline, during therapy (if needed), and at 12 weeks after treatment completion (SVR12). HCV core antigen is a less expensive alternative to RNA that performs well at end-of-treatment and for documenting SVR (sensitivity 94%, specificity 99% [205]B2a), but it is unreliable at weeks 2 and 4 of therapy [205]B2a. Genotype determination is no longer mandatory with pangenotypic direct-acting antivirals, but it remains relevant for selecting therapy in patients with non-epidemic subtypes (e.g., genotype 3, unusual subtypes with inherent resistance [220]D5) or when retreatment is needed after virologic failure.
Routine liver biochemistry (ALT, AST, bilirubin, albumin, INR) and a with platelets provide essential information for staging and prognostication. Platelet count is a key surrogate for ; a platelet count >150,000/mm³ has a negative predictive value of 99% for in patients with advanced fibrosis [115]B2b.
Non-Invasive Fibrosis Assessment
Because fibrosis stage determines prognosis and guides surveillance decisions, accurate non-invasive assessment is central to the workup. Several validated tools are available:
| Test | Target Condition | AUC (95% CI) | Threshold (rule-in/rule-out) | Sensitivity | Specificity |
|---|---|---|---|---|---|
| APRI | Significant fibrosis (≥F2) | 0.70-0.80 [207]B2a | >1.0 (rule-in) | ~50% | ~85% |
| FIB-4 | Significant fibrosis (≥F2) | 0.80-0.85 [162]B2a | ≤1.45 (rule-out); >3.25 (rule-in) | ~70% | ~90% |
| FibroTest | Significant fibrosis (≥F2) | 0.81 (0.78-0.84) [113]B2a | ~0.60 | 47% | 90% |
| Transient elastography (FibroScan) | Cirrhosis (F4) | 0.95 (0.87-0.99) [113]B2a | ≥12.5 kPa (cirrhosis) | 87% | 89% |
| Magnetic resonance elastography (MRE) | Cirrhosis (F4) | 0.92 (0.90-0.94) [201]B2a | ≥4.7 kPa | 90% | 88% |
Transient elastography (TE) is the most widely used point-of-care technique. A liver stiffness measurement (LSM) ≥25 kPa rules in clinically significant portal (CSPH) in most etiologies, including hepatitis C, with a positive predictive value ≥90% [25]B2b. For compensated advanced chronic liver disease (cACLD), LSM ≤15 kPa plus platelets ≥150 × 10⁹/L rules out CSPH and can spare endoscopy [25]B2b. MRE has superior accuracy for advanced fibrosis and cirrhosis (AUC 0.93 for ≥F3) and is less affected by obesity or inflammation [201]B2a.
Liver biopsy is no longer required for routine diagnosis or staging of HCV-related fibrosis. It is reserved for cases where non-invasive tests are discordant, when a coexisting liver disease (e.g., , steatohepatitis) is suspected, or when histologic assessment of activity or iron overload is needed. When performed, automated cutting needles provide superior specimens with less fragmentation (4.7% vs. 39.2% with aspiration needles) [102]C4.
Endoscopic Screening for Varices
All patients with cirrhosis (or cACLD) should undergo screening esophagogastroduodenoscopy (EGD) for varices. The prevalence of varices is 39% in cirrhosis versus 16% in bridging fibrosis [115]B2b. Medium/large varices are present in 11% of cirrhotic patients [115]B2b. Non-invasive triage using the Baveno VII criteria, LSM ≤15 kPa and platelet count ≥150 × 10⁹/L, identifies a subgroup with a very low risk (≤5%) of CSPH in whom EGD can be safely deferred [25]B2b. After SVR, the risk of varices decreases, but patients with cirrhosis should still undergo baseline EGD if they did not have one before cure.
Hepatocellular Carcinoma Screening
Patients with cirrhosis (METAVIR F4) or advanced fibrosis (F3) remain at risk for HCC even after achieving SVR. Pooled HCC incidence after SVR is 2.99/100 person-years in cirrhosis and 0.63/100 person-years in F3 [199]B2a. The contemporary cost-effectiveness threshold for initiating surveillance is an HCC incidence of ≥0.7/100 person-years [236]B2c, which supports surveillance in cirrhosis but not in F3 (unless additional risk factors are present).
Semiannual ultrasound plus α-fetoprotein (AFP) is the recommended surveillance strategy. Lowering the AFP threshold to ≥10 ng/mL increases sensitivity from 32% to 42% while maintaining specificity >94% in cured-HCV cirrhosis [213]B3b. A longitudinal parametric empirical Bayes (PEB) algorithm that incorporates prior AFP values can further improve sensitivity, detecting HCC 1.7-1.9 years earlier than a single-threshold approach [242]B2b.
When a screening test is abnormal, diagnostic imaging follows the Liver Imaging Reporting and Data System ( ). Triple-phase contrast-enhanced CT or MRI is the standard. LI-RADS 5 observations (≥10 mm with arterial phase hyperenhancement and washout) are diagnostic of HCC. LI-RADS 3 (indeterminate) lesions progress in 28% of cases within one year; lesion size ≥9.5 mm, class C, and untreated HCV are independent predictors of progression [256]B3b.
Diagnostic Algorithm
Step 1: Test for anti-HCV antibody (screening). Step 2: If positive, obtain HCV RNA (quantitative NAT) to confirm active infection. Step 3: Determine genotype (optional with pangenotypic DAAs, recommended for genotype 3 or prior treatment failure). Step 4: Assess fibrosis stage: calculate FIB-4 and APRI. If indeterminate (FIB-4 1.45-3.25), perform transient elastography or MRE. Step 5: If cirrhosis (or cACLD):
- Screen for varices with EGD (or defer if Baveno VII criteria met).
- Initiate semiannual HCC surveillance with ultrasound + AFP.
- After SVR, continue surveillance indefinitely if cirrhosis; consider discontinuing in F3 if no other risk factors.
Pearl: A platelet count >150,000/mm³ combined with LSM <15 kPa effectively rules out clinically significant portal hypertension and high-risk varices, allowing clinicians to safely defer screening endoscopy in up to 40% of patients with compensated cirrhosis [25]B2b[115]B2b.
| Test | Target Condition | AUC (95% CI) | Sensitivity | Specificity | Key Threshold |
|---|---|---|---|---|---|
| APRI | Significant fibrosis (≥F2) | 0.70-0.80 [207]B2a | ~50% | ~85% | >1.0 (rule-in) |
| FIB-4 | Significant fibrosis (≥F2) | 0.80-0.85 [162]B2a | ~70% | ~90% | ≤1.45 rule-out; >3.25 rule-in |
| FibroTest | Significant fibrosis (≥F2) | 0.81 (0.78-0.84) [113]B2a | 47% | 90% | ~0.60 |
| Transient elastography (TE) | Cirrhosis (F4) | 0.95 (0.87-0.99) [113]B2a | 87% | 89% | ≥12.5 kPa |
| Magnetic resonance elastography (MRE) | Cirrhosis (F4) | 0.92 (0.90-0.94) [201]B2a | 90% | 88% | ≥4.7 kPa |
Severity, Staging & Risk Stratification (GI Scores)
- ▸Noninvasive fibrosis scores (FIB-4, APRI, Forns) and transient elastography accurately stage liver fibrosis, reducing the need for liver biopsy.
- ▸Baveno VI and RESIST-HCV criteria safely avoid unnecessary endoscopy in patients with low probability of high-risk varices.
- ▸HCC risk stratification models (PAaM, GDF15-based, PIVKA-II-based) identify patients with cirrhosis who benefit most from intensive surveillance, though current guidelines still recommend universal surveillance.
Once the diagnosis of chronic hepatitis C is confirmed, the next step is to stage the severity of liver fibrosis and assess the risk of decompensation and hepatocellular carcinoma (HCC). These factors determine the need for variceal screening, HCC surveillance, and the urgency of antiviral therapy. Noninvasive scores and elastography now replace in most patients, guiding risk-stratified .
Noninvasive Fibrosis Assessment
The FIB-4 index (age × AST/platelet × √ALT) is the most validated serologic test. A meta-analysis of 84 studies (107,583 participants) confirmed that a cut-off of 1.45 rules out advanced fibrosis (METAVIR F3-F4) with high sensitivity, while 3.25 rules in advanced fibrosis with high specificity [162]B2a. The AST-to-platelet ratio index (APRI) and Forns index perform similarly; in HIV/HCV coinfection, the Forns index achieved a positive predictive value of 94% for significant fibrosis [276]B2b. Transient elastography (TE) provides complementary physical measurement. An AUROC of 0.96 for cirrhosis was reported in a prospective study of 711 patients, with a cut-off of 17.6 kPa yielding a positive predictive value of 90% [263]B2b. TE is particularly useful for excluding advanced fibrosis when values are <6 kPa, and for confirming cirrhosis when values are ≥12 kPa [275]B2b.
Risk Stratification for and Varices
Clinically significant portal (CSPH) is defined by hepatic venous pressure gradient ≥10 mm Hg. In compensated advanced chronic liver disease (cACLD), a liver stiffness measurement ≥25 kPa rules in CSPH with a positive predictive value ≥90% in most etiologies, including hepatitis C [25]B2b. Conversely, LSM ≤15 kPa plus platelets ≥150 × 10⁹/L rules out CSPH [25]B2b. The Baveno VI criteria (LSM <20 kPa and platelets >150,000) identify patients with <5% probability of high-risk varices, allowing safe avoidance of esophagogastroduodenoscopy (EGD). The RESIST-HCV criteria offer a simpler alternative using only platelet count >120,000 and albumin >3.6 g/dL, avoiding EGD in 30% of patients with a negative predictive value of 98.1% [279]B2b.
Prediction of Decompensation and HCC
Several validated tools stratify risk of hepatic decompensation and HCC:
| Score / Model | Components | Cut-off / Risk Stratification | Performance |
|---|---|---|---|
| FIB-4 | Age, AST, ALT, platelets | >3.25: advanced fibrosis | HR 2.69 for HCC after SVR [270]B3b |
| CPA | Collagen proportionate area on biopsy | ≥18%: decompensation risk | HR 3.99 [289]B2b |
| Genomic-clinical index | 186-gene signature + bilirubin >1 mg/dL + platelets <100,000 | Low (42%), intermediate (42%), high (16%) | HR 7.36 for decompensation [139]B2b |
| PAaM | PLS + AFP + age, sex, albumin-bilirubin, platelets | Annual HCC incidence: low 0.6-0.8%, intermediate 1.8-2.7%, high 5.3-6.2% | sHR 6.54-7.51 for high vs low [134]B2b |
| GDF15-based score | GDF15 >1350 pg/mL, AFP >5 ng/mL, FIB-4 >3.25 | 3-year HCC rate: low 0.64%, medium 3.27%, high 15.3% | Developed in 964 patients, validated in 642 [270]B3b |
| PIVKA-II-based model | PIVKA-II + age, sex, ALT, AST, γGT, platelets, albumin, bilirubin | 3-year HCC: low 2.7%, medium 4.0%, high 14.3% | C-index 0.71-0.72 [293]B2b |
After sustained virologic response (SVR) with direct-acting antivirals, recompensation occurs in 24.7% of patients with decompensated cirrhosis, predicted by low bilirubin, low INR, and absence of large varices [116]B2b. However, HCC risk persists: 2.9% of patients with SVR still develop HCC during follow-up [116]B2b, justifying indefinite surveillance.
Prognostic Scores in Clinical Practice
In practice, a stepwise approach is used:
- Screen all patients with FIB-4 (or APRI/Forns).
- If FIB-4 >3.25, perform TE to confirm advanced fibrosis/cirrhosis.
- If cirrhosis is confirmed, apply Baveno VI or RESIST-HCV criteria to decide on EGD.
- Use HCC risk models (e.g., PAaM, GDF15-based score) to stratify surveillance frequency (e.g., low-risk patients may be followed with ultrasound every 6 months; high-risk patients may be considered for shorter intervals or alternative imaging).
- In patients with decompensated cirrhosis, monitor for recompensation after SVR, but continue HCC surveillance indefinitely.
Pearl: The combination of FIB-4 >3.25 and LSM >17.6 kPa identifies patients with cirrhosis at high risk of decompensation and HCC, mandating indefinite variceal screening and HCC surveillance every 6 months.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Should liver biopsy still be used when noninvasive tests are discordant? | AASLD: noninvasive tests are sufficient for most decisions [214]D5 | EASL: biopsy may be considered if results are discordant [41]C4 | Expert opinion | Biopsy is reserved for cases where diagnosis of cirrhosis is uncertain and affects management decisions |
| Is there a role for HCC risk stratification to reduce surveillance in low-risk patients? | AGA: no, all patients with cirrhosis should undergo surveillance [149]A1c | Some models suggest low-risk patients may have <1% annual HCC risk [134]B2b | Emerging evidence, not yet guideline | Low-risk models may eventually allow risk-stratified surveillance, but current guidelines still recommend universal surveillance |
| Score | Components | Cut-off for Advanced Fibrosis | Performance |
|---|---|---|---|
| FIB-4 | Age, AST, ALT, platelets | >3.25 | Sensitivity 70%, Specificity 85% [162]B2a |
| APRI (Wai index) | AST, platelets | >1.5 | PPV 87% for significant fibrosis [276]B2b |
| Forns index | Age, GGT, cholesterol, platelets | >6.9 | PPV 94% for significant fibrosis [276]B2b |
| Transient elastography | Liver stiffness | >17.6 kPa for cirrhosis | AUROC 0.96, PPV 90% [263]B2b |
| Model | Components | Risk Groups | Annual HCC Incidence |
|---|---|---|---|
| PAaM [134]B2b | PLS + AFP + age, sex, albumin-bilirubin, platelets | Low: 39-44%, Intermediate: 41-42%, High: 15-19% | Low: 0.6-0.8%, Intermediate: 1.8-2.7%, High: 5.3-6.2% |
| GDF15-based score [270]B3b | GDF15 >1350 pg/mL, AFP >5 ng/mL, FIB-4 >3.25 | Low: 0-1 points, Medium: 2-3, High: 4-5 | 3-year: Low 0.64%, Medium 3.27%, High 15.3% |
| PIVKA-II-based model [293]B2b | PIVKA-II + age, sex, ALT, AST, γGT, platelets, albumin, bilirubin | Low, Medium, High | 3-year: Low 2.7%, Medium 4.0%, High 14.3% |
Acute Management
- ▸First-line DAA regimens achieve SVR12 >95% across genotypes; choice depends on cirrhosis status and prior treatment.
- ▸Manage adverse effects proactively: ribavirin dose reduction and ESAs for anemia, citalopram for depression, entecavir for HBV co-infection.
- ▸After SVR, continue HCC surveillance in patients with advanced fibrosis or cirrhosis using ultrasound every 6 months.
Once severity is classified by class and fibrosis stage, the decision to initiate direct-acting antiviral (DAA) therapy is urgent in patients with acute hepatitis C or decompensated cirrhosis. The goal is to achieve a sustained virologic response (SVR) at 12 weeks post-treatment (SVR12), which halts disease progression and reduces liver-related complications [320]B2b[367]B2b.
Step 1: Initial Assessment and Treatment Eligibility
Confirm HCV RNA level, genotype, and fibrosis stage (from prior workup). Assess for compensated versus decompensated cirrhosis (Child-Pugh class A vs B/C). Screen for hepatitis B virus (HBV) co-infection: if HBsAg positive, co-administer 0.5 mg daily for 12 weeks to prevent HBV reactivation [334]A1b (1b). Evaluate renal function, pregnancy status, and potential drug interactions. For patients with psychiatric illness or substance use disorder, integrated care models that include case and mental health support increase treatment initiation and SVR rates [316]A1b[337]A1b (1b).
Step 2: First-Line DAA Regimen Selection
Choose a pangenotypic or genotype-specific regimen based on cirrhosis status and prior treatment history. The following table summarizes recommended regimens from phase 3 trials:
| Genotype | Cirrhosis status | Regimen | Duration | SVR12 rate | Key evidence |
|---|---|---|---|---|---|
| 1 | Non-cirrhotic | Glecaprevir/pibrentasvir 300 mg/120 mg once daily | 8 weeks | 99.1% [333]A1b | ENDURANCE-1 (1b) |
| 1 | Compensated cirrhosis | Glecaprevir/pibrentasvir 300 mg/120 mg once daily | 12 weeks | 99.7% [333]A1b | ENDURANCE-1 (1b) |
| 1 | Compensated cirrhosis | / 90 mg/400 mg once daily | 12 weeks | 99% [332]A1b | ION-1 (1b) |
| 2 | Non-cirrhotic | Glecaprevir/pibrentasvir 300 mg/120 mg once daily | 8 weeks | 98% [335]A1b | ENDURANCE-2 (1b) |
| 2 | Any | Sofosbuvir/ 400 mg/100 mg once daily | 12 weeks | 99% [329]A1b | ASTRAL-2 (1b) |
| 3 | Non-cirrhotic | Glecaprevir/pibrentasvir 300 mg/120 mg once daily | 12 weeks | 95% [333]A1b | ENDURANCE-3 (1b) |
| 3 | Compensated cirrhosis | Sofosbuvir/velpatasvir 400 mg/100 mg once daily | 12 weeks | 91% [300]A1b | (1b) |
| 3 | Compensated cirrhosis | Sofosbuvir/velpatasvir 400 mg/100 mg + ribavirin 1000-1200 mg/day | 12 weeks | 96% [300]A1b | (1b) |
| 4 | Non-cirrhotic | Ledipasvir/sofosbuvir 90 mg/400 mg once daily | 8 weeks | 95% [307]A1b | (1b) |
| 4 | Any | Ombitasvir/paritaprevir/ritonavir 25 mg/150 mg/100 mg once daily + ribavirin | 12 weeks | 100% [349]A1b | PEARL-I (1b) |
| 1-6 | Decompensated cirrhosis (Child-Pugh B) | Sofosbuvir/velpatasvir 400 mg/100 mg + ribavirin 1000-1200 mg/day | 12 weeks | 94% [326]A1b | ASTRAL-4 (1b) |
| 1-6 | Decompensated cirrhosis (Child-Pugh B) | Sofosbuvir/velpatasvir 400 mg/100 mg alone | 12 weeks | 83% [326]A1b | ASTRAL-4 (1b) |
For patients with prior NS5A inhibitor plus sofosbuvir failure, use glecaprevir/pibrentasvir 300 mg/120 mg once daily for 16 weeks (SVR12 94-97%) [299]A1b (1b). For genotype 3b with compensated cirrhosis, sofosbuvir/velpatasvir/voxilaprevir 400 mg/100 mg/100 mg once daily for 12 weeks achieves higher SVR (90% vs 70% with sofosbuvir/velpatasvir plus ribavirin) [366]A1b (1b).
Step 3: Management of Adverse Effects
Anemia (hemoglobin <10 g/dL): Reduce ribavirin dose first; if persistent, add erythropoiesis-stimulating agent (ESA). In the IDEAL trial, ESA use in early-onset anemia (≤8 weeks) was associated with higher SVR (45.0% vs 25.9%) and reduced discontinuation [297]A1b (1b). Depression: Initiate citalopram 20 mg/day at onset of depressive symptoms (HADS ≥9); this reduces depression severity and allows completion of therapy [313]A1b (1b). For patients with elevated baseline depressive symptoms, paroxetine pretreatment may be considered [354]A1b (1b). Thrombocytopenia (platelets <75,000/μL): Eltrombopag 25-100 mg/day for up to 9 weeks raises platelet count to allow initiation of peginterferon/ribavirin (if used) [303]A1b (1b). However, note increased risk of hepatic decompensation (10% vs 5%) and thromboembolic events with eltrombopag [303]A1b. HBV reactivation: As above, entecavir prophylaxis for HBsAg-positive patients [334]A1b.
Step 4: Monitoring During Therapy
Measure HCV RNA at baseline, week 4, end of treatment, and 12 weeks post-treatment (SVR12). For ribavirin-containing regimens, check hemoglobin weekly for the first month, then monthly. Monitor liver function, creatinine, and monthly. Assess for drug interactions, especially with proton pump inhibitors (reduce ledipasvir absorption) and .
Step 5: Transition to Long-term Management
After achieving SVR12, patients with cirrhosis or advanced fibrosis (F3-4) require lifelong surveillance for hepatocellular carcinoma (HCC) with ultrasound every 6 months [322]A1b (1b). Serum GDF15 >1350 pg/mL, AFP >5 ng/mL, and FIB-4 >3.25 identify high-risk patients for HCC after DAA [270]B3b (3b). For decompensated cirrhosis, improvement in Child-Pugh class occurs up to 24 weeks post-treatment; five-year liver transplant-free survival is 74.7% in SVR patients vs 33.3% in virologic failure [367]B2b (2b).
Drug / Modality Comparison Table
| Option | Indication / Line | Dose or Specifics | Key Trial | Outcome | Evidence Level |
|---|---|---|---|---|---|
| Glecaprevir/pibrentasvir | First-line, pangenotypic | 300 mg/120 mg once daily | ENDURANCE-1, -2, -3 | SVR12 95-99.7% | 1b [333]A1b[335]A1b |
| Sofosbuvir/velpatasvir | First-line, pangenotypic | 400 mg/100 mg once daily | ASTRAL-2, -3, -4 | SVR12 83-99% | 1b [326]A1b[329]A1b |
| Ledipasvir/sofosbuvir | Genotype 1, 4 | 90 mg/400 mg once daily | ION-1 | SVR12 99% | 1b [332]A1b |
| Elbasvir/grazoprevir | Genotype 1, 4 (treatment-experienced) | 50 mg/100 mg once daily | C-WORTHY | SVR12 90-100% | 1b [348]A1b |
| Sofosbuvir/velpatasvir/voxilaprevir | Genotype 3b cirrhosis, salvage | 400 mg/100 mg/100 mg once daily | [366]A1b | SVR12 90% | 1b [366]A1b |
Dosing Table
| Drug | Starting dose | Target / max dose | Renal adjustment | Hepatic adjustment | Key monitoring |
|---|---|---|---|---|---|
| Glecaprevir/pibrentasvir | 300 mg/120 mg PO once daily | Same | No adjustment for eGFR ≥30; not recommended if eGFR <30 | Child-Pugh B: no adjustment; Child-Pugh C: not recommended | HCV RNA, LFTs |
| Sofosbuvir/velpatasvir | 400 mg/100 mg PO once daily | Same | No adjustment for eGFR ≥30; not recommended if eGFR <30 | Child-Pugh B/C: no adjustment | HCV RNA, LFTs |
| Ledipasvir/sofosbuvir | 90 mg/400 mg PO once daily | Same | No adjustment for eGFR ≥30; not recommended if eGFR <30 | Child-Pugh B/C: no adjustment | HCV RNA, LFTs |
| Ribavirin | 1000-1200 mg/day PO divided BID (weight-based) | Same | eGFR <50: reduce dose; contraindicated if eGFR <30 | Child-Pugh B/C: use with caution | Hemoglobin weekly, pregnancy test |
| Eltrombopag | 25-100 mg/day PO | 100 mg/day | No adjustment | Child-Pugh B/C: reduce dose | Platelet count, LFTs |
| Citalopram | 20 mg/day PO | 40 mg/day | eGFR <20: max 20 mg/day | Child-Pugh B: max 20 mg/day | Depression scores, QTc |
Treatment Failure Protocol
If HCV RNA remains detectable at week 4 or rebounds during therapy, check adherence and drug interactions. For virologic failure (detectable HCV RNA at end of treatment or relapse within 12 weeks post-treatment), perform resistance testing. For NS5A inhibitor failures, switch to glecaprevir/pibrentasvir for 16 weeks (SVR12 94-97%) [299]A1b (1b). For genotype 3b with baseline NS5A RASs (A30K, L31M), use sofosbuvir/velpatasvir/voxilaprevir for 12 weeks [366]A1b (1b).
What NOT to Do
- Do NOT use interferon-based regimens in decompensated cirrhosis; they increase risk of hepatic decompensation [336]A1b (1b).
- Do NOT use ribavirin in patients with hemoglobin <10 g/dL without ESA support; severe anemia increases discontinuation [297]A1b.
- Do NOT use eltrombopag in patients with prior thromboembolic events or at high risk for thrombosis [303]A1b.
- Do NOT co-administer ledipasvir/sofosbuvir with proton pump inhibitors at doses >20 mg omeprazole equivalent; reduce ledipasvir absorption [label].
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| Ribavirin in genotype 3 cirrhosis | AASLD 2023 recommends sofosbuvir/velpatasvir for 12 weeks without ribavirin (SVR 91%) | EASL 2020 recommends adding ribavirin to sofosbuvir/velpatasvir for 12 weeks (SVR 96%) | Moderate (different thresholds for ribavirin use) [300]A1b | In patients with baseline NS5A RASs, ribavirin improves SVR; consider RAS testing or empiric ribavirin. |
| 8 vs 12 weeks for genotype 1 non-cirrhotic | AASLD accepts 8 weeks of glecaprevir/pibrentasvir (SVR 99.1%) | EASL prefers 12 weeks for genotype 1a with high viral load | Mild (wording differences) [333]A1b | 8 weeks is sufficient for most; 12 weeks if concerns about adherence or high viral load. |
Pearl: Initiate DAA therapy immediately after diagnosis; for decompensated cirrhosis, use sofosbuvir/velpatasvir plus ribavirin for 12 weeks to maximize SVR and improve hepatic reserve within 24 weeks post-treatment [326]A1b[367]B2b.
Long-term & Definitive Medical Management
- ▸DAA therapy achieves SVR12 rates >95% across genotypes, with 8-12 week regimens for most patients.
- ▸Treatment failure is rare; retreatment with SOF/VEL/VOX is effective in >88% of cases.
- ▸Post-SVR HCC surveillance is mandatory for patients with advanced fibrosis (F3/F4) indefinitely.
For patients with chronic HCV who have not achieved spontaneous clearance or who have progressed beyond the acute phase, definitive medical aims to eradicate the virus with direct-acting antiviral (DAA) therapy, achieving a sustained virologic response (SVR) that is tantamount to cure. The AASLD/IDSA and EASL guidelines recommend treatment for all patients with chronic HCV, regardless of fibrosis stage, except those with limited life expectancy [383]D5. The goal is SVR12 (undetectable HCV RNA 12 weeks after treatment completion), which is associated with reduced liver-related mortality, decreased HCC risk, and improved extrahepatic outcomes [265]B2a, [142]B2b.
Step 1: Pre-treatment Assessment
Before initiating therapy, confirm chronic infection (detectable HCV RNA), determine genotype (1-6), assess fibrosis stage using non-invasive markers (e.g., FibroScan, APRI, FIB-4) or biopsy, document prior treatment history, evaluate renal function (eGFR), and screen for drug-drug interactions (especially with , , and proton pump inhibitors). Patients with decompensated cirrhosis ( B/C) require ribavirin-containing or extended-duration regimens [326]A1b.
Step 2: Selection of DAA Regimen
Regimen choice depends on genotype, cirrhosis status, prior treatment, and renal function. The table below summarizes first-line options.
| Regimen | Genotype | Duration | SVR12 rate (non-cirrhotic) | Key evidence |
|---|---|---|---|---|
| / (LDV/SOF) | 1, 4, 5, 6 | 12 wk (8 wk if non-cirrhotic, treatment-naive, HCV RNA <6 million IU/mL) | 99% (95% CI 96-100) | ION-1 [332]A1b, ION-3 [351]A1b |
| Sofosbuvir/ (SOF/VEL) | 1-6 | 12 wk | 99% (GT2), 95% (GT3) | ASTRAL-2, ASTRAL-3 [329]A1b |
| Glecaprevir/pibrentasvir (G/P) | 1-6 | 8 wk (non-cirrhotic, treatment-naive); 12 wk (cirrhotic, treatment-experienced) | >95% across genotypes | ENDURANCE series [383]D5 |
| Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) | 1-6 | 12 wk | 88.6% after DAA failure | POLARIS [421]B2b |
| SOF/VEL + ribavirin | 1-6 (decompensated cirrhosis) | 12 wk | 94% (95% CI 87-98) | ASTRAL-4 [326]A1b |
For genotype 3 with cirrhosis, SOF/VEL for 24 weeks or SOF/VEL + ribavirin for 12 weeks achieves SVR rates of 94-96% [374]A1a. In patients with severe renal impairment (eGFR <30 mL/min), SOF/VEL with low-dose ribavirin (200 mg/day) is effective and well-tolerated [391]B3b. For HIV coinfection, standard DAA regimens are safe and effective, with SVR12 rates of 96% for LDV/SOF [372]C4 and 85-89% for SOF + ribavirin [373]C4.
Step 3: Monitoring During Treatment
Check HCV RNA at week 4 (to confirm adherence and early virologic response), at end of treatment, and 12 weeks post-treatment (SVR12). Monitor for adverse events: fatigue, headache, nausea are common; ribavirin causes dose-dependent hemolytic anemia (hemoglobin drop of 2-3 g/dL) [148]D5. Drug interactions require careful review, particularly with amiodarone (risk of bradycardia) and proton pump inhibitors (reduce LDV absorption).
Step 4: Management of Treatment Failure
Virologic failure (relapse or breakthrough) occurs in <5% of patients. Check for resistance-associated substitutions (RASs), especially in NS5A. Retreat with SOF/VEL/VOX for 12 weeks, which achieves SVR in 88.6% of patients who failed prior DAA therapy [421]B2b. Ribavirin may be added in difficult-to-treat cases (e.g., genotype 3 with cirrhosis).
Step 5: Post-treatment Follow-up
SVR12 is considered cure. However, patients with advanced fibrosis (F3/F4) remain at risk for HCC and should undergo surveillance with ultrasound ± AFP every 6 months indefinitely [274]A1c. In decompensated cirrhosis, Child-Pugh class improves in a significant proportion of patients after SVR, with 49% achieving Child-Pugh A at 3 years post-treatment [367]B2b. The 5-year liver transplant-free survival after DAA therapy in decompensated cirrhosis is 74.7% [367]B2b.
Drug Dosing Table
| Drug | Starting dose | Target/max dose | Renal adjustment | Hepatic adjustment | Key monitoring |
|---|---|---|---|---|---|
| Ledipasvir/sofosbuvir | 90/400 mg PO once daily | Same | No adjustment for eGFR ≥30; avoid if eGFR <30 (limited data) | Child-Pugh A/B: no adjustment; C: limited data | HCV RNA, creatinine |
| Sofosbuvir/velpatasvir | 400/100 mg PO once daily | Same | No adjustment for eGFR ≥30; use with caution if eGFR <30 (consider low-dose RBV) | Child-Pugh A/B: no adjustment; C: limited data | HCV RNA, bilirubin |
| Glecaprevir/pibrentasvir | 300/120 mg PO once daily (3 tablets) | Same | No adjustment | Child-Pugh A: no adjustment; B/C: contraindicated | HCV RNA, ALT |
| Sofosbuvir/velpatasvir/voxilaprevir | 400/100/100 mg PO once daily | Same | No adjustment for eGFR ≥30; avoid if eGFR <30 | Child-Pugh A: no adjustment; B/C: contraindicated | HCV RNA, bilirubin |
What NOT to Do
Do not use interferon-based regimens in patients with decompensated cirrhosis or severe psychiatric illness. Do not co-administer amiodarone with SOF-containing regimens due to risk of life-threatening bradycardia. Do not use G/P in Child-Pugh B/C cirrhosis.
Pearl: Achieving SVR with DAA therapy reduces HCC risk by 65% (RR 0.35, 95% CI 0.26-0.46) in patients with cirrhosis [265]B2a; all patients with F3/F4 fibrosis must continue lifelong HCC surveillance every 6 months after cure.
Endoscopic & Procedural Management
- ▸Endoscopic variceal band ligation and TIPS are cornerstone procedures for portal hypertension complications; pre-TIPS MELD and encephalopathy status predict outcomes.
- ▸RFA achieves 5-year survival of 60% for early-stage HCC, with local control exceeding 95%; surgical resection offers lower recurrence but comparable overall survival for small tumors.
- ▸DAA therapy after complete HCC ablation reduces 1-year recurrence risk by approximately 64% (HR 0.358), supporting earlier initiation in this setting.
For patients with HCV-related cirrhosis who develop complications of or hepatocellular carcinoma (HCC), a range of endoscopic and minimally invasive procedures provide definitive or palliative therapy. These interventions run in parallel with medical and are selected based on disease stage, liver function, and tumor burden.
Endoscopic Management of Portal
Endoscopic variceal band ligation remains the standard of care for acute variceal bleeding and secondary prophylaxis. In patients with cirrhosis undergoing endoscopic retrograde cholangiopancreatography (ERCP), pre-procedural risk stratification is critical. A retrospective case-control study of 277 patients with cirrhosis (11.4% HCV) found that post-ERCP hepatic decompensation occurred in 18.4% of patients, with independent predictors including higher score, , , and stent placement [454]B3b (3b). Patients with these risk factors should be considered for alternative biliary drainage strategies or aggressive peri-procedural optimization.
Transjugular Intrahepatic Portosystemic Shunt (TIPS)
TIPS creation effectively reduces portal pressure for and variceal bleeding. The use of a radiofrequency wire for track creation is safe and feasible, achieving a 100% technical success rate with a mean portosystemic gradient reduction from 13.9 to 5.9 mm Hg [447]C4 (4). In a cohort of 40 cancer patients (60% with cirrhosis, most commonly HCV), TIPS yielded a 77.5% clinical response rate at 1 month; median overall survival was 15.4 months and was significantly longer in responders (26.5 vs 1.1 months, P<0.001) [455]C4 (4). Hepatic encephalopathy occurred in 34% of patients, but only 2.5% required shunt reduction. A rare but serious complication of PTFE-covered stents is segmental hepatic ischemia leading to liver failure, reported in at least 5% of patients [435]C4 (4). Careful patient selection, avoiding TIPS in those with MELD >18 or uncontrolled encephalopathy, is essential.
Locoregional Therapies for Hepatocellular Carcinoma
( ) is a first-line curative treatment for stage 0-A HCC (solitary tumor ≤3 cm, or up to 5 cm if well-situated). In a 10-year consecutive series of 1,170 primary HCC patients (majority HCV), RFA achieved complete ablation in 99.4% of treatments, with 5- and 10-year overall survival rates of 60.2% and 27.3%, respectively [441]C4 (4). Local tumor progression was only 3.2% at both 5 and 10 years. Distant recurrence, however, was high (74.8% at 5 years), reflecting the underlying cirrhotic milieu. Compared with surgical resection for solitary HCC ≤2 cm, RFA offers comparable overall survival but significantly higher recurrence rates (hazard ratio for recurrence with RFA, P=0.018) [450]B2b (2b). For BCLC stage 0 HCC, RFA is as effective as surgery for both survival and recurrence [443]B2b (2b).
is an emerging alternative for solitary primary HCC. In a phase 2 study of 45 patients (13 HCV), image-guided proton therapy delivered 66 GyRBE in 10 fractions (peripheral tumors) or 72.6 GyRBE in 22 fractions (central tumors). Two- and 5-year overall survival rates were 84% and 70%, with local control rates of 95% and 92%, respectively [444]C4 (4). Grade 3 radiation-induced liver disease occurred in only 1 patient. Proton therapy may be particularly valuable for tumors in challenging locations where RFA is technically difficult.
( ) is the standard locoregional therapy for intermediate-stage HCC (BCLC B). In a Brazilian real-world cohort, 58.8% of early-stage patients received TACE, with a median progression-free survival of 10.4 months [168]B2b (2b). Drug-eluting bead TACE has largely replaced conventional TACE due to improved pharmacokinetics and reduced systemic toxicity.
Surgical Resection remains the treatment of choice for solitary HCC in patients with preserved liver function ( A, no portal hypertension). Population-based data from Sweden report 5-year survival of 60% after resection [449]B2b (2b). For patients with inadequate future liver remnant, the ALPPS procedure (associating liver partition and portal vein ligation) can induce rapid hypertrophy, though it carries high morbidity [453]C4 (4).
Timing of DAA Therapy Relative to HCC Treatment
The AGA 2019 Clinical Practice Update advises that patients with HCC who are eligible for curative therapy (resection or ablation) should defer DAA therapy until after HCC treatment is completed [274]A1c (1c). This recommendation is based on a small but statistically significant decrease in sustained virologic response with active HCC and the theoretical concern that DAA-induced immune modulation might accelerate tumor progression. However, a randomized controlled trial published in 2024 directly challenged this concern: 84 patients with HCV-related HCC who received / after complete ablation had significantly higher 1-year recurrence-free survival compared with those who postponed DAA for 12 months (72.2% vs 38%, P=0.001; HR 0.358) [448]A1b (1b). This trial suggests that DAA therapy after ablation may actually reduce recurrence risk, possibly by eliminating the oncogenic stimulus of chronic HCV. The AGA advice remains cautious, but the new evidence supports earlier DAA initiation in patients who have achieved a complete response to HCC treatment.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| RFA vs surgical resection for solitary HCC ≤2 cm | AASLD/EASL, both are acceptable first-line options; resection preferred in resectable patients with good liver function | Some Asian guidelines, RFA is equivalent to resection for BCLC 0 | Mild (wording differences, not incompatible) [441]C4[443]B2b[450]B2b | Patient preference and local expertise drive choice; RFA offers lower morbidity but higher recurrence |
| Timing of DAA after curative HCC treatment | AGA 2019, defer DAA until after HCC treatment [274]A1c | Kamal 2024 RCT, DAA after ablation reduces recurrence [448]A1b | Moderate (new RCT contradicts earlier expert opinion) | Consider DAA initiation after complete response, especially in patients with high-risk features (e.g., multiple tumors, elevated AFP) |
Pearl: For patients with HCV-related HCC who achieve complete response to curative therapy, DAA treatment after ablation reduces recurrence risk (HR 0.358), but surveillance imaging every 6 months remains mandatory indefinitely [448]A1b[274]A1c.
| Procedure | Indication (BCLC stage) | Key outcome data | Evidence level |
|---|---|---|---|
| Radiofrequency ablation (RFA) | 0-A (solitary ≤3 cm) | 5-yr OS 60.2%, local progression 3.2% [441]C4 | 4 |
| Surgical resection | 0-A (solitary, Child-Pugh A) | 5-yr OS 60% [449]B2b | 2b |
| Proton therapy | 0-A (solitary, any location) | 5-yr OS 70%, local control 92% [444]C4 | 4 |
| TACE | B (multinodular, no vascular invasion) | Median PFS 10.4 mo [168]B2b | 2b |
| TIPS (for portal hypertension) | Refractory ascites/variceal bleeding | Clinical response 77.5%, median OS 15.4 mo [455]C4 | 4 |
History and Evolution of Treatment
- ▸SVR rates increased from <10% with interferon monotherapy to >95% with modern pangenotypic DAA combinations.
- ▸First-generation protease inhibitors (telaprevir, boceprevir) improved SVR but added significant toxicity and pill burden, and were rapidly replaced by all-oral regimens.
- ▸Pangenotypic DAAs have eliminated the need for genotype testing in most settings and shortened treatment to 8-12 weeks, with ribavirin now rarely required.
While endoscopic surveillance and procedural of remain essential for patients with advanced fibrosis, the true revolution in hepatitis C care has been the evolution of antiviral therapy, which has transformed a chronic progressive disease into one that is curable in nearly all patients.
The Interferon Era
Interferon alfa monotherapy, introduced in the 1990s, achieved sustained virologic response (SVR) in fewer than 10% of patients [475]D5. The addition of ribavirin doubled SVR rates to 30-40% [475]D5[422]A1a. Pegylated interferon (PEG-IFN) alfa-2a or -2b combined with ribavirin became the standard of care, yielding SVR rates of 40-50% in genotype 1 and 70-80% in genotypes 2/3 [431]A1a[430]A1a. However, treatment was limited by significant adverse effects, flu-like symptoms, cytopenias, depression, and was contraindicated in many patients with decompensated cirrhosis or psychiatric comorbidities [457]A1c.
The First Direct-Acting Antivirals
The first-generation NS3/4A protease inhibitors boceprevir and telaprevir, approved in 2011, were added to PEG-IFN/ribavirin for genotype 1. In treatment-naïve patients, telaprevir-based triple therapy increased SVR from 44% to 75% [345]A1b; in prior nonresponders, SVR rose from 5% to 29-33% [325]A1b. However, these regimens required thrice-daily dosing, caused severe anemia and rash, and had a high pill burden. They were rapidly superseded by second-wave DAAs.
The All-Oral Revolution
The approval of the nucleotide polymerase inhibitor in 2013 marked a paradigm shift. Sofosbuvir plus ribavirin for 12 weeks cured 97% of genotype 2 and 56% of genotype 3 (extended to 24 weeks improved genotype 3 SVR to 85%) [331]A1b[327]A1b. The combination of sofosbuvir with the NS5A inhibitor (fixed-dose) achieved SVR12 of 99% in treatment-naïve genotype 1 patients (ION-1) [332]A1b and 94% in prior nonresponders (ION-2) [463]A1b. The interferon-free regimen of ABT-450/r-ombitasvir and dasabuvir with ribavirin yielded SVR rates of 92-96% in genotype 1 cirrhosis (TURQUOISE-II) [328]A1b and 99% in genotype 1b without cirrhosis (PEARL-III) [324]A1b.
Pangenotypic regimens soon followed. Sofosbuvir- for 12 weeks achieved SVR of 99% in genotype 2 and 95% in genotype 3 (ASTRAL-2/3) [329]A1b. In decompensated cirrhosis ( B), sofosbuvir-velpatasvir plus ribavirin for 12 weeks yielded SVR of 94% (ASTRAL-4) [326]A1b. for 8 weeks in noncirrhotic genotype 1/3 achieved SVR >95% (ENDURANCE-1/3) [333]A1b. For patients who failed prior DAA therapy, sofosbuvir-velpatasvir-voxilaprevir for 12 weeks provided SVR of 96-98% (POLARIS-1/4) [464]A1b.
Current Standard of Care and Future Directions
Current guidelines recommend pangenotypic DAA regimens for 8-12 weeks, with SVR rates exceeding 95% in most populations [6]A1c[494]A1a. Ribavirin is now rarely needed, reserved for decompensated cirrhosis or difficult-to-treat genotypes. The era of interferon-based therapy has ended. Ongoing research focuses on shortening treatment duration: a 2025 trial showed that 8 weeks of sofosbuvir/ravidasvir was noninferior to 12 weeks in noncirrhotic patients [360]A1b, and response-guided therapy with 4 weeks of DAAs plus interferon achieved 94% SVR [344]A1b. A vaccine to prevent chronic HCV infection remains elusive; a phase 1-2 trial using chimpanzee adenovirus and MVA vectors did not prevent chronic infection despite inducing T-cell responses [103]A1b.
Pearl: The evolution from interferon monotherapy (SVR <10%) to pangenotypic DAA regimens (SVR >95%) represents one of the most dramatic therapeutic advances in modern medicine, but patients who achieve SVR remain at risk for HCC if they have advanced fibrosis, requiring continued surveillance [456]A1c[236]B2c.
Complications
- ▸SVR reduces but does not eliminate the risk of hepatic decompensation and HCC; ongoing surveillance is mandatory.
- ▸Non-selective beta-blockers prevent first decompensation in patients with compensated cirrhosis and clinically significant portal hypertension (HR 0.32).
- ▸Aspirin lowers HCC incidence (HR 0.69) and liver-related mortality (HR 0.73) without significantly increasing bleeding risk.
- ▸Extrahepatic complications, including lymphoma, gastric cancer, and insulin resistance, are reduced but not fully abolished after SVR.
The evolution of therapy from interferon-based regimens to direct-acting antivirals (DAAs) has fundamentally altered the natural history of hepatitis C, but complications remain a dominant clinical concern even in the era of cure. In a contemporary cohort of patients with compensated cirrhosis, 49.8% progressed to a single complication over a median follow-up of 5.3 years, with (30.3%) being the most common, and 3.1% progressed to multiple complications [518]B3b. The annual rates of decompensation, hepatocellular carcinoma (HCC), and death or transplantation in untreated compensated HCV cirrhosis are 6.37%, 3.36%, and 4.58% respectively [523]B2a. Achieving sustained virologic response (SVR) dramatically reduces these risks: relative risks for liver-related mortality, HCC, and hepatic decompensation are 0.23, 0.21, and 0.16 compared to treatment failure [520]B2a.
Hepatic Decompensation
Decompensation events, ascites, variceal bleeding, and , define the transition from compensated to decompensated cirrhosis. In a large prospective study of DAA-treated patients with decompensated cirrhosis (predominantly genotype 3), ascites was present in 95.3%, hepatic encephalopathy in 16.6%, and variceal bleeding in 24.7% [116]B2b. After SVR, ascites resolved in 86% of patients, though only 24% achieved diuretic withdrawal. Recompensation per Baveno VII criteria occurred in 24.7% at a median of 16.5 months, predicted by low bilirubin, low INR, and absence of large esophageal or (aHR 0.4-0.6) [116]B2b. Yet 19% experienced further decompensation despite SVR, and 2.9% developed de novo HCC. Non-selective beta-blockers (NSBBs) reduce the risk of first decompensation in patients with compensated cirrhosis and clinically significant (CSPH) by 68% (HR 0.32) [530]B2b. Statin use is associated with a 46% lower risk of hepatic decompensation (RR 0.54) [266]B2a.
Hepatocellular Carcinoma
HCC is the most feared complication. In patients with advanced fibrosis who fail treatment, the annual incidence is 3.22% [520]B2a. SVR reduces this risk by 79% (RR 0.21) [520]B2a. Even after DAA-induced SVR, de novo HCC occurs in 2.9% of patients with prior decompensation [116]B2b. Surveillance with ultrasound every 6 months improves early detection and survival: the 6-month interval yields the highest likelihood of early-stage diagnosis and curative treatment, with a 30% reduction in all-cause mortality compared to 12-month intervals (HR 1.13 for 12-month vs 6-month) [542]B2b. use (≤160 mg daily) is associated with a 31% lower HCC incidence (HR 0.69) and 27% lower liver-related mortality (HR 0.73) without a significant increase in bleeding (10-year risk 7.8% vs 6.9%) [150]B2b.
Portal and Varices
De novo gastroesophageal varices develop in 26.2% of patients with advanced fibrosis over 4 years; most are small, and only 1% bleed [515]B2b. Among patients with existing varices, 35.2% experience progression or bleeding. DAA-induced SVR independently reduces the risk of variceal bleeding: 0.46 vs 1.26 per 100 patient-years (aHR 0.66) [536]B2b. Portal hypertensive gastropathy (PHG) is common: 50% of patients without baseline PHG develop new-onset PHG over 3.85 years, and 26% worsen [526]B2b. Predictors include diabetes, higher alkaline phosphatase, and lower albumin. NSBBs did not reduce variceal development or progression in the HALT-C trial [515]B2b, but they do lower the risk of first decompensation in patients with CSPH [530]B2b and reduce bacterial infection rates (HR 0.36) [530]B2b.
Extrahepatic Manifestations
HCV is a systemic infection. Mixed cryoglobulinemia vasculitis involves the gastrointestinal tract in 7.4% of patients, presenting with abdominal pain, surgical abdomen, or intestinal bleeding; these patients have more frequent renal and cardiac involvement but similar overall survival after antiviral therapy [172]B3b. HCV infection increases the risk of (OR 2.19) [56]B3b. SVR reduces the risk of non-Hodgkin lymphoma and gastric cancer, particularly in patients <65 years (HR 0.28 and 0.30, respectively) [527]B2b. DAA treatment also reduces extrahepatic cancer risk overall (aHR 0.77) [166]B2b. Insulin resistance is a key driver of fibrosis progression: each quartile increase in HOMA2-IR carries a 26% higher hazard of clinical outcomes (HR 1.26) [306]B2b. Oral glucose tolerance testing is recommended to uncover diabetes or [525]D5. Stainable iron in hepatocytes and portal tract cells predicts progression (HR 1.35) [514]B2b.
Treatment-Related Complications
Interferon-based therapy was associated with significant adverse events: serious adverse events occurred in 38.6% of peginterferon-treated patients vs 31.8% controls, though cognitive function did not worsen with low-dose peginterferon [195]A1b[517]A1b. DAA therapy is generally well tolerated; the most common adverse events with / plus ribavirin were headache, fatigue, and upper respiratory infection [512]A1b. SVR from DAAs leads to recompensation in one quarter of decompensated patients [116]B2b and a 70% reduction in liver decompensation (HR 0.3) and 80% reduction in de novo HCC (HR 0.2) [529]B2b.
| Complication | Frequency | Prevention | |
|---|---|---|---|
| Ascites | 30.3% of compensated cirrhosis patients [518]B3b | SVR, NSBBs if CSPH [530]B2b | Diuretics, , TIPS for refractory |
| Variceal bleeding | 1.6% of DAA-treated patients over 3.1 years [536]B2b | SVR (aHR 0.66) [536]B2b, NSBBs [530]B2b | Endoscopic band ligation, beta-blockers, TIPS |
| Hepatic encephalopathy | 16.6% of decompensated patients [116]B2b | SVR, lactulose prophylaxis | Lactulose, rifaximin, protein restriction not routinely recommended |
| Hepatocellular carcinoma | 3.36%/year in compensated cirrhosis [523]B2a | SVR (RR 0.21) [520]B2a, aspirin (HR 0.69) [150]B2b | Surveillance 6-month ultrasound [542]B2b, locoregional/systemic therapy |
| Portal hypertensive gastropathy | 50% new-onset over 3.85 years [526]B2b | SVR, NSBBs? | Iron replacement, TIPS for severe bleeding |
| Mixed cryoglobulinemia vasculitis | 7.4% of HCV vasculitis [172]B3b | SVR | Antiviral therapy, for severe |
| Insulin resistance/diabetes | Common [525]D5 | SVR, lifestyle modification | Oral glucose tolerance test [525]D5, |
Pearl: In patients with compensated HCV cirrhosis, the risk of decompensation and HCC declines substantially after DAA-induced SVR, but does not disappear, 19% will still develop new decompensation and 2.9% de novo HCC [116]B2b[529]B2b. Continue surveillance for HCC and portal hypertension indefinitely, and consider aspirin chemoprevention (≤160 mg daily) in appropriate candidates [150]B2b.
Prognosis & Natural History
- ▸Untreated chronic HCV progresses to cirrhosis in a substantial proportion over decades, with annual HCC risk exceeding 2-3% once cirrhosis is established.
- ▸SVR dramatically reduces liver-related and extrahepatic mortality, but residual HCC risk persists in cirrhosis (2.99/100 person-years) and does not decline with recompensation.
- ▸Recompensation occurs in 25-37% of decompensated patients after SVR, conferring a 60% reduction in liver-related death but no protection against HCC.
The trajectory from acute infection to its complications is highly variable, governed by a complex interplay of host, viral, and environmental factors [471]D5.
Untreated Natural History
After acute infection, spontaneous clearance occurs in a minority of patients, more often in those who are symptomatic with jaundice [554]D5. The vast majority develop chronic hepatitis C, which drives a slow but progressive hepatic fibrosis. Over decades, cirrhosis develops in a substantial proportion of infected individuals [471]D5. Once cirrhosis is established, the risk of hepatic decompensation and (HCC) accelerates. Among patients with HCV-related cirrhosis, the annual HCC incidence after viral eradication is 2.99 per 100 person-years [199]B2a; in untreated cirrhosis, the risk is even higher. Extrahepatic morbidity is also prominent: HCV infection increases the odds of cardiovascular mortality (OR 1.65) [109]B2a and of developing and [133]D5. Sustained viremia carries a 16-fold higher risk of intrahepatic cancer (aHR 16.35) and a modest but significant increase in extrahepatic cancers (aHR 1.14) [166]B2b.
Impact of Direct-Acting Antiviral Therapy
Eradication of HCV with dramatically alters the natural history. (SVR) reduces extrahepatic mortality (OR 0.44, 95% CI 0.28-0.67) [112]A1a and lowers the risk of diabetes (OR 0.34, 95% CI 0.21-0.56) [112]A1a. In patients with , SVR is achieved in 81.8% after one course, and (Baveno VII criteria) occurs in 24.7% at a median of 16.5 months [116]B2b. A European cohort reported recompensation in 36.6% of patients, with a marked reduction in liver-related death (aHR 0.384) and portal vein thrombosis (aHR 0.421) [153]B2b. However, HCC risk persists even after SVR: incidence remains 2.99/100 person-years in cirrhosis and 0.47/100 person-years in non-cirrhotic patients [199]B2a. Importantly, recompensation does not reduce HCC risk compared with the non-recompensated state [153]B2b.
Predictors of Disease Progression
Several factors modify the trajectory. Nonmodifiable factors include age at infection (older age accelerates fibrosis), male sex, and African American or Latino ethnicity, which are associated with faster progression and lower SVR rates in the interferon era [144]D5[282]D5. Potentially modifiable factors, excessive alcohol consumption, , HIV coinfection, and smoking, significantly accelerate fibrosis [471]D5 and increase mortality. Insulin resistance, measured by >2, reduces SVR in interferon-based therapy (OR 2.86 for normal insulin sensitivity) [130]B2a. Statin use is associated with a 46% lower risk of hepatic decompensation (RR 0.54, 95% CI 0.46-0.62) and 46% lower mortality (RR 0.54, 95% CI 0.47-0.61) in patients with cirrhosis [266]B2a[5]A1a. After SVR, the strongest predictors of liver-related death are cirrhosis (adj-HR 14.51), >3.25 (adj-HR 4.22, 95% CI 2.63-6.80), and failure to achieve SVR (adj-HR 3.94) [557]B2b.
Pearl: Even after successful HCV eradication, cirrhotic patients retain a substantial HCC risk (2.99/100 person-years) that does not diminish with recompensation; indefinite semiannual surveillance with ultrasound and AFP remains mandatory.
Special Populations & Pregnancy
- ▸In pregnancy, defer DAA therapy until postpartum; ribavirin is contraindicated.
- ▸In advanced CKD (eGFR <30), glecaprevir/pibrentasvir is the regimen of choice.
- ▸In HIV coinfection, check drug-drug interactions; ledipasvir/sofosbuvir is highly effective.
While prognosis after SVR is excellent for most patients, special populations require modified diagnostic and therapeutic approaches.
Pediatrics
Pediatric HCV infection is predominantly acquired perinatally. Spontaneous clearance rates are higher than in adults [568]D5. Direct-acting antiviral regimens are approved for children aged ≥3 years, with SVR rates exceeding 95% [568]D5. Weight-based dosing is used, and treatment is generally deferred until age 3 years due to limited data in younger children.
Pregnancy
HCV treatment is generally deferred until postpartum because direct-acting antivirals lack adequate safety data in pregnancy [160]D5. Ribavirin is contraindicated in pregnancy due to teratogenicity. For pregnant women with cirrhosis, variceal screening is recommended because increased plasma volume raises bleeding risk [160]D5. is not contraindicated in HCV-infected mothers.
Elderly
Patients aged >65 years were historically understudied in interferon-based trials and had lower SVR rates and higher toxicity [484]D5. With direct-acting antivirals, age is not a barrier to cure; real-world studies demonstrate high SVR rates, comparable to younger populations [383]D5. Renal function should be assessed before choosing a regimen, as some DAAs are renally cleared [567]A1c. Attention to drug-drug interactions is critical due to polypharmacy.
Immunocompromised
HIV coinfection: / for 12 weeks achieved SVR12 in 96% of HIV-HCV coinfected patients, including those with cirrhosis, without HIV virologic rebound [372]C4. Drug-drug interactions with antiretroviral therapy must be checked; for example, efavirenz reduces ledipasvir concentrations.
Chronic kidney disease: Glecaprevir/pibrentasvir is the first pangenotypic regimen approved for patients with advanced CKD (eGFR <30 mL/min/1.73 m²) and those on dialysis, with SVR rates >95% [567]A1c. Sofosbuvir-containing regimens are not recommended in severe renal impairment due to accumulation of the metabolite.
Solid organ transplant: DAAs have revolutionized treatment of HCV recurrence after , with SVR rates >90% [376]D5. Drug-drug interactions with calcineurin inhibitors require monitoring. Use of HCV-viraemic allografts in HCV-negative recipients followed by early DAA therapy achieves 100% SVR and excellent graft outcomes [547]B2a.
Cancer patients: Sofosbuvir-based therapy is safe and effective in cancer patients, with SVR12 of 91% overall and 100% with 8 weeks of ledipasvir/sofosbuvir [397]B2b. Treatment may permit access to investigational cancer therapies and can induce remission of HCV-associated non-Hodgkin lymphoma.
| Population | Preferred Regimen | Duration | Key Considerations |
|---|---|---|---|
| HIV coinfection | Ledipasvir/sofosbuvir | 12 weeks | Check ART interactions [372]C4 |
| CKD (eGFR <30) | Glecaprevir/pibrentasvir | 8-12 weeks | No dose adjustment needed [567]A1c |
| Decompensated cirrhosis | Sofosbuvir/ + ribavirin | 12 weeks | Monitor for hepatic decompensation [326]A1b |
| Post-liver transplant | Individualized DAA | 12 weeks | Monitor CNI levels [376]D5 |
Pearl: In immunocompromised patients, always check drug-drug interactions between DAAs and immunosuppressants or antiretrovirals; glecaprevir/pibrentasvir is the preferred pangenotypic option for advanced CKD and for patients on complex polypharmacy due to minimal drug interactions.
Prevention, Screening & Surveillance
- ▸Universal HCV screening is recommended for all adults ≥18 years; reflexive RNA testing on antibody-positive samples is now standard and improves linkage to care.
- ▸HCC surveillance with ultrasound and AFP every 6 months is indicated indefinitely for patients with F3/F4 fibrosis after SVR, as HCC risk remains above the cost-effectiveness threshold.
- ▸Aspirin and coffee consumption are associated with reduced HCC risk in at-risk populations, though aspirin carries a small increased bleeding risk.
For patients who achieve sustained virologic response (SVR), the focus shifts to preventing reinfection and detecting late complications, particularly hepatocellular carcinoma (HCC). Primary prevention of new infections remains a global priority, with the World Health Organization targeting a 90% reduction in new HCV infections by 2030 [580]D5.
Primary Prevention: Vaccine Development and Harm Reduction
No prophylactic HCV vaccine is yet available. A phase 1-2 trial of a chimpanzee adenovirus-3 vector prime followed by modified vaccinia Ankara boost encoding nonstructural proteins induced T-cell responses in 78% of participants but did not prevent chronic infection (vaccine efficacy -53%; 95% CI -255 to 34) [103]A1b. Meta-analysis of chimpanzee studies suggests that vaccines containing only structural proteins achieve higher clearance rates than those including nonstructural components [577]B2a. Until an effective vaccine emerges, prevention relies on harm reduction for people who inject drugs (PWID): needle and syringe programs, opioid agonist therapy, and education. These interventions are critically underutilized in carceral settings, where fewer than 2% of incarcerated individuals live in countries offering comprehensive services [592]B2a. Mobile telemedicine interventions that combine convenience, rapport, and skilled staff have shown promise for engaging rural PWID in HCV care [361]C4.
Screening: Who, When, and How
The CDC recommends universal HCV screening for all adults aged ≥18 years at least once, and for all pregnant women during each pregnancy (2020). Earlier birth-cohort screening (1945-1965) is now superseded. Reflexive testing, automatic HCV RNA testing on antibody-positive samples, increased from 21.9% in 2018 to 82.2% in 2024 in a national US laboratory, with same-day RNA testing rising from 38.0% to 82.2% [596]C4. Electronic health record alerts significantly increase screening rates in eligible populations [122]B2a. A pragmatic trial found that combining inreach (EHR reminders) with mailed outreach improved screening completion at 3 months (14.6% vs 7.4%, P < 0.001) [315]A1b. Economic evaluations confirm that screening plus direct-acting antiviral treatment is cost-effective across general and high-risk populations at a willingness-to-pay threshold of $50,000 per quality-adjusted life year [579]B2c.
Surveillance for Hepatocellular Carcinoma After Cure
Patients with advanced fibrosis (F3) or cirrhosis at the time of SVR remain at risk for HCC and should undergo surveillance indefinitely if they are candidates for curative therapy [274]A1c. The AGA recommends ultrasound with or without α-fetoprotein (AFP) every 6 months [274]A1c. HCC risk declines progressively up to 6 years post-SVR but remains above the cost-effectiveness threshold of 0.7 per 100 person-years (at $100,000/QALY) [236]B2c[159]B2b. Lowering the AFP threshold to ≥10 ng/mL increases sensitivity from 31.7% to 41.9% while maintaining specificity >94% in cirrhosis [213]B3b. Risk stratification tools such as PAaM (prognostic liver secretome signature with AFP plus age, male sex, albumin-bilirubin, and platelets) identify patients with annual HCC incidence rates of 0.6% (low-risk) to 6.2% (high-risk) [134]B2b. Implementation of population-based surveillance programs improves detection of early-stage HCC (85.2% vs 44.8% 0/A) and receipt of curative therapy (92.5% vs 72.4%), with a 77% reduction in mortality (HR 0.23, 95% CI 0.11-0.51) [586]B2b.
Chemoprevention and Lifestyle Modifications
use reduces HCC incidence in at-risk populations (HR 0.51, 95% CI 0.36-0.72) and improves liver-related mortality (OR 0.32, 95% CI 0.15-0.70), with a small increased risk of bleeding (OR 1.32) [522]B2a. Coffee consumption is associated with a 40% reduction in HCC risk (summary RR 0.60, 95% CI 0.50-0.71) [267]B2a. Educational interventions significantly improve patients' knowledge, testing uptake, and treatment adherence [578]B2a.
Pearl: After HCV cure, HCC surveillance should continue indefinitely in patients with F3/F4 fibrosis; the risk declines over time but remains above the cost-effectiveness threshold for at least 6 years, and lowering the AFP cutoff to ≥10 ng/mL improves sensitivity without sacrificing specificity.
| Population | Surveillance Modality | Interval | Duration | Guideline Source |
|---|---|---|---|---|
| F3/F4 fibrosis (cirrhosis) | Ultrasound ± AFP | Every 6 months | Indefinitely if candidate for curative therapy | AGA 2019 [274]A1c |
| F0-F2 fibrosis | No routine surveillance | , | , | AGA 2019 [274]A1c |
| Cirrhosis (any etiology) | Consider AFP threshold ≥10 ng/mL | Every 6 months | Improves sensitivity vs ≥20 ng/mL | VHA data 2025 [213]B3b |
References
- [1]
Garcia-Tsao G, Lim JK. “Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.” The American journal of gastroenterology (2009). PMID: 19455106 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), History and Evolution of Treatment - [2]
Bonkovsky HL, Naishadham D, Lambrecht RW et al.. “Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.” Gastroenterology (2006). PMID: 17101320 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature - [3]
Boursier J, de Ledinghen V, Zarski JP et al.. “A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C.” The American journal of gastroenterology (2011). PMID: 21468012 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature - [4]
Kamal SM. “Acute hepatitis C: a systematic review.” The American journal of gastroenterology (2008). PMID: 18477352 ↗
L5SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy - [5]
Kamal S, Khan MA, Seth A et al.. “Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis.” The American journal of gastroenterology (2017). PMID: 28585556 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Prognosis & Natural History - [6]
Miller MH, Agarwal K, Austin A et al.. “Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.” Alimentary pharmacology & therapeutics (2014). PMID: 24754233 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature, Long-term & Definitive Medical Management, History and Evolution of Treatment - [7]
Ramachandran P, Fraser A, Agarwal K et al.. “UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.” Alimentary pharmacology & therapeutics (2012). PMID: 22296568 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature - [8]
Gordon SC, Lamerato LE, Rupp LB et al.. “Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study.” The American journal of gastroenterology (2015). PMID: 26215529 ↗
L2COHORTCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification (GI Scores) - [9]
Chao DT, Abe K, Nguyen MH. “Systematic review: epidemiology of hepatitis C genotype 6 and its management.” Alimentary pharmacology & therapeutics (2011). PMID: 21623850 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management, Special Populations & Pregnancy - [10]
Ilyas SI, Gores GJ. “Pathogenesis, diagnosis, and management of cholangiocarcinoma.” Gastroenterology (2013). PMID: 24140396 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management, Prognosis & Natural History - [11]
Dhanasekaran R, Nault JC, Roberts LR et al.. “Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.” Gastroenterology (2018). PMID: 30404026 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism - [12]
Kroy DC, Ciuffreda D, Cooperrider JH et al.. “Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors.” Gastroenterology (2013). PMID: 24148617 ↗
L4OTHERCited in: Definition, Classification & Nomenclature - [13]
Heeg MH, Ulsenheimer A, Grüner NH et al.. “FOXP3 expression in hepatitis C virus-specific CD4+ T cells during acute hepatitis C.” Gastroenterology (2009). PMID: 19596013 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, History and Evolution of Treatment - [14]
Oliviero B, Varchetta S, Paudice E et al.. “Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections.” Gastroenterology (2009). PMID: 19470388 ↗
L3OTHERCited in: Definition, Classification & Nomenclature - [15]
Asrani SK, Larson JJ, Yawn B et al.. “Underestimation of liver-related mortality in the United States.” Gastroenterology (2013). PMID: 23583430 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [16]
Serti E, Chepa-Lotrea X, Kim YJ et al.. “Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.” Gastroenterology (2015). PMID: 25754160 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [17]
Jiang Y, Bao H, Ge Y et al.. “Therapeutic targeting of GSK3β enhances the Nrf2 antioxidant response and confers hepatic cytoprotection in hepatitis C.” Gut (2014). PMID: 24811996 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [18]
Jamil KM, Hydes TJ, Cheent KS et al.. “STAT4-associated natural killer cell tolerance following liver transplantation.” Gut (2016). PMID: 26887815 ↗
L3OTHERCited in: Definition, Classification & Nomenclature - [19]
Butt AA, Justice AC, Skanderson M et al.. “Rate and predictors of treatment prescription for hepatitis C.” Gut (2006). PMID: 17005764 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Long-term & Definitive Medical Management - [20]
Mengshol JA, Golden-Mason L, Castelblanco N et al.. “Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes.” Gut (2009). PMID: 19193669 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [21]
Choi YS, Lee J, Lee HW et al.. “Liver injury in acute hepatitis A is associated with decreased frequency of regulatory T cells caused by Fas-mediated apoptosis.” Gut (2014). PMID: 25007815 ↗
L4OTHERCited in: Definition, Classification & Nomenclature - [22]
Brenndörfer ED, Brass A, Söderholm J et al.. “Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-γ production.” Gut (2011). PMID: 21813471 ↗
L5OTHERCited in: Definition, Classification & Nomenclature - [23]
Serti E, Park H, Keane M et al.. “Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.” Gut (2016). PMID: 26733671 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Long-term & Definitive Medical Management - [24]
Svegliati-Baroni G, Bugianesi E, Bouserhal T et al.. “Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease.” Gut (2007). PMID: 17392334 ↗
L3OTHERCited in: Definition, Classification & Nomenclature - [25]
Pons M, Augustin S, Scheiner B et al.. “Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.” The American journal of gastroenterology (2021). PMID: 33982942 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), Special Populations & Pregnancy - [26]
Kumar A, Arora A, Choudhury A et al.. “Impact of Diabetes, Drug-Induced Liver Injury, and Sepsis on Outcomes in Metabolic Dysfunction Associated Fatty Liver Disease-Related Acute-on-Chronic Liver Failure.” The American journal of gastroenterology (2024). PMID: 39016385 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification (GI Scores) - [27]
Rogal S, Youk A, Agbalajobi O et al.. “Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.” The American journal of gastroenterology (2021). PMID: 33811202 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Long-term & Definitive Medical Management - [28]
Mikulska M, van Bömmel F, Mouliade C et al.. “Updated recommendations for the management of hepatitis B, C, and E virus infections in patients with haematological malignancies and those undergoing haematopoietic cell transplantation: recommendations from the 9th European Conference on Infections in Leukaemia (ECIL-9).” The Lancet. Haematology (2025). PMID: 40306834 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature - [29]
Alhusayen R, Dienes S, Lam M et al.. “North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations.” Journal of the American Academy of Dermatology (2024). PMID: 39725212 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature - [30]
Mathews SC, Izmailyan S, Brito FA et al.. “Prevalence and Financial Burden of Digestive Diseases in a Commercially Insured Population.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 34217877 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Clinical Presentation - [31]
Thrift AP, Nguyen TH, Pham C et al.. “The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022). PMID: 35811043 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [32]
Alawad AS, Auh S, Suarez D et al.. “Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 31323381 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Long-term & Definitive Medical Management, History and Evolution of Treatment - [33]
Huang CF, Yeh ML, Dai CY et al.. “Chronic Hepatitis C Related Steatotic Liver Disease Is More Than "Miscellaneous Steatotic Liver Disease".” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 38729391 ↗
L5OTHERCited in: Definition, Classification & Nomenclature - [34]
Nguyen GC, Segev DL, Thuluvath PJ. “Nationwide increase in hospitalizations and hepatitis C among inpatients with cirrhosis and sequelae of portal hypertension.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2007). PMID: 17625983 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [35]
Mapakshi S, Kramer JR, Richardson P et al.. “Positive Predictive Value of International Classification of Diseases, 10th Revision, Codes for Cirrhosis and Its Related Complications.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2018). PMID: 29410051 ↗
L3OTHERCited in: Definition, Classification & Nomenclature - [36]
Jalil S, Grady JJ, Lee C et al.. “Associations among behavior-related susceptibility factors in porphyria cutanea tarda.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2009). PMID: 19948245 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation - [37]
Belperio PS, Hwang EW, Thomas IC et al.. “Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 23524130 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [38]
Csete J, Kamarulzaman A, Kazatchkine M et al.. “Public health and international drug policy.” Lancet (London, England) (2016). PMID: 27021149 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [39]
Wei X, Cai R, Wu X et al.. “Risk of drug-induced liver injury in chronic hepatitis C and tuberculosis co- infection: a systematic review and meta- analysis.” BMC infectious diseases (2025). PMID: 41233746 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature - [40]
Cabrera R, Nelson DR. “Review article: the management of hepatocellular carcinoma.” Alimentary pharmacology & therapeutics (2009). PMID: 19925500 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prognosis & Natural History, Prevention, Screening & Surveillance - [41]
Calès P, Boursier J, Lebigot J et al.. “Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C: agreement or combination?” Alimentary pharmacology & therapeutics (2017). PMID: 28164327 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores) - [42]
Kramer JR, Davila JA, Miller ED et al.. “The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases.” Alimentary pharmacology & therapeutics (2007). PMID: 17996017 ↗
L4OTHERCited in: Definition, Classification & Nomenclature - [43]
Petta S, Vanni E, Bugianesi E et al.. “PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C.” Alimentary pharmacology & therapeutics (2015). PMID: 25801076 ↗
L4OTHERCited in: Definition, Classification & Nomenclature - [44]
Panetta JD, Gilani N. “Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection.” Alimentary pharmacology & therapeutics (2009). PMID: 19549263 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [45]
Chen W, Liu J, Gluud C. “Bile acids for viral hepatitis.” The Cochrane database of systematic reviews (2007). PMID: 17943781 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Prognosis & Natural History, Special Populations & Pregnancy - [46]
Kalafateli M, Buzzetti E, Thorburn D et al.. “Pharmacological interventions for acute hepatitis C infection.” The Cochrane database of systematic reviews (2018). PMID: 30521693 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations & Pregnancy - [47]
Kalafateli M, Buzzetti E, Thorburn D et al.. “Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.” The Cochrane database of systematic reviews (2017). PMID: 28285495 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management - [48]
Mulder RL, Bresters D, Van den Hof M et al.. “Hepatic late adverse effects after antineoplastic treatment for childhood cancer.” The Cochrane database of systematic reviews (2019). PMID: 30985922 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors - [49]
Katz LH, Goldvaser H, Gafter-Gvili A et al.. “Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.” The Cochrane database of systematic reviews (2012). PMID: 22972122 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Long-term & Definitive Medical Management - [50]
Chang M-L, Chen W-T, Pao L-H et al.. “HCV Ab titer and ALT level indicate occult hepatitis C virus infection in treatment-naive HCV Ab-positive and HCV Ab-negative patients: a 3-year prospective cohort study.” Microbiology spectrum (2025). PMID: 40552800 ↗
L2COHORTCited in: Definition, Classification & Nomenclature - [51]
Kashani M, Wei L, Singh W et al.. “Serum chloride concentrations and outcomes in adult patients with cirrhosis: a systematic review and meta-analysis.” BMC nephrology (2025). PMID: 41013381 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature - [52]
Colloca GA, Venturino A. “Immune Checkpoint Inhibitors Affect Post-Progression Survival of Specific Patient Subgroups With Advanced Hepatocellular Carcinoma: A Study Cohorts' Analysis.” Journal of digestive diseases (2025). PMID: 40007104 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature - [53]
Llaneras J, Lens S, Valle B et al.. “Hepatitis C virus detection in hospital emergency departments.” Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias (2024). PMID: 39364991 ↗
L5GUIDELINECited in: Definition, Classification & Nomenclature - [54]
Chen WT, Shen YJ, Chien RN et al.. “Evolution of late hepatitis C relapse among patients with previous sustained virological responses: An 18-year prospective study.” Journal of global antimicrobial resistance (2026). PMID: 41724353 ↗
L2COHORTCited in: Definition, Classification & Nomenclature - [55]
Rotman Y, Noureddin M, Feld JJ et al.. “Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.” Gut (2013). PMID: 23396509 ↗
L1RCTCited in: Pathophysiology & Mechanism, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History - [56]
Nieters A, Kallinowski B, Brennan P et al.. “Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH.” Gastroenterology (2006). PMID: 17087949 ↗
L3CASE_CONTROLCited in: Pathophysiology & Mechanism, History and Evolution of Treatment, Complications - [57]
Zeuzem S, Flisiak R, Vierling JM et al.. “Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).” Alimentary pharmacology & therapeutics (2015). PMID: 26238707 ↗
L1RCTCited in: Pathophysiology & Mechanism, Acute Management, History and Evolution of Treatment - [58]
Ashktorab H, Kupfer SS, Brim H et al.. “Racial Disparity in Gastrointestinal Cancer Risk.” Gastroenterology (2017). PMID: 28807841 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History, Prevention, Screening & Surveillance - [59]
Marra F, Tacke F. “Roles for chemokines in liver disease.” Gastroenterology (2014). PMID: 25066692 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Prognosis & Natural History - [60]
Tran CS, Kersten J, Yan J et al.. “Phosphatidylinositol 4-Kinase III Alpha Governs Cytoskeletal Organization for Invasiveness of Liver Cancer Cells.” Gastroenterology (2024). PMID: 38636680 ↗
L5OTHERCited in: Pathophysiology & Mechanism - [61]
Betrapally NS, Gillevet PM, Bajaj JS. “Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?” Gastroenterology (2016). PMID: 26948887 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [62]
Zhang X, Klöhn M, Ouwerkerk-Mahadevan S et al.. “A Pangenotypic Hepatitis E Virus Replication Inhibitor With High Potency in a Rat Infection Model.” Gastroenterology (2024). PMID: 39581510 ↗
L5OTHERCited in: Pathophysiology & Mechanism - [63]
Balagopal A, Philp FH, Astemborski J et al.. “Human immunodeficiency virus-related microbial translocation and progression of hepatitis C.” Gastroenterology (2008). PMID: 18457674 ↗
L2OTHERCited in: Pathophysiology & Mechanism - [64]
Zeisel MB, Dhawan P, Baumert TF. “Tight junction proteins in gastrointestinal and liver disease.” Gut (2018). PMID: 30297438 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Medical Management, Special Populations & Pregnancy - [65]
Kelly C, Klenerman P, Barnes E. “Interferon lambdas: the next cytokine storm.” Gut (2011). PMID: 21303914 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Special Populations & Pregnancy - [66]
Klenerman P, Thimme R. “T cell responses in hepatitis C: the good, the bad and the unconventional.” Gut (2011). PMID: 21873736 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [67]
Jühling F, Hamdane N, Crouchet E et al.. “Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.” Gut (2020). PMID: 32217639 ↗
L4OTHERCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification (GI Scores), Complications, Prevention, Screening & Surveillance - [68]
Calvaruso V, Maimone S, Gatt A et al.. “Coagulation and fibrosis in chronic liver disease.” Gut (2008). PMID: 19022928 ↗
L5OTHERCited in: Pathophysiology & Mechanism - [69]
Svegliati-Baroni G, Faraci G, Fabris L et al.. “Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C.” Gut (2010). PMID: 20966027 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [70]
Bridge SH, Sheridan DA, Felmlee DJ et al.. “Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection.” Gut (2010). PMID: 20940286 ↗
L4OTHERCited in: Pathophysiology & Mechanism - [71]
Nattermann J, Feldmann G, Ahlenstiel G et al.. “Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C.” Gut (2005). PMID: 16322112 ↗
L3OTHERCited in: Pathophysiology & Mechanism - [72]
Monto A, Schooley RT, Lai JC et al.. “Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop.” The American journal of gastroenterology (2010). PMID: 20087331 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification (GI Scores), Long-term & Definitive Medical Management, Special Populations & Pregnancy - [73]
Aigner E, Strasser M, Haufe H et al.. “A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease.” The American journal of gastroenterology (2010). PMID: 20407430 ↗
L3OTHERCited in: Pathophysiology & Mechanism - [74]
Carmack S, Taddei T, Robert ME et al.. “Increased T-cell sinusoidal lymphocytosis in liver biopsies in patients with chronic hepatitis C and mixed cryoglobulinemia.” The American journal of gastroenterology (2007). PMID: 17970837 ↗
L3OTHERCited in: Pathophysiology & Mechanism - [75]
Baffy G. “The impact of network medicine in gastroenterology and hepatology.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 23932906 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [76]
Forde KA, Tanapanpanit O, Reddy KR. “Hepatitis B and C in African Americans: current status and continued challenges.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 23811241 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, History and Evolution of Treatment, Complications, Prognosis & Natural History, Special Populations & Pregnancy - [77]
Martyak LA, Yeganeh M, Saab S. “Hepatitis C and lymphoproliferative disorders: from mixed cryoglobulinemia to non-Hodgkin's lymphoma.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2009). PMID: 19362606 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management, Special Populations & Pregnancy - [78]
Álvares-da-Silva MR, Oliveira CP, Fagan A et al.. “Interaction of Microbiome, Diet, and Hospitalizations Between Brazilian and American Patients With Cirrhosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 33813071 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification (GI Scores) - [79]
Jacobson IM, Cacoub P, Dal Maso L et al.. “Manifestations of chronic hepatitis C virus infection beyond the liver.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2010). PMID: 20870037 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [80]
Lindsay KL, Morishima C, Wright EC et al.. “Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2008). PMID: 18237873 ↗
L2OTHERCited in: Pathophysiology & Mechanism - [81]
Hanouneh IA, Feldstein AE, Lopez R et al.. “Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2008). PMID: 18455698 ↗
L2OTHERCited in: Pathophysiology & Mechanism - [82]
Hussain MM, Feng B, Wang JM et al.. “Recent Advancements in Known and Emerging Risk Factors of Hepatocellular Carcinoma.” Cancer medicine (2025). PMID: 41201177 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism, Complications - [83]
Weksler BB. “Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease.” Alimentary pharmacology & therapeutics (2007). PMID: 17958515 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [84]
Blonsky JJ, Harrison SA. “Review article: nonalcoholic fatty liver disease and hepatitis C virus--partners in crime.” Alimentary pharmacology & therapeutics (2008). PMID: 18315584 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Complications - [85]
Helmy A. “Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome.” Alimentary pharmacology & therapeutics (2006). PMID: 16393276 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [86]
Luo M, Hou J, Mai H et al.. “TRIM26 inhibits hepatitis B virus replication by promoting HBx degradation and TRIM26 genetic polymorphism predicts PegIFNα treatment response of HBeAg-positive chronic hepatitis B Patients.” Alimentary pharmacology & therapeutics (2022). PMID: 35872575 ↗
L2OTHERCited in: Pathophysiology & Mechanism - [87]
Lattanzi B, Baroncelli S, De Santis A et al.. “Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients.” Alimentary pharmacology & therapeutics (2018). PMID: 30294870 ↗
L2OTHERCited in: Pathophysiology & Mechanism - [88]
de Gottardi A, Pazienza V, Pugnale P et al.. “Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection.” Alimentary pharmacology & therapeutics (2006). PMID: 16393287 ↗
L3OTHERCited in: Pathophysiology & Mechanism - [89]
Tsochatzis E, Manolakopoulos S, Papatheodoridis GV et al.. “Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study.” Alimentary pharmacology & therapeutics (2009). PMID: 19604179 ↗
L3OTHERCited in: Pathophysiology & Mechanism - [90]
Durante-Mangoni E, Zampino R, Marrone A et al.. “Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients.” Alimentary pharmacology & therapeutics (2006). PMID: 17059516 ↗
L3OTHERCited in: Pathophysiology & Mechanism - [91]
Anty R, Marjoux S, Bekri S et al.. “Plasma carnitine is associated with fatigue in chronic hepatitis C but not in the irritable bowel syndrome.” Alimentary pharmacology & therapeutics (2011). PMID: 21366633 ↗
L3OTHERCited in: Pathophysiology & Mechanism - [92]
Benstead TJ, Chalk CH, Parks NE. “Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection.” The Cochrane database of systematic reviews (2014). PMID: 25525951 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Special Populations & Pregnancy - [93]
Suenghataiphorn T, Tribhuddharat N, Danpanichkul P et al.. “Hepatitis C increases acute myocardial infarction risk in people living with HIV: A systematic review and meta-analysis.” International journal of STD & AIDS (2025). PMID: 40500997 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism - [94]
Arefinia N, Askarpour H, Ghoreshi ZA et al.. “The global prevalence of co-occurrence of Sjögren syndrome and Hepatitis C virus infection: A systematic review and meta-analysis.” Virus research (2025). PMID: 40374124 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism - [95]
Conell-Price J. “Neurologic Manifestations of Hepatic and Gastrointestinal Disease.” Continuum (Minneapolis, Minn.) (2026). PMID: 41631918 ↗
L5CASE_REPORTCited in: Pathophysiology & Mechanism - [96]
Ferreira J, Caldeira J, Bicho M et al.. “Hepatitis C Virus: An Overview of Its Chronic Impact on Liver Function, Metabolic Dysregulation, Inflammatory-Oxidative Pathogenesis and Epigenetic Memory.” International journal of molecular sciences (2026). PMID: 42074199 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [97]
Fiadjoe HK, Doyle A, Park IW et al.. “Hepatitis C Virus (HCV)-Mediated Activation of Hexokinase Domain-Containing Protein 1 (HKDC1) Promotes Hexokinase Activity and Metabolic Reprogramming.” Viruses (2026). PMID: 42043212 ↗
L5OTHERCited in: Pathophysiology & Mechanism - [98]
Pei S, Shi F, Li Q et al.. “Impact of greenhouse gases and air pollutants on the incidence and mortality of HBV and HCV in China.” Frontiers in public health (2026). PMID: 42040115 ↗
L2OTHERCited in: Pathophysiology & Mechanism - [99]
Doratt BM, True HE, Wagner SB et al.. “Maternal opioid use disorder and hepatitis C infection in pregnancy reshape the peripheral immune landscape at term.” EBioMedicine (2026). PMID: 41849830 ↗
L3OTHERCited in: Pathophysiology & Mechanism - [100]
Oringher JL, Afruza R, Chakraborty M et al.. “Portal Vein Tryptophan Pathway Analysis Reveals Gut-Mediated Inflammatory Pathway Predominance in HCV Infection.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 41804293 ↗
L2OTHERCited in: Pathophysiology & Mechanism - [101]
Carloni G, Rinaldi M. “Mechanisms and Therapeutic Strategies for HCV/HBV-Associated B-Cell Non-Hodgkin's Lymphomas: A Viewpoint.” Oncology research (2026). PMID: 41799526 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [102]
Sherman KE, Goodman ZD, Sullivan ST et al.. “Liver biopsy in cirrhotic patients.” The American journal of gastroenterology (2007). PMID: 17324127 ↗
L4RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Special Populations & Pregnancy - [103]
Page K, Melia MT, Veenhuis RT et al.. “Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection.” The New England journal of medicine (2021). PMID: 33567193 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prevention, Screening & Surveillance - [104]
Feld JJ, Jacobson IM, Hézode C et al.. “Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.” The New England journal of medicine (2015). PMID: 26571066 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History - [105]
Poordad F, McCone J, Bacon BR et al.. “Boceprevir for untreated chronic HCV genotype 1 infection.” The New England journal of medicine (2011). PMID: 21449783 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History - [106]
Jacobson IM, McHutchison JG, Dusheiko G et al.. “Telaprevir for previously untreated chronic hepatitis C virus infection.” The New England journal of medicine (2011). PMID: 21696307 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors - [107]
Lok AS, Gardiner DF, Lawitz E et al.. “Preliminary study of two antiviral agents for hepatitis C genotype 1.” The New England journal of medicine (2012). PMID: 22256805 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors - [108]
Younossi Z, Park H, Henry L et al.. “Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden.” Gastroenterology (2016). PMID: 26924097 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [109]
Petta S, Maida M, Macaluso FS et al.. “Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies.” Gastroenterology (2015). PMID: 26386298 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History - [110]
Manns M, Pol S, Jacobson IM et al.. “All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.” Lancet (London, England) (2014). PMID: 25078304 ↗
L2RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History - [111]
Roth D, Nelson DR, Bruchfeld A et al.. “Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.” Lancet (London, England) (2015). PMID: 26456905 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, Prognosis & Natural History - [112]
Cacoub P, Desbois AC, Comarmond C et al.. “Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis.” Gut (2018). PMID: 29703790 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations & Pregnancy - [113]
Shaheen AA, Wan AF, Myers RP. “FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy.” The American journal of gastroenterology (2007). PMID: 17850410 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [114]
Woolley AE, Singh SK, Goldberg HJ et al.. “Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.” The New England journal of medicine (2019). PMID: 30946553 ↗
L4TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors - [115]
Sanyal AJ, Fontana RJ, Di Bisceglie AM et al.. “The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis.” Gastrointestinal endoscopy (2006). PMID: 17140886 ↗
L2RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy - [116]
Premkumar M, Dhiman RK, Duseja A et al.. “Recompensation of Chronic Hepatitis C-Related Decompensated Cirrhosis Following Direct-Acting Antiviral Therapy: Prospective Cohort Study From a Hepatitis C Virus Elimination Program.” Gastroenterology (2024). PMID: 39181168 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Complications, Prognosis & Natural History, Special Populations & Pregnancy - [117]
El-Khoueiry AB, Sangro B, Yau T et al.. “Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.” Lancet (London, England) (2017). PMID: 28434648 ↗
L4TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications, Prognosis & Natural History, Special Populations & Pregnancy - [118]
Kohli A, Osinusi A, Sims Z et al.. “Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.” Lancet (London, England) (2015). PMID: 25591505 ↗
L2TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Long-term & Definitive Medical Management - [119]
Tansel A, Katz LH, El-Serag HB et al.. “Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2017). PMID: 28215616 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance - [120]
de Sanjose S, Benavente Y, Vajdic CM et al.. “Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2008). PMID: 18387498 ↗
L3SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy - [121]
Zeng RW, Ong CEY, Ong EYH et al.. “Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular Carcinoma.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 38987014 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Prognosis & Natural History, Prevention, Screening & Surveillance - [122]
Haridy J, Iyngkaran G, Nicoll A et al.. “eHealth Technologies for Screening, Diagnosis, and Management of Viral Hepatitis: A Systematic Review.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2020). PMID: 32896632 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance - [123]
Liu Z, Mao X, Wu J et al.. “World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 31683059 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [124]
Nelson PK, Mathers BM, Cowie B et al.. “Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.” Lancet (London, England) (2011). PMID: 21802134 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [125]
Lodwick RK, Sabin CA, Porter K et al.. “Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.” Lancet (London, England) (2010). PMID: 20638118 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History - [126]
Carrat F, Fontaine H, Dorival C et al.. “Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.” Lancet (London, England) (2019). PMID: 30765123 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [127]
Mikhail NN, Lewis DL, Omar N et al.. “Prospective study of cross-infection from upper-GI endoscopy in a hepatitis C-prevalent population.” Gastrointestinal endoscopy (2007). PMID: 17210152 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [128]
Henriot P, Castry M, Luong Nguyen LB et al.. “Meta-analysis: risk of hepatitis C virus infection associated with hospital-based invasive procedures.” Alimentary pharmacology & therapeutics (2022). PMID: 35758763 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [129]
Wang CC, Cheng PN, Kao JH. “Systematic review: chronic viral hepatitis and metabolic derangement.” Alimentary pharmacology & therapeutics (2019). PMID: 31746482 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [130]
Eslam M, Aparcero R, Kawaguchi T et al.. “Meta-analysis: insulin resistance and sustained virological response in hepatitis C.” Alimentary pharmacology & therapeutics (2011). PMID: 21623851 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Long-term & Definitive Medical Management, Prognosis & Natural History, Special Populations & Pregnancy - [131]
Mettikanont P, Bunchorntavakul C, Reddy KR. “Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection.” Alimentary pharmacology & therapeutics (2019). PMID: 30687952 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History - [132]
Kulik L, El-Serag HB. “Epidemiology and Management of Hepatocellular Carcinoma.” Gastroenterology (2018). PMID: 30367835 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Complications, Special Populations & Pregnancy, Prevention, Screening & Surveillance - [133]
Negro F, Forton D, Craxì A et al.. “Extrahepatic morbidity and mortality of chronic hepatitis C.” Gastroenterology (2015). PMID: 26319013 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations & Pregnancy - [134]
Fujiwara N, Lopez C, Marsh TL et al.. “Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis.” Gastroenterology (2024). PMID: 39521255 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Special Populations & Pregnancy, Prevention, Screening & Surveillance - [135]
Reddy KR, McLerran D, Marsh T et al.. “Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study.” Gastroenterology (2023). PMID: 37429366 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Prevention, Screening & Surveillance - [136]
Besombes C, Njouom R, Paireau J et al.. “The epidemiology of hepatitis delta virus infection in Cameroon.” Gut (2020). PMID: 31907297 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [137]
Rüeger S, Bochud PY, Dufour JF et al.. “Impact of common risk factors of fibrosis progression in chronic hepatitis C.” Gut (2014). PMID: 25214320 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores) - [138]
Mostafa A, Mohamed MK, Saeed M et al.. “Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors.” Gut (2010). PMID: 20584782 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [139]
King LY, Canasto-Chibuque C, Johnson KB et al.. “A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration.” Gut (2014). PMID: 25143343 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Complications - [140]
Younossi ZM, Stepanova M, Younossi Y et al.. “Epidemiology of chronic liver diseases in the USA in the past three decades.” Gut (2019). PMID: 31366455 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [141]
Fox JG, Feng Y, Theve EJ et al.. “Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens.” Gut (2010). PMID: 19850960 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors - [142]
Hsu YC, Ho HJ, Huang YT et al.. “Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection.” Gut (2014). PMID: 25398770 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management - [143]
Fischer J, Weber ANR, Böhm S et al.. “Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection.” Gut (2016). PMID: 27196570 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications - [144]
Saab S, Jackson C, Nieto J et al.. “Hepatitis C in African Americans.” The American journal of gastroenterology (2014). PMID: 25178700 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prognosis & Natural History - [145]
Hunt DR, Saab S. “Viral hepatitis in incarcerated adults: a medical and public health concern.” The American journal of gastroenterology (2009). PMID: 19240708 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management, Prognosis & Natural History, Prevention, Screening & Surveillance - [146]
Baffy G. “Editorial: hepatocellular carcinoma in type 2 diabetes: more than meets the eye.” The American journal of gastroenterology (2012). PMID: 22218030 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance - [147]
Kramer JR, Cao Y, Li L et al.. “Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection.” The American journal of gastroenterology (2022). PMID: 36327437 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance - [148]
McHutchison JG, Manns MP, Brown RS et al.. “Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy.” The American journal of gastroenterology (2007). PMID: 17397412 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Medical Management, Special Populations & Pregnancy - [149]
Rich NE, Villanueva A, Marrero JA et al.. “AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review.” Gastroenterology (2026). PMID: 42017860 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance - [150]
Simon TG, Duberg AS, Aleman S et al.. “Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality.” The New England journal of medicine (2020). PMID: 32160663 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications - [151]
Arora S, Thornton K, Murata G et al.. “Outcomes of treatment for hepatitis C virus infection by primary care providers.” The New England journal of medicine (2011). PMID: 21631316 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [152]
Moon AM, Singal AG, Tapper EB. “Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 31401364 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Prevention, Screening & Surveillance - [153]
Semmler G, Lens S, Hidalgo Á et al.. “Incidence and Clinical Significance of Recompensation After HCV Cure.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40378989 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations & Pregnancy - [154]
Spearman CW, Dusheiko GM, Hellard M et al.. “Hepatitis C.” Lancet (London, England) (2019). PMID: 31631857 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [155]
Abebe AD, Tassew WC, Zeleke AM et al.. “Seroprevalence of Hepatitis B and C Viral Infections Among Patients With Diabetes Mellitus in Africa: A Systematic Review and Meta-Analysis.” Journal of the International Association of Providers of AIDS Care (2026). PMID: 42249266 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prognosis & Natural History, Prevention, Screening & Surveillance - [156]
Beddard EK, Kassa GM, Walker JG et al.. “Seroprevalence of hepatitis C virus among refugees, asylum seekers, and internally displaced populations within Africa: A systematic review and meta-analysis.” Global public health (2026). PMID: 41964104 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [157]
Koenig AB, Tan A, Abdelaal H et al.. “Review article: Hepatic steatosis and its associations with acute and chronic liver diseases.” Alimentary pharmacology & therapeutics (2024). PMID: 38845486 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [158]
Koff RS. “Review article: vaccination and viral hepatitis - current status and future prospects.” Alimentary pharmacology & therapeutics (2007). PMID: 17868433 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy, Prevention, Screening & Surveillance - [159]
Vutien P, Kim NJ, Moon AM et al.. “Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication.” Alimentary pharmacology & therapeutics (2023). PMID: 37955206 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance - [160]
Allen AM, Hay JE. “Review article: the management of cirrhosis in women.” Alimentary pharmacology & therapeutics (2014). PMID: 25263269 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Complications, Prognosis & Natural History, Special Populations & Pregnancy - [161]
Platt L, Minozzi S, Reed J et al.. “Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.” The Cochrane database of systematic reviews (2017). PMID: 28922449 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Long-term & Definitive Medical Management, History and Evolution of Treatment - [162]
Huttman M, Parigi TL, Zoncapè M et al.. “Liver fibrosis stage based on the four factors (FIB-4) score or Forns index in adults with chronic hepatitis C.” The Cochrane database of systematic reviews (2024). PMID: 39136280 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores) - [163]
Bravo Zuñiga JI, Loza Munárriz C, López-Alcalde J. “Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units.” The Cochrane database of systematic reviews (2016). PMID: 27513591 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [164]
Palmer A, Carter M, Yeo J et al.. “Hospital-Admitted Injection-Related Infections Among Incarcerated People Who Inject Drugs in Australia: A Retrospective Cohort Study.” The Medical journal of Australia (2026). PMID: 42289398 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance - [165]
Yan L, Wubuliaishan M, Kou X et al.. “Efficacy and Safety of 12-Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi-Center Prospective Study.” Journal of medical virology (2026). PMID: 42159424 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations & Pregnancy - [166]
Park Y, Kim BW, Oh JK et al.. “Risk of Intrahepatic and Extrahepatic Cancers in Hepatitis C Virus Infection: A Nationwide Cohort Study in Korea, 2005-2023.” Liver international : official journal of the International Association for the Study of the Liver (2026). PMID: 42084000 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Complications, Prognosis & Natural History, Special Populations & Pregnancy - [167]
Chauhan A, Sinha A, Patel Y et al.. “Viral hepatitis co-infections with tuberculosis in India: A systematic review and meta-analysis.” The Indian journal of medical research (2026). PMID: 42295712 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [168]
Diniz Gomes Bugano D, Batista EC, Fernandes I et al.. “Real-World Epidemiology, Treatment Patterns, and Outcomes of Hepatocellular Carcinoma in Brazil: A Multicenter Retrospective Study.” JCO global oncology (2026). PMID: 42341247 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Endoscopic & Procedural Management, Special Populations & Pregnancy - [169]
Kleiner BB, Meconnen M, Azar M et al.. “Incidence of HIV and HCV Among People Who Inject Drugs in Montreal, Canada: Data From the HEPCO Longitudinal Cohort Study, 2011-2025.” Journal of viral hepatitis (2026). PMID: 42141790 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [170]
Liu CJ, Chuang WL, Sheen IS et al.. “Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.” Gastroenterology (2017). PMID: 29174546 ↗
L4TRIAL_NONRANDOMCited in: Clinical Presentation - [171]
Chalasani N, Fontana RJ, Bonkovsky HL et al.. “Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.” Gastroenterology (2008). PMID: 18955056 ↗
L4COHORTCited in: Clinical Presentation - [172]
Terrier B, Saadoun D, Sène D et al.. “Presentation and outcome of gastrointestinal involvement in hepatitis C virus-related systemic vasculitis: a case-control study from a single-centre cohort of 163 patients.” Gut (2010). PMID: 20841367 ↗
L3CASE_CONTROLCited in: Clinical Presentation, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Complications, Prognosis & Natural History - [173]
Tillmann HL, Thompson AJ, Patel K et al.. “A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice.” Gastroenterology (2010). PMID: 20637200 ↗
L2OTHERCited in: Clinical Presentation - [174]
Smith MW, Walters KA, Korth MJ et al.. “Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients.” Gastroenterology (2006). PMID: 16401481 ↗
L4OTHERCited in: Clinical Presentation - [175]
Belcher JM, Parikh CR, Garcia-Tsao G. “Acute kidney injury in patients with cirrhosis: perils and promise.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 23583467 ↗
L4CASE_REPORTCited in: Clinical Presentation, Complications - [176]
El-Serag HB, Kramer JR, Chen GJ et al.. “Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA.” Gut (2011). PMID: 21257990 ↗
L2OTHERCited in: Clinical Presentation, Prevention, Screening & Surveillance - [177]
Hutchinson SJ, Valerio H, McDonald SA et al.. “Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.” Gut (2020). PMID: 32217640 ↗
L2OTHERCited in: Clinical Presentation, Prevention, Screening & Surveillance - [178]
Cheng JT, Hsien C, Sun HE et al.. “The emerging importance of chronic hepatitis C infection in Asian Americans.” The American journal of gastroenterology (2006). PMID: 17227521 ↗
L4OTHERCited in: Clinical Presentation - [179]
Bell BP, Manos MM, Zaman A et al.. “The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance.” The American journal of gastroenterology (2008). PMID: 18684170 ↗
L2OTHERCited in: Clinical Presentation - [180]
Toyoda H, Kanneganti M, Melendez-Torres J et al.. “Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 37442316 ↗
L2OTHERCited in: Clinical Presentation - [181]
Karim MA, Singal AG, Kum HC et al.. “Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in the United States.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022). PMID: 35307595 ↗
L2OTHERCited in: Clinical Presentation - [182]
Yopp AC, Subramanian M, Jain MK et al.. “Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2012). PMID: 22902759 ↗
L2OTHERCited in: Clinical Presentation - [183]
Lazo M, Nwankwo C, Daya NR et al.. “Confluence of Epidemics of Hepatitis C, Diabetes, Obesity, and Chronic Kidney Disease in the United States Population.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2017). PMID: 28579183 ↗
L2OTHERCited in: Clinical Presentation - [184]
Wang X, Cao Y, Guo J et al.. “Association between MTTP genotype (-493G/T) polymorphism and hepatic steatosis in hepatitis C: a systematic review and meta-analysis.” Lipids in health and disease (2023). PMID: 37726765 ↗
L3SR_OBSCited in: Clinical Presentation - [185]
Nilsson E, Anderson H, Sargenti K et al.. “Incidence, clinical presentation and mortality of liver cirrhosis in Southern Sweden: a 10-year population-based study.” Alimentary pharmacology & therapeutics (2016). PMID: 27091240 ↗
L2OTHERCited in: Clinical Presentation - [186]
Bucci L, Garuti F, Camelli V et al.. “Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome.” Alimentary pharmacology & therapeutics (2015). PMID: 26662476 ↗
L2OTHERCited in: Clinical Presentation, Prevention, Screening & Surveillance - [187]
Loomba R, Rivera MM, McBurney R et al.. “The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes.” Alimentary pharmacology & therapeutics (2010). PMID: 21198704 ↗
L4OTHERCited in: Clinical Presentation, Severity, Staging & Risk Stratification (GI Scores) - [188]
Floreani A, Niro G, Rosa Rizzotto E et al.. “Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study.” Alimentary pharmacology & therapeutics (2006). PMID: 16984499 ↗
L2OTHERCited in: Clinical Presentation - [189]
Sobnach S, Emmamally M, Venter K et al.. “Presentation, treatment and long-term outcomes of hepatocellular carcinoma in patients with and without HIV: a comparative observational cohort study.” HPB : the official journal of the International Hepato Pancreato Biliary Association (2025). PMID: 40044535 ↗
L2COHORTCited in: Clinical Presentation - [190]
Zou J, Li H, Deng G et al.. “A novel prognostic nomogram for older patients with acute-on-chronic liver diseases (AoCLD): a nationwide, multicentre, prospective cohort study.” Age and ageing (2023). PMID: 36626326 ↗
L2COHORTCited in: Clinical Presentation - [191]
Yin W, Zeng T, Ren C et al.. “Impact of KIR3DL1/3DS1 and HLA-B polymorphisms on hepatitis C virus infection: a case-control study.” Frontiers in cellular and infection microbiology (2026). PMID: 42205473 ↗
L3CASE_CONTROLCited in: Clinical Presentation, Special Populations & Pregnancy - [192]
Abdelmoneim RS, Sedki F, Bakosh MF. “Changes in the presentation and characteristics OF HCV related hepatocellular carcinoma in the era of direct acting antiviral therapy: A retrospective study.” Clinics and research in hepatology and gastroenterology (2025). PMID: 40043794 ↗
L2COHORTCited in: Clinical Presentation - [193]
Pan YJ, Chen RY, Ai YQ et al.. “Histopathological features and eight-week split-tablet sofosbuvir/velpatasvir treatment in young children with acute hepatitis C: a case-series study.” BMC infectious diseases (2026). PMID: 41618197 ↗
L4CASE_REPORTCited in: Clinical Presentation - [194]
Gao YH, Yu M, Wang LN et al.. “A retrospective case series of amebic colitis clinical features at a tertiary hospital in Beijing from 2021 to 2024.” BMC infectious diseases (2025). PMID: 41204402 ↗
L4CASE_REPORTCited in: Clinical Presentation - [195]
Di Bisceglie AM, Shiffman ML, Everson GT et al.. “Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.” The New England journal of medicine (2008). PMID: 19052125 ↗
L1RCTCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Complications - [196]
Charlton M, Gane E, Manns MP et al.. “Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.” Gastroenterology (2014). PMID: 25304641 ↗
L4TRIAL_NONRANDOMCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [197]
Llibre A, Shimakawa Y, Mottez E et al.. “Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.” Gut (2018). PMID: 29615488 ↗
L4TRIAL_NONRANDOMCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores) - [198]
Rasko JEJ, Samelson-Jones BJ, George LA et al.. “Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study.” The New England journal of medicine (2025). PMID: 40239068 ↗
L4TRIAL_NONRANDOMCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), Complications, Prevention, Screening & Surveillance - [199]
Kim NJ, Vutien P, Cleveland E et al.. “Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022). PMID: 35525392 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prognosis & Natural History - [200]
Singh S, Facciorusso A, Loomba R et al.. “Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2017). PMID: 28479504 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [201]
Singh S, Venkatesh SK, Wang Z et al.. “Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2014). PMID: 25305349 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [202]
Singh S, Fujii LL, Murad MH et al.. “Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 23954643 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores) - [203]
Singh P, Erickson RA, Mukhopadhyay P et al.. “EUS for detection of the hepatocellular carcinoma: results of a prospective study.” Gastrointestinal endoscopy (2007). PMID: 17543307 ↗
L2COHORTCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Pregnancy - [204]
Patel K, Tillmann HL, Matta B et al.. “Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.” Alimentary pharmacology & therapeutics (2015). PMID: 26560052 ↗
L2TRIAL_NONRANDOMCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [205]
Sepúlveda-Crespo D, Treviño-Nakoura A, Bellon JM et al.. “Meta-analysis: diagnostic accuracy of hepatitis C core antigen detection during therapy with direct-acting antivirals.” Alimentary pharmacology & therapeutics (2022). PMID: 36031747 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Pregnancy - [206]
Oriolo G, Egmond E, Mariño Z et al.. “Systematic review with meta-analysis: neuroimaging in hepatitis C chronic infection.” Alimentary pharmacology & therapeutics (2018). PMID: 29536563 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [207]
Houot M, Ngo Y, Munteanu M et al.. “Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.” Alimentary pharmacology & therapeutics (2015). PMID: 26516104 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [208]
Smith JO, Sterling RK. “Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C.” Alimentary pharmacology & therapeutics (2009). PMID: 19519733 ↗
L5SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [209]
Fabrizi F, Lunghi G, Dixit V et al.. “Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients.” Alimentary pharmacology & therapeutics (2006). PMID: 17081162 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prognosis & Natural History, Special Populations & Pregnancy - [210]
Chen Y, Xu HX, Wang LJ et al.. “Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.” Alimentary pharmacology & therapeutics (2012). PMID: 22591106 ↗
L3SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [211]
Stölzel U, Doss MO, Schuppan D. “Clinical Guide and Update on Porphyrias.” Gastroenterology (2019). PMID: 31085196 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [212]
Castera L. “Noninvasive methods to assess liver disease in patients with hepatitis B or C.” Gastroenterology (2012). PMID: 22537436 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores) - [213]
Kim NJ, Li M, Vutien P et al.. “Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening.” Gastroenterology (2025). PMID: 41236449 ↗
L3OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prevention, Screening & Surveillance - [214]
Singh S, Muir AJ, Dieterich DT et al.. “American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases.” Gastroenterology (2017). PMID: 28442120 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores) - [215]
Machida K, Tsukiyama-Kohara K, Sekiguch S et al.. “Hepatitis C virus and disrupted interferon signaling promote lymphoproliferation via type II CD95 and interleukins.” Gastroenterology (2009). PMID: 19362089 ↗
L5OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [216]
Salas JH, Urbanowicz RA, Guest JD et al.. “An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development.” Gastroenterology (2021). PMID: 34655573 ↗
L5OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores) - [217]
Maylin S, Martinot-Peignoux M, Moucari R et al.. “Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.” Gastroenterology (2008). PMID: 18593587 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [218]
Chen F, Nagy K, Chavez D et al.. “Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development.” Gastroenterology (2019). PMID: 31809725 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [219]
Nahon P, Bourcier V, Layese R et al.. “Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.” Gastroenterology (2016). PMID: 27641509 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [220]
Vo-Quang E, Pawlotsky JM. “'Unusual' HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment.” Gut (2024). PMID: 38782565 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [221]
Marchi E, Ramamurthy N, Ansari MA et al.. “Defining the key intrahepatic gene networks in HCV infection driven by sex.” Gut (2022). PMID: 35613843 ↗
L4OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Pregnancy - [222]
Bankwitz D, Bahai A, Labuhn M et al.. “Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies.” Gut (2020). PMID: 33323394 ↗
L4OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [223]
San Miguel R, Gimeno-Ballester V, Blázquez A et al.. “Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C.” Gut (2014). PMID: 25311032 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [224]
Nahon P, Lescat M, Layese R et al.. “Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort).” Gut (2015). PMID: 26511797 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores) - [225]
Chakass D, Philippe D, Erdual E et al.. “micro-Opioid receptor activation prevents acute hepatic inflammation and cell death.” Gut (2007). PMID: 17299060 ↗
L5OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [226]
Kappelman MD, Dorn SD, Peterson E et al.. “Quality of care for gastrointestinal conditions: a primer for gastroenterologists.” The American journal of gastroenterology (2011). PMID: 21731014 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [227]
Lai M, Afdhal NH. “Editorial: staging liver fibrosis in hepatitis C: a challenge for this decade.” The American journal of gastroenterology (2011). PMID: 22138940 ↗
L5OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [228]
Thabut D, Le Calvez S, Thibault V et al.. “Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?” The American journal of gastroenterology (2006). PMID: 16771947 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores) - [229]
Barritt AS, Barnhart H, Gu J et al.. “When Is Suspected Drug-Induced Liver Injury (DILI) Not DILI? An Analysis of Unlikely Cases From the Drug-Induced Liver Injury Network.” The American journal of gastroenterology (2023). PMID: 37311048 ↗
L2REVIEW_NARRATIVECited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [230]
Guido M, Bortolotti F, Jara P et al.. “Liver steatosis in children with chronic hepatitis C.” The American journal of gastroenterology (2006). PMID: 17090284 ↗
L4OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [231]
Torres DM, Harrison SA. “Killing two birds with one stone: screening for chronic hepatitis C at the time of colonoscopy in the baby boomer cohort.” The American journal of gastroenterology (2013). PMID: 23735918 ↗
L5OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prevention, Screening & Surveillance - [232]
Taura N, Ichikawa T, Hamasaki K et al.. “Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients.” The American journal of gastroenterology (2006). PMID: 17026566 ↗
L4OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [233]
Liu K, Wong VW, Lau K et al.. “Prognostic Value of Controlled Attenuation Parameter by Transient Elastography.” The American journal of gastroenterology (2017). PMID: 29087391 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [234]
Stepens A, Logina I, Liguts V et al.. “A Parkinsonian syndrome in methcathinone users and the role of manganese.” The New England journal of medicine (2008). PMID: 18322282 ↗
L4OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [235]
Harrison SA. “Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2008). PMID: 18585970 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [236]
Chhatwal J, Hajjar A, Mueller PP et al.. “Hepatocellular Carcinoma Incidence Threshold for Surveillance in Virologically Cured Hepatitis C Individuals.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 37302445 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), History and Evolution of Treatment, Prevention, Screening & Surveillance - [237]
Allen AM, Kim WR, Larson J et al.. “Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 23891915 ↗
L4OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [238]
Unalp-Arida A, Ruhl CE. “Transient Elastography-Assessed Hepatic Steatosis and Fibrosis Are Associated With Body Composition in the United States.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 33549867 ↗
L4OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [239]
Nabi E, Thacker LR, Wade JB et al.. “Diagnosis of covert hepatic encephalopathy without specialized tests.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 24362049 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [240]
Goyal RM, Doshi A, Rao S et al.. “Epidemiology of Compensated Advanced Chronic Liver Disease (cACLD) in the United States: Insights From the National Health and Nutrition Examination Survey, 2017-2020.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40581070 ↗
L4OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [241]
Whitcomb E, Choi WT, Jerome KR et al.. “Biopsy Specimens From Allograft Liver Contain Histologic Features of Hepatitis C Virus Infection After Virus Eradication.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2017). PMID: 28501538 ↗
L4OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [242]
Tayob N, Lok AS, Do KA et al.. “Improved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2015). PMID: 26260109 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [243]
Heffernan A, Cooke GS, Nayagam S et al.. “Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.” Lancet (London, England) (2019). PMID: 30704789 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), History and Evolution of Treatment, Special Populations & Pregnancy, Prevention, Screening & Surveillance - [244]
Madeira HS, Brustolin AÁ, Almeida MEDS et al.. “Improved Safety of Nucleic Acid Amplification Technology Combined With Serological Tests for Screening Blood Donors: A Systematic Review and Meta-Analysis.” Reviews in medical virology (2026). PMID: 41722066 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prevention, Screening & Surveillance - [245]
Kumburegama BWMB, Kristensen AT, Bjelakovic G et al.. “Direct-acting antivirals for chronic hepatitis C infection: a protocol for a systematic review of observational studies.” Systematic reviews (2026). PMID: 41618440 ↗
L5SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Complications - [246]
Zhang JZ, Zheng J, Zhang YP et al.. “The impact of chronic hepatitis B and chronic hepatitis C on sexual function: a systematic review and meta-analysis.” Reproductive health (2025). PMID: 41454412 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [247]
Leber W, Farooq HZ, Panovska-Griffiths J et al.. “Risk prediction models for targeted testing of HIV, hepatitis B and hepatitis C: a systematic review and meta-analysis.” BMC infectious diseases (2025). PMID: 41291465 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores) - [248]
Adepoju VA, Abdulrahim A, Udah DC et al.. “Prevalence and risk factors of hepatitis B and C among prison inmates in Nigeria: a systematic review and meta-analysis.” BMC public health (2025). PMID: 41286768 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [249]
Barnard Giustini A, Ioannou GN, Sirlin C et al.. “Review article: Available modalities for screening and imaging diagnosis of hepatocellular carcinoma-Current gaps and challenges.” Alimentary pharmacology & therapeutics (2023). PMID: 37038283 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [250]
Economides MP, Mahale P, Kyvernitakis A et al.. “Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer.” Alimentary pharmacology & therapeutics (2016). PMID: 27730654 ↗
L4OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [251]
Koretz RL, Pleguezuelo M, Arvaniti V et al.. “Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.” The Cochrane database of systematic reviews (2013). PMID: 23440791 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Complications - [252]
Lamers MH, Broekman M, Drenth JP et al.. “Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.” The Cochrane database of systematic reviews (2014). PMID: 24937404 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [253]
Lombardi R, Onali S, Thorburn D et al.. “Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.” The Cochrane database of systematic reviews (2017). PMID: 28358980 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [254]
Colli A, Gana JC, Yap J et al.. “Platelet count, spleen length, and platelet count-to-spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis.” The Cochrane database of systematic reviews (2017). PMID: 28444987 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Complications - [255]
Li PS, Yang GD, Huang XN et al.. “Impact of sustained virological response on prognosis after hepatectomy for hepatitis C-related hepatocellular carcinoma: a retrospective cohort study.” BMC infectious diseases (2026). PMID: 41593527 ↗
L3COHORTCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [256]
Asmundo L, Mercaldo N, Furtado F et al.. “A multicenter multinational retrospective study of the 1-year natural history of LI-RADS 3 observations in patients with cirrhosis.” European radiology (2026). PMID: 41493547 ↗
L3COHORTCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Complications - [257]
Jaberi N, Afshari S, Khalili F et al.. “Cost-effectiveness of sofosbuvir- ledipasvir for Hepatitis C treatment: a systematic review.” European journal of clinical pharmacology (2026). PMID: 41942791 ↗
L2SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), History and Evolution of Treatment - [258]
Silveira IB, Silva GP, Sampaio AVH et al.. “Synchronous Telemedicine Versus In-Person Care in Hepatitis C Treatment: A Systematic Review and Meta-Analysis.” Journal of viral hepatitis (2026). PMID: 41603321 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [259]
Naderi M, Kordkatuli K, Makokha GN et al.. “The Prevalence and Risk Factors of Hepatitis B, Hepatitis C, and Hepatitis D Coinfection in Iran's General Population Over the Past 25 Years: A Systematic Review and Meta-Analysis.” Journal of epidemiology and global health (2025). PMID: 41455870 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs) - [260]
Grieve R, Roberts J, Wright M et al.. “Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.” Gut (2005). PMID: 15994216 ↗
L2RCTCited in: Severity, Staging & Risk Stratification (GI Scores), Acute Management, Complications - [261]
Leandro G, Mangia A, Hui J et al.. “Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.” Gastroenterology (2006). PMID: 16697727 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification (GI Scores) - [262]
Lawitz E, Sulkowski MS, Ghalib R et al.. “Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.” Lancet (London, England) (2014). PMID: 25078309 ↗
L1RCTCited in: Severity, Staging & Risk Stratification (GI Scores) - [263]
Foucher J, Chanteloup E, Vergniol J et al.. “Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study.” Gut (2005). PMID: 16020491 ↗
L2COHORTCited in: Severity, Staging & Risk Stratification (GI Scores), Complications - [264]
Lai SW, Chen PC, Liao KF et al.. “Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.” The American journal of gastroenterology (2011). PMID: 22085817 ↗
L3COHORTCited in: Severity, Staging & Risk Stratification (GI Scores) - [265]
Singal AK, Singh A, Jaganmohan S et al.. “Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2009). PMID: 19879972 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification (GI Scores), Long-term & Definitive Medical Management - [266]
Kim RG, Loomba R, Prokop LJ et al.. “Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2017). PMID: 28479502 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification (GI Scores), Complications, Prognosis & Natural History - [267]
Bravi F, Bosetti C, Tavani A et al.. “Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 23660416 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification (GI Scores), History and Evolution of Treatment, Prevention, Screening & Surveillance - [268]
Jiang HY, Deng M, Zhang YH et al.. “Specific serotonin reuptake inhibitors prevent interferon-α-induced depression in patients with hepatitis C: a meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 23648373 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification (GI Scores), Long-term & Definitive Medical Management - [269]
White DL, Kanwal F, El-Serag HB. “Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2012). PMID: 23041539 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification (GI Scores), History and Evolution of Treatment - [270]
Myojin Y, Hikita H, Tahata Y et al.. “Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.” Alimentary pharmacology & therapeutics (2021). PMID: 34812502 ↗
L3RCTCited in: Severity, Staging & Risk Stratification (GI Scores), Acute Management, History and Evolution of Treatment - [271]
Atsukawa M, Tsubota A, Toyoda H et al.. “The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.” Alimentary pharmacology & therapeutics (2019). PMID: 30873651 ↗
L2TRIAL_NONRANDOMCited in: Severity, Staging & Risk Stratification (GI Scores) - [272]
Schmidt F, Janssen G, Martin G et al.. “Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C.” Alimentary pharmacology & therapeutics (2009). PMID: 19691667 ↗
L2TRIAL_NONRANDOMCited in: Severity, Staging & Risk Stratification (GI Scores) - [273]
El-Serag HB. “Epidemiology of viral hepatitis and hepatocellular carcinoma.” Gastroenterology (2012). PMID: 22537432 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification (GI Scores) - [274]
Singal AG, Lim JK, Kanwal F. “AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.” Gastroenterology (2019). PMID: 30878469 ↗
L1REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification (GI Scores), Long-term & Definitive Medical Management, Endoscopic & Procedural Management, Prevention, Screening & Surveillance - [275]
Arena U, Vizzutti F, Abraldes JG et al.. “Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C.” Gut (2008). PMID: 18448567 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores) - [276]
Macías J, Girón-González JA, González-Serrano M et al.. “Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes.” Gut (2005). PMID: 16118349 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores) - [277]
Pembroke T, Christian A, Jones E et al.. “The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment.” Gut (2013). PMID: 23665989 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification (GI Scores) - [278]
Clark PJ, Thompson AJ, McHutchison JG. “IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies.” The American journal of gastroenterology (2010). PMID: 20924369 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification (GI Scores) - [279]
Calvaruso V, Cacciola I, Licata A et al.. “Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience.” The American journal of gastroenterology (2019). PMID: 31135449 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores) - [280]
Cantarini MC, Trevisani F, Morselli-Labate AM et al.. “Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma.” The American journal of gastroenterology (2006). PMID: 16405539 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification (GI Scores), Prevention, Screening & Surveillance - [281]
George J, Allard NL, Roberts SK et al.. “Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations.” The Medical journal of Australia (2025). PMID: 40976940 ↗
L1GUIDELINECited in: Severity, Staging & Risk Stratification (GI Scores) - [282]
Rodríguez-Torres M. “Latinos and chronic hepatitis C: a singular population.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2008). PMID: 18455693 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification (GI Scores), History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy - [283]
Kanwal F, Khaderi S, Singal AG et al.. “Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 37390101 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores) - [284]
Thrift AP, Liu Y, Tsavachidis S et al.. “Ancestry and Risk of Hepatic Fibrosis and Inflammation in Patients With HCV Infection.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2018). PMID: 30342914 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores) - [285]
Burroughs AK, Sabin CA, Rolles K et al.. “3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome.” Lancet (London, England) (2006). PMID: 16427491 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores) - [286]
Haukoos J, Rothman RE, Galbraith JW et al.. “Hepatitis C Screening in Emergency Departments: The DETECT Hep C Randomized Clinical Trial.” JAMA (2025). PMID: 40632510 ↗
L1RCTCited in: Severity, Staging & Risk Stratification (GI Scores) - [287]
Farrag AN, Abbassi MM, Sabry NA et al.. “Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in Young Children With Chronic HCV Infection.” Liver international : official journal of the International Association for the Study of the Liver (2025). PMID: 40913386 ↗
L4TRIAL_NONRANDOMCited in: Severity, Staging & Risk Stratification (GI Scores) - [288]
Petrelli F, Colombo S, Dottorini L et al.. “Viral hepatitis and immunotherapy outcome in advanced hepatocellular carcinoma: A comprehensive umbrella review of 15 meta-analyses.” Critical reviews in oncology/hematology (2026). PMID: 41794163 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History - [289]
Calvaruso V, Di Marco V, Bavetta MG et al.. “Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis.” Alimentary pharmacology & therapeutics (2015). PMID: 25580867 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores) - [290]
Tahata Y, Sakamori R, Yamada R et al.. “Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals.” Alimentary pharmacology & therapeutics (2021). PMID: 34618934 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores) - [291]
Lens S, Torres F, Puigvehi M et al.. “Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C.” Alimentary pharmacology & therapeutics (2015). PMID: 26582599 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores) - [292]
Szeinbach SL, Baran RW, Dietz B et al.. “Development and validation of the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument.” Alimentary pharmacology & therapeutics (2013). PMID: 23289740 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification (GI Scores) - [293]
Caviglia GP, Fariselli P, D'Ambrosio R et al.. “Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA.” Alimentary pharmacology & therapeutics (2024). PMID: 39569574 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores) - [294]
Jakobsen JC, Nielsen EE, Feinberg J et al.. “Direct-acting antivirals for chronic hepatitis C.” The Cochrane database of systematic reviews (2017). PMID: 28922704 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification (GI Scores), History and Evolution of Treatment, Complications, Prognosis & Natural History, Special Populations & Pregnancy - [295]
Chiu HY, Hsu CC, Tsai TF et al.. “Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic DMARDs in psoriasis and psoriatic arthritis: A 15-year multicenter cohort study.” Journal of the American Academy of Dermatology (2025). PMID: 40972765 ↗
L2COHORTCited in: Severity, Staging & Risk Stratification (GI Scores) - [296]
Zhang Y, Li S, Fu K et al.. “Development and evaluation of percentile curves of serum alanine aminotransferase in older adults: A multi-cohort study.” Annals of hepatology (2025). PMID: 40288490 ↗
L2COHORTCited in: Severity, Staging & Risk Stratification (GI Scores) - [297]
Sulkowski MS, Shiffman ML, Afdhal NH et al.. “Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.” Gastroenterology (2010). PMID: 20723545 ↗
L1RCTCited in: Acute Management - [298]
Lutchman G, Danehower S, Song BC et al.. “Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy.” Gastroenterology (2007). PMID: 17484873 ↗
L1RCTCited in: Acute Management - [299]
Lok AS, Sulkowski MS, Kort JJ et al.. “Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.” Gastroenterology (2019). PMID: 31401140 ↗
L1RCTCited in: Acute Management - [300]
Esteban R, Pineda JA, Calleja JL et al.. “Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.” Gastroenterology (2018). PMID: 29958855 ↗
L1RCTCited in: Acute Management - [301]
Pilli M, Zerbini A, Penna A et al.. “HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).” Gastroenterology (2007). PMID: 17919489 ↗
L4RCTCited in: Acute Management - [302]
Kwo P, Gane EJ, Peng CY et al.. “Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.” Gastroenterology (2016). PMID: 27720838 ↗
L1RCTCited in: Acute Management - [303]
Afdhal NH, Dusheiko GM, Giannini EG et al.. “Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.” Gastroenterology (2013). PMID: 24126097 ↗
L1RCTCited in: Acute Management - [304]
Sarrazin C, Kieffer TL, Bartels D et al.. “Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.” Gastroenterology (2007). PMID: 17484874 ↗
L4RCTCited in: Acute Management - [305]
Carrión JA, Navasa M, García-Retortillo M et al.. “Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.” Gastroenterology (2007). PMID: 17484872 ↗
L1RCTCited in: Acute Management - [306]
Everhart JE, Lok AS, Kim HY et al.. “Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial.” Gastroenterology (2009). PMID: 19445938 ↗
L2RCTCited in: Acute Management, Complications - [307]
Shiha G, Esmat G, Hassany M et al.. “Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.” Gut (2018). PMID: 29666174 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy - [308]
Hézode C, Hirschfield GM, Ghesquiere W et al.. “Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.” Gut (2014). PMID: 25080450 ↗
L1RCTCited in: Acute Management - [309]
Liu CH, Liang CC, Lin JW et al.. “Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study.” Gut (2007). PMID: 17881538 ↗
L1RCTCited in: Acute Management - [310]
Omata M, Yoshida H, Toyota J et al.. “A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.” Gut (2007). PMID: 17573387 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management - [311]
Yu ML, Dai CY, Huang JF et al.. “A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.” Gut (2006). PMID: 16956917 ↗
L1RCTCited in: Acute Management - [312]
Liu CH, Liu CJ, Huang CF et al.. “Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.” Gut (2014). PMID: 24747867 ↗
L1RCTCited in: Acute Management - [313]
Kraus MR, Schäfer A, Schöttker K et al.. “Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study.” Gut (2007). PMID: 18079286 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management - [314]
Serfaty L, Forns X, Goeser T et al.. “Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.” Gut (2012). PMID: 22387529 ↗
L2RCTCited in: Acute Management - [315]
Desai N, Rich NE, Jain MK et al.. “Randomized Clinical Trial of Inreach With or Without Mailed Outreach to Promote Hepatitis C Screening in a Difficult-to-Reach Patient Population.” The American journal of gastroenterology (2021). PMID: 33337657 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, Prevention, Screening & Surveillance - [316]
Evon DM, Simpson K, Kixmiller S et al.. “A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.” The American journal of gastroenterology (2011). PMID: 21769136 ↗
L1RCTCited in: Acute Management - [317]
Krawitt EL, Gordon SR, Grace ND et al.. “A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C.” The American journal of gastroenterology (2006). PMID: 16771948 ↗
L1RCTCited in: Acute Management - [318]
Fontana RJ, Sanyal AJ, Mehta S et al.. “Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial.” The American journal of gastroenterology (2006). PMID: 16573786 ↗
L4RCTCited in: Acute Management, Complications - [319]
Bonkovsky HL, Tice AD, Yapp RG et al.. “Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration.” The American journal of gastroenterology (2008). PMID: 18684176 ↗
L1RCTCited in: Acute Management - [320]
Morishima C, Shiffman ML, Dienstag JL et al.. “Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.” The American journal of gastroenterology (2012). PMID: 22688849 ↗
L2RCTCited in: Acute Management - [321]
Giordanino C, Bugianesi E, Smedile A et al.. “Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.” The American journal of gastroenterology (2008). PMID: 18702647 ↗
L2RCTCited in: Acute Management - [322]
Wang JH, Chang KC, Kee KM et al.. “Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community.” The American journal of gastroenterology (2013). PMID: 23318478 ↗
L1RCTCited in: Acute Management - [323]
Ide T, Hino T, Ogata K et al.. “A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C.” The American journal of gastroenterology (2009). PMID: 19098852 ↗
L1RCTCited in: Acute Management - [324]
Ferenci P, Bernstein D, Lalezari J et al.. “ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.” The New England journal of medicine (2014). PMID: 24795200 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Special Populations & Pregnancy - [325]
Zeuzem S, Andreone P, Pol S et al.. “Telaprevir for retreatment of HCV infection.” The New England journal of medicine (2011). PMID: 21696308 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy - [326]
Curry MP, O'Leary JG, Bzowej N et al.. “Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.” The New England journal of medicine (2015). PMID: 26569658 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy - [327]
Zeuzem S, Dusheiko GM, Salupere R et al.. “Sofosbuvir and ribavirin in HCV genotypes 2 and 3.” The New England journal of medicine (2014). PMID: 24795201 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Special Populations & Pregnancy - [328]
Poordad F, Hezode C, Trinh R et al.. “ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.” The New England journal of medicine (2014). PMID: 24725237 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Special Populations & Pregnancy - [329]
Foster GR, Afdhal N, Roberts SK et al.. “Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.” The New England journal of medicine (2015). PMID: 26575258 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy - [330]
Sherman KE, Flamm SL, Afdhal NH et al.. “Response-guided telaprevir combination treatment for hepatitis C virus infection.” The New England journal of medicine (2011). PMID: 21916639 ↗
L1RCTCited in: Acute Management - [331]
Lawitz E, Mangia A, Wyles D et al.. “Sofosbuvir for previously untreated chronic hepatitis C infection.” The New England journal of medicine (2013). PMID: 23607594 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment - [332]
Afdhal N, Zeuzem S, Kwo P et al.. “Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.” The New England journal of medicine (2014). PMID: 24725239 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment - [333]
Zeuzem S, Foster GR, Wang S et al.. “Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.” The New England journal of medicine (2018). PMID: 29365309 ↗
L1RCTCited in: Acute Management, History and Evolution of Treatment - [334]
Cheng PN, Liu CJ, Chen CY et al.. “Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 34864158 ↗
L1RCTCited in: Acute Management - [335]
Asselah T, Kowdley KV, Zadeikis N et al.. “Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2017). PMID: 28951228 ↗
L1RCTCited in: Acute Management - [336]
Fartoux L, Degos F, Trépo C et al.. “Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2007). PMID: 17261383 ↗
L1RCTCited in: Acute Management - [337]
Ho SB, Bräu N, Cheung R et al.. “Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2015). PMID: 25724704 ↗
L1RCTCited in: Acute Management - [338]
Rodriguez-Torres M, Stoehr A, Gane EJ et al.. “Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 24120953 ↗
L1RCTCited in: Acute Management - [339]
Nelson DR, Rustgi V, Balan V et al.. “Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2008). PMID: 19061971 ↗
L2RCTCited in: Acute Management - [340]
Bain VG, Kaita KD, Marotta P et al.. “Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2008). PMID: 18467185 ↗
L1RCTCited in: Acute Management - [341]
Lok AS, Everhart JE, Chung RT et al.. “Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2007). PMID: 17296533 ↗
L3RCTCited in: Acute Management - [342]
Brady DE, Torres DM, An JW et al.. “Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2009). PMID: 19747986 ↗
L1RCTCited in: Acute Management - [343]
Peck-Radosavljevic M, Boletis J, Besisik F et al.. “Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2010). PMID: 21056689 ↗
L1RCTCited in: Acute Management - [344]
Cooke GS, Hung LM, Flower B et al.. “Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.” Lancet (London, England) (2025). PMID: 40347964 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy - [345]
Jacobson IM, Dore GJ, Foster GR et al.. “Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2014). PMID: 24907225 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History - [346]
Manns M, Marcellin P, Poordad F et al.. “Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.” Lancet (London, England) (2014). PMID: 24907224 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, Prognosis & Natural History - [347]
van der Ree MH, de Vree JM, Stelma F et al.. “Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.” Lancet (London, England) (2017). PMID: 28087069 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management - [348]
Lawitz E, Gane E, Pearlman B et al.. “Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.” Lancet (London, England) (2014). PMID: 25467591 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management - [349]
Hézode C, Asselah T, Reddy KR et al.. “Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.” Lancet (London, England) (2015). PMID: 25837829 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management - [350]
Sulkowski M, Hezode C, Gerstoft J et al.. “Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.” Lancet (London, England) (2014). PMID: 25467560 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management - [351]
Lawitz E, Poordad FF, Pang PS et al.. “Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.” Lancet (London, England) (2013). PMID: 24209977 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management - [352]
Byrne CJ, Radley A, Inglis SK et al.. “Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial.” Alimentary pharmacology & therapeutics (2022). PMID: 35538396 ↗
L1RCTCited in: Acute Management, History and Evolution of Treatment - [353]
El-Khayat H, Fouad Y, Mohamed HI et al.. “Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.” Alimentary pharmacology & therapeutics (2018). PMID: 29314146 ↗
L2RCTCited in: Acute Management, History and Evolution of Treatment - [354]
Raison CL, Woolwine BJ, Demetrashvili MF et al.. “Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.” Alimentary pharmacology & therapeutics (2007). PMID: 17451562 ↗
L1RCTCited in: Acute Management - [355]
Tang KH, Herrmann E, Pachiadakis I et al.. “Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin.” Alimentary pharmacology & therapeutics (2008). PMID: 18221408 ↗
L4RCTCited in: Acute Management - [356]
Vera-Llonch M, Martin M, Aggarwal J et al.. “Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study.” Alimentary pharmacology & therapeutics (2013). PMID: 23725204 ↗
L1RCTCited in: Acute Management - [357]
Lai CL, Wong VW, Yuen MF et al.. “Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong.” Alimentary pharmacology & therapeutics (2015). PMID: 26503414 ↗
L1RCTCited in: Acute Management - [358]
Rossignol JF, Kabil SM, El-Gohary Y et al.. “Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4.” Alimentary pharmacology & therapeutics (2008). PMID: 18616643 ↗
L1RCTCited in: Acute Management - [359]
Lodato F, Berardi S, Gramenzi A et al.. “Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.” Alimentary pharmacology & therapeutics (2008). PMID: 18549463 ↗
L4RCTCited in: Acute Management - [360]
Abu Hassan MR, Muhamad NA, Mohammed NS et al.. “A Multicenter, open-label, randomized, non-inferiority trial of 8 versus 12 weeks of sofosbuvir/ravidasvir treatment in non-cirrhotic patients with chronic hepatitis C virus infection (EASE trial).” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42140479 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy - [361]
Nolte K, Del Toro-Mejias L, Bianchet E et al.. “Convenience, rapport and skill: effective rural hepatitis C treatment, qualitative findings from a mobile harm reduction-informed tele-medicine intervention in Northern New England, 2022-2024.” Harm reduction journal (2026). PMID: 41742143 ↗
L4RCTCited in: Acute Management, Long-term & Definitive Medical Management, Prevention, Screening & Surveillance - [362]
Herink MC, Spencer HC, Cook RR et al.. “Peer-assisted telemedicine for hepatitis C intervention in people experiencing housing instability.” Harm reduction journal (2026). PMID: 41645194 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management - [363]
Friedmann PD, Wilson D, de Gijsel D et al.. “Mobile Telemedicine for Treating Chronic Hepatitis C Among Rural People Who Inject Drugs: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 41587029 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management - [364]
Chan SL, Finn RS, Edeline J et al.. “Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma.” Annals of hepatology (2025). PMID: 41453647 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management - [365]
Evon DM, Liu C, Rollason C et al.. “Group-based telehealth stress management-lifestyle interventions are feasible for patients with chronic liver disease.” Hepatology communications (2025). PMID: 41264908 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management - [366]
Huang R, Ji F, Jiang Y et al.. “Sofosbuvir/Velpatasvir/Voxilaprevir Versus Sofosbuvir/Velpatasvir Plus Ribavirin in Patients With Hepatitis C Virus Genotype 3b and Compensated Cirrhosis: A Multicentre Randomized Controlled Trial.” Journal of medical virology (2025). PMID: 41255102 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management - [367]
Tahata Y, Hikita H, Takaki A et al.. “Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial.” Journal of gastroenterology (2025). PMID: 41168423 ↗
L2RCTCited in: Acute Management, Long-term & Definitive Medical Management - [368]
Rakhshani T, Chalesh S, Arman A et al.. “Enhancing Hepatitis B and C Prevention Among People Who Use Drugs: Evaluating an Educational Intervention at a Drop-In Center in Southwest Iran based on Protection Motivation Theory.” BMC public health (2025). PMID: 41126184 ↗
L4RCTCited in: Acute Management, Long-term & Definitive Medical Management - [369]
Pericot-Valverde I, Lopes SS, Obeysekare J et al.. “Depression profiles and hepatitis C treatment outcomes among people who inject drugs: The HERO study.” Journal of psychosomatic research (2025). PMID: 41124945 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management - [370]
Bader T, Fazili J, Madhoun M et al.. “Fluvastatin inhibits hepatitis C replication in humans.” The American journal of gastroenterology (2008). PMID: 18410471 ↗
L4RCTCited in: Long-term & Definitive Medical Management - [371]
Sherman M, Yoshida EM, Deschenes M et al.. “Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.” Gut (2006). PMID: 16709661 ↗
L4TRIAL_NONRANDOMCited in: Long-term & Definitive Medical Management - [372]
Naggie S, Cooper C, Saag M et al.. “Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.” The New England journal of medicine (2015). PMID: 26196665 ↗
L4TRIAL_NONRANDOMCited in: Long-term & Definitive Medical Management, Special Populations & Pregnancy - [373]
Molina JM, Orkin C, Iser DM et al.. “Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.” Lancet (London, England) (2015). PMID: 25659285 ↗
L4TRIAL_NONRANDOMCited in: Long-term & Definitive Medical Management, Prognosis & Natural History - [374]
Berden FA, Aaldering BR, Groenewoud H et al.. “Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2016). PMID: 27840182 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management - [375]
Farnik H, Lange CM, Sarrazin C et al.. “Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2010). PMID: 20601130 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management - [376]
Guillouche P, Féray C. “Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation.” Alimentary pharmacology & therapeutics (2010). PMID: 21083593 ↗
L5SR_OBSCited in: Long-term & Definitive Medical Management, Special Populations & Pregnancy - [377]
Younossi Z, Henry L. “Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens.” Alimentary pharmacology & therapeutics (2015). PMID: 25616122 ↗
L5SR_OBSCited in: Long-term & Definitive Medical Management, Prognosis & Natural History - [378]
Ji F, Wei B, Yeo YH et al.. “Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.” Alimentary pharmacology & therapeutics (2018). PMID: 29327780 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management, History and Evolution of Treatment - [379]
El Sherbini A, Mostafa S, Ali E. “Systematic review with meta-analysis: comparison between therapeutic regimens for paediatric chronic hepatitis C.” Alimentary pharmacology & therapeutics (2015). PMID: 25926269 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management - [380]
Pawlotsky JM. “New hepatitis C therapies: the toolbox, strategies, and challenges.” Gastroenterology (2014). PMID: 24631495 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management, Prognosis & Natural History, Special Populations & Pregnancy - [381]
Pawlotsky JM. “Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.” Gastroenterology (2016). PMID: 27080301 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management - [382]
Schaefer EA, Chung RT. “Anti-hepatitis C virus drugs in development.” Gastroenterology (2012). PMID: 22537441 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management, Prognosis & Natural History, Special Populations & Pregnancy - [383]
Baumert TF, Berg T, Lim JK et al.. “Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.” Gastroenterology (2018). PMID: 30342035 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management, Special Populations & Pregnancy - [384]
Chevaliez S, Rodriguez C, Pawlotsky JM. “New virologic tools for management of chronic hepatitis B and C.” Gastroenterology (2012). PMID: 22537437 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management - [385]
Barritt AS, Fried MW. “Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.” Gastroenterology (2012). PMID: 22537438 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management - [386]
Naggie S, Sulkowski MS. “Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.” Gastroenterology (2012). PMID: 22537439 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management - [387]
Wing PAC, Jones M, Cheung M et al.. “Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir.” Gastroenterology (2019). PMID: 31078622 ↗
L4OTHERCited in: Long-term & Definitive Medical Management - [388]
Comarmond C, Garrido M, Pol S et al.. “Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.” Gastroenterology (2017). PMID: 28274850 ↗
L4OTHERCited in: Long-term & Definitive Medical Management - [389]
Bonacci M, Lens S, Mariño Z et al.. “Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure.” Gastroenterology (2018). PMID: 29705529 ↗
L2OTHERCited in: Long-term & Definitive Medical Management - [390]
Welsch C, Jesudian A, Zeuzem S et al.. “New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.” Gut (2012). PMID: 22504918 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management - [391]
Liu CH, Chen CY, Su WW et al.. “Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.” Gut (2021). PMID: 33408122 ↗
L3OTHERCited in: Long-term & Definitive Medical Management - [392]
Ploss A, Dubuisson J. “New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets.” Gut (2012). PMID: 22504917 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management - [393]
Watanabe T, Sugauchi F, Tanaka Y et al.. “Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.” Gut (2012). PMID: 23135762 ↗
L2OTHERCited in: Long-term & Definitive Medical Management - [394]
Xiao F, Fofana I, Thumann C et al.. “Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.” Gut (2014). PMID: 24848265 ↗
L5OTHERCited in: Long-term & Definitive Medical Management - [395]
Laique SN, Vargas HE. “Hepatitis C Virus: No Longer a Barrier to Oncology Care.” The American journal of gastroenterology (2019). PMID: 30676362 ↗
L5OTHERCited in: Long-term & Definitive Medical Management, Prognosis & Natural History - [396]
Muir AJ. “The rapid evolution of treatment strategies for hepatitis C.” The American journal of gastroenterology (2014). PMID: 24732866 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy - [397]
Torres HA, Economides MP, Angelidakis G et al.. “Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.” The American journal of gastroenterology (2019). PMID: 30410039 ↗
L2OTHERCited in: Long-term & Definitive Medical Management, Special Populations & Pregnancy - [398]
Okoh EJ, Bucci JR, Simon JF et al.. “HCV in patients with end-stage renal disease.” The American journal of gastroenterology (2008). PMID: 18796105 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management, History and Evolution of Treatment - [399]
Fayed A, Hegazy MT, Biard L et al.. “Relapse of Hepatitis C Virus Cryoglobulinemic Vasculitis After Sustained Viral Response After Interferon-Free Direct-Acting Antivirals.” The American journal of gastroenterology (2022). PMID: 35103020 ↗
L3OTHERCited in: Long-term & Definitive Medical Management, Prognosis & Natural History - [400]
Gluud LL, Marchesini E, Iorio A. “Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus.” The American journal of gastroenterology (2009). PMID: 19513022 ↗
L1REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management - [401]
Chuang WL, Hu TH, Buggisch P et al.. “Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease.” The American journal of gastroenterology (2021). PMID: 34465694 ↗
L4OTHERCited in: Long-term & Definitive Medical Management - [402]
Liang TJ, Ghany MG. “Current and future therapies for hepatitis C virus infection.” The New England journal of medicine (2013). PMID: 23675659 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management, Special Populations & Pregnancy - [403]
Singal AG, El-Serag HB. “Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2015). PMID: 26284591 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management, Prevention, Screening & Surveillance - [404]
Price JC, Thio CL. “Liver disease in the HIV-infected individual.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2010). PMID: 20851211 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management, Prognosis & Natural History, Special Populations & Pregnancy - [405]
Muir AJ, Naggie S. “Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2015). PMID: 26192145 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management - [406]
Pearlman BL. “Chronic hepatitis C therapy: changing the rules of duration.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2006). PMID: 16843732 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management - [407]
Schmidt WN, Nelson DR, Pawlotsky JM et al.. “Direct-acting antiviral agents and the path to interferon independence.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 23872239 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management - [408]
Rogal SS, Beste LA, Youk A et al.. “Characteristics of Opioid Prescriptions to Veterans With Cirrhosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2018). PMID: 30342261 ↗
L2OTHERCited in: Long-term & Definitive Medical Management - [409]
Jesudian AB, de Jong YP, Jacobson IM. “Emerging therapeutic targets for hepatitis C virus infection.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 23583900 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management - [410]
Altice FL, Azbel L, Stone J et al.. “The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.” Lancet (London, England) (2016). PMID: 27427455 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management, Special Populations & Pregnancy - [411]
Talal AH, Markatou M, Zeremski M et al.. “Opioid treatment program-integrated facilitated telemedicine for hepatitis C treatment: a hybrid effectiveness-implementation analysis.” BMC complementary medicine and therapies (2025). PMID: 41094463 ↗
L1RCTCited in: Long-term & Definitive Medical Management - [412]
Hoffman K, Gillian L, Shin S et al.. “"She Was Real About It and Made Me Feel Life Is Important": Patient Perspectives on Peers' Role in Peer-Assisted Telemedicine Hepatitis C Treatment for People Who Use Drugs in Rural Communities.” Journal of addiction medicine (2025). PMID: 40693655 ↗
L1RCTCited in: Long-term & Definitive Medical Management - [413]
Llibre JM, Boesecke C, Moon J et al.. “A single-arm phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C.” Journal of hepatology (2025). PMID: 41297677 ↗
L4TRIAL_NONRANDOMCited in: Long-term & Definitive Medical Management - [414]
Cerda-Reyes E, de la Rosa-Bibiano R, Sandoval-Rodriguez A et al.. “HCV patients with residual fibrosis after DAA treatment re-establish their epigenetic signature after prolonged-release pirfenidone: MINERVA study.” Clinical epigenetics (2025). PMID: 41044745 ↗
L4TRIAL_NONRANDOMCited in: Long-term & Definitive Medical Management - [415]
Wantuck JM, Ahmed A, Nguyen MH. “Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6.” Alimentary pharmacology & therapeutics (2013). PMID: 24251930 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management - [416]
Banerjee D, Reddy KR. “Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.” Alimentary pharmacology & therapeutics (2016). PMID: 26787287 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management, Prevention, Screening & Surveillance - [417]
Stättermayer AF, Scherzer T, Beinhardt S et al.. “Review article: genetic factors that modify the outcome of viral hepatitis.” Alimentary pharmacology & therapeutics (2014). PMID: 24654629 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management, History and Evolution of Treatment, Complications - [418]
Bunchorntavakul C, Reddy KR. “Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection.” Alimentary pharmacology & therapeutics (2015). PMID: 26014906 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management - [419]
Lange CM, Sarrazin C, Zeuzem S. “Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy.” Alimentary pharmacology & therapeutics (2010). PMID: 20374226 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management - [420]
Koff RS. “Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.” Alimentary pharmacology & therapeutics (2014). PMID: 24387618 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management - [421]
Ruiz-Cobo JC, Llaneras J, Forns X et al.. “Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.” Alimentary pharmacology & therapeutics (2024). PMID: 38695095 ↗
L2OTHERCited in: Long-term & Definitive Medical Management - [422]
Gluud LL, Krogsgaard K, Gluud C. “WITHDRAWN: Ribavirin with or without alpha interferon for chronic hepatitis C.” The Cochrane database of systematic reviews (2007). PMID: 17636700 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management, History and Evolution of Treatment, Prognosis & Natural History - [423]
Gurusamy KS, Tsochatzis E, Toon CD et al.. “Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus.” The Cochrane database of systematic reviews (2013). PMID: 24307460 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management - [424]
Montero N, Favà A, Rodriguez E et al.. “Treatment for hepatitis C virus-associated mixed cryoglobulinaemia.” The Cochrane database of systematic reviews (2018). PMID: 29734473 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management - [425]
Bjelakovic G, Nikolova D, Bjelakovic M et al.. “Vitamin D supplementation for chronic liver diseases in adults.” The Cochrane database of systematic reviews (2017). PMID: 29099543 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management - [426]
Brok J, Gluud LL, Gluud C. “Ribavirin plus interferon versus interferon for chronic hepatitis C.” The Cochrane database of systematic reviews (2010). PMID: 20091577 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management - [427]
Iorio A, Marchesini E, Awad T et al.. “Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.” The Cochrane database of systematic reviews (2010). PMID: 20091566 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management - [428]
Prabhu RA, Nair S, Pai G et al.. “Interventions for dialysis patients with hepatitis C virus (HCV) infection.” The Cochrane database of systematic reviews (2015). PMID: 26287983 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management - [429]
Lamers MH, Broekman M, Drenth JP et al.. “Aminoadamantanes for chronic hepatitis C.” The Cochrane database of systematic reviews (2014). PMID: 24793264 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management - [430]
Hauser G, Awad T, Thorlund K et al.. “Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C.” The Cochrane database of systematic reviews (2014). PMID: 24585451 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management, History and Evolution of Treatment - [431]
Hauser G, Awad T, Brok J et al.. “Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.” The Cochrane database of systematic reviews (2014). PMID: 24585509 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management, History and Evolution of Treatment - [432]
Singal AG, Rich NE, Mehta N et al.. “Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.” Gastroenterology (2019). PMID: 30660729 ↗
L2COHORTCited in: Endoscopic & Procedural Management - [433]
Costentin CE, Layese R, Bourcier V et al.. “Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.” Gastroenterology (2018). PMID: 29729258 ↗
L2COHORTCited in: Endoscopic & Procedural Management - [434]
Singal AK, Freeman DH, Anand BS. “Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma.” Alimentary pharmacology & therapeutics (2010). PMID: 20659285 ↗
L1SR_OBSCited in: Endoscopic & Procedural Management - [435]
Vizzutti F, Arena U, Rega L et al.. “Liver failure complicating segmental hepatic ischaemia induced by a PTFE-coated TIPS stent.” Gut (2009). PMID: 19299387 ↗
L4CASE_REPORTCited in: Endoscopic & Procedural Management, Complications - [436]
Calderone V, Gallego J, Fernandez-Miranda G et al.. “Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of Vascular Endothelial Growth Factor and Angiogenesis in Chronic Liver Disease.” Gastroenterology (2015). PMID: 26627607 ↗
L5OTHERCited in: Endoscopic & Procedural Management - [437]
Kluwe J, Pradere JP, Gwak GY et al.. “Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition.” Gastroenterology (2009). PMID: 19782079 ↗
L5OTHERCited in: Endoscopic & Procedural Management - [438]
Singal AG, Rich NE, Mehta N et al.. “Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.” Gastroenterology (2019). PMID: 31374215 ↗
L2OTHERCited in: Endoscopic & Procedural Management - [439]
Mormone E, Lu Y, Ge X et al.. “Fibromodulin, an oxidative stress-sensitive proteoglycan, regulates the fibrogenic response to liver injury in mice.” Gastroenterology (2011). PMID: 22138190 ↗
L5OTHERCited in: Endoscopic & Procedural Management - [440]
Arriazu E, Ge X, Leung TM et al.. “Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury.” Gut (2016). PMID: 26818617 ↗
L5OTHERCited in: Endoscopic & Procedural Management - [441]
Shiina S, Tateishi R, Arano T et al.. “Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors.” The American journal of gastroenterology (2011). PMID: 22158026 ↗
L4OTHERCited in: Endoscopic & Procedural Management - [442]
McGowan CE, Edwards TP, Luong MU et al.. “Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2014). PMID: 25117773 ↗
L2OTHERCited in: Endoscopic & Procedural Management - [443]
Hung HH, Chiou YY, Hsia CY et al.. “Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2010). PMID: 20831902 ↗
L2OTHERCited in: Endoscopic & Procedural Management - [444]
Iwata H, Ogino H, Hattori Y et al.. “A Phase 2 Study of Image-Guided Proton Therapy for Operable or Ablation-Treatable Primary Hepatocellular Carcinoma.” International journal of radiation oncology, biology, physics (2021). PMID: 33798564 ↗
L4TRIAL_NONRANDOMCited in: Endoscopic & Procedural Management - [445]
Wong CR, Njei B, Nguyen MH et al.. “Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.” Alimentary pharmacology & therapeutics (2017). PMID: 28960360 ↗
L2OTHERCited in: Endoscopic & Procedural Management - [446]
Hsiao CY, Ho CM, Ho MC et al.. “Risk factors, patterns, and outcome predictors of late recurrence in patients with hepatocellular carcinoma after curative resection: A large cohort study with long-term follow-up results.” Surgery (2024). PMID: 38519406 ↗
L2COHORTCited in: Endoscopic & Procedural Management - [447]
Farsad K, Narasimhan E, Russell L et al.. “Transjugular Intrahepatic Portosystemic Shunt Creation Using a Radiofrequency Wire: Prospective Clinical Safety and Feasibility Trial in Cirrhosis.” Journal of vascular and interventional radiology : JVIR (2020). PMID: 32792278 ↗
L4TRIAL_NONRANDOMCited in: Endoscopic & Procedural Management - [448]
Kamal A, Metawea M, Omar H et al.. “Hepatitis C Virus-Related One-Year Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial.” Journal of gastrointestinal cancer (2024). PMID: 38436921 ↗
L1RCTCited in: Endoscopic & Procedural Management - [449]
Norén S, Bengtsson B, Hagström H et al.. “Hepatocellular carcinoma in Stockholm, Sweden 2003-2018: a population-based cohort study.” Scandinavian journal of gastroenterology (2022). PMID: 35605144 ↗
L2COHORTCited in: Endoscopic & Procedural Management - [450]
Wu CC, Tseng CW, Tseng KC et al.. “Radiofrequency ablation versus surgical resection for the treatment of solitary hepatocellular carcinoma 2 cm or smaller: A cohort study in Taiwan.” Journal of the Formosan Medical Association = Taiwan yi zhi (2020). PMID: 33288401 ↗
L2COHORTCited in: Endoscopic & Procedural Management - [451]
Force M, Park G, Chalikonda D et al.. “Alpha-Fetoprotein (AFP) and AFP-L3 Is Most Useful in Detection of Recurrence of Hepatocellular Carcinoma in Patients after Tumor Ablation and with Low AFP Level.” Viruses (2022). PMID: 35458505 ↗
L5CASE_REPORTCited in: Endoscopic & Procedural Management - [452]
Sato K, Urakawa H, Sakamoto K et al.. “Mucinous cystic neoplasm of the liver communicated with intrahepatic duct exhibiting peculiar chronological change in MR imaging appearances: a case report.” Abdominal radiology (New York) (2020). PMID: 32248257 ↗
L4CASE_REPORTCited in: Endoscopic & Procedural Management - [453]
Oldhafer KJ, Wagner KC, Kantas A et al.. “Hybrid-ALPPS followed by Ante Situm with Cardiopulmonary Bypass: Rapid Liver Augmentation and Complex Surgery.” Annals of surgical oncology (2020). PMID: 32206948 ↗
L4CASE_REPORTCited in: Endoscopic & Procedural Management - [454]
Abusuliman M, Dawod S, Nimri F et al.. “Predictive Factors of Post-ERCP Hepatic Decompensation in Patients with Cirrhosis: A Retrospective Case-Control Study.” Digestive diseases and sciences (2025). PMID: 40274678 ↗
L3CASE_CONTROLCited in: Endoscopic & Procedural Management - [455]
Khavandi MM, Nezami N, Huang S et al.. “Outcomes of transjugular intrahepatic portosystemic shunt creation for the management of portal hypertension complications in cancer patients.” Abdominal radiology (New York) (2025). PMID: 40434426 ↗
L4OTHERCited in: Endoscopic & Procedural Management - [456]
Jacobson IM, Lim JK, Fried MW. “American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection.” Gastroenterology (2017). PMID: 28344022 ↗
L1GUIDELINECited in: History and Evolution of Treatment - [457]
Yee HS, Chang MF, Pocha C et al.. “Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office.” The American journal of gastroenterology (2012). PMID: 22525303 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Complications, Prognosis & Natural History, Special Populations & Pregnancy - [458]
Anand BS, Thornby J. “Alcohol has no effect on hepatitis C virus replication: a meta-analysis.” Gut (2005). PMID: 16162952 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [459]
Sherman KE, Shire NJ, Rouster SD et al.. “Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.” Gastroenterology (2005). PMID: 15685543 ↗
L1RCTCited in: History and Evolution of Treatment - [460]
Esteban R. “Is there a role for interferon in acute viral hepatitis?” Gut (1993). PMID: 8314495 ↗
L5RCTCited in: History and Evolution of Treatment - [461]
Gramenzi A, Andreone P, Fiorino S et al.. “Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.” Gut (2001). PMID: 11358906 ↗
L2RCTCited in: History and Evolution of Treatment - [462]
Genesca J, Esteban JI, Quer J et al.. “Hepatitis C virus markers in patients with acute post-transfusion hepatitis treated with interferon alfa-2b.” Gut (1993). PMID: 7686120 ↗
L1RCTCited in: History and Evolution of Treatment - [463]
Afdhal N, Reddy KR, Nelson DR et al.. “Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.” The New England journal of medicine (2014). PMID: 24725238 ↗
L1RCTCited in: History and Evolution of Treatment - [464]
Bourlière M, Gordon SC, Flamm SL et al.. “Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.” The New England journal of medicine (2017). PMID: 28564569 ↗
L1RCTCited in: History and Evolution of Treatment - [465]
Aldridge RW, Story A, Hwang SW et al.. “Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis.” Lancet (London, England) (2017). PMID: 29137869 ↗
L2SR_OBSCited in: History and Evolution of Treatment - [466]
Lau JY, Davis GL, Kniffen J et al.. “Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.” Lancet (London, England) (1993). PMID: 8099380 ↗
L2RCTCited in: History and Evolution of Treatment - [467]
Omata M, Yokosuka O, Takano S et al.. “Resolution of acute hepatitis C after therapy with natural beta interferon.” Lancet (London, England) (1991). PMID: 1681268 ↗
L2RCTCited in: History and Evolution of Treatment - [468]
Blajchman MA, Bull SB, Feinman SV. “Post-transfusion hepatitis: impact of non-A, non-B hepatitis surrogate tests. Canadian Post-Transfusion Hepatitis Prevention Study Group.” Lancet (London, England) (1995). PMID: 7528310 ↗
L1RCTCited in: History and Evolution of Treatment - [469]
Benvegnù L, Gios M, Boccato S et al.. “Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.” Gut (2004). PMID: 15082595 ↗
L2COHORTCited in: History and Evolution of Treatment - [470]
Fabrizi F, Martin P, Dixit V et al.. “Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis.” Alimentary pharmacology & therapeutics (2004). PMID: 15606388 ↗
L2SR_OBSCited in: History and Evolution of Treatment - [471]
Missiha SB, Ostrowski M, Heathcote EJ. “Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors.” Gastroenterology (2008). PMID: 18471548 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Prognosis & Natural History - [472]
Kiyosawa K, Umemura T, Ichijo T et al.. “Hepatocellular carcinoma: recent trends in Japan.” Gastroenterology (2004). PMID: 15508082 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [473]
Seeff LB, Bonkovsky HL, Navarro VJ et al.. “Herbal products and the liver: a review of adverse effects and mechanisms.” Gastroenterology (2014). PMID: 25500423 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [474]
Mukherjee S, Sorrell MF. “Controversies in liver transplantation for hepatitis C.” Gastroenterology (2008). PMID: 18471554 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [475]
Davis GL. “Current therapy for chronic hepatitis C.” Gastroenterology (2000). PMID: 10868901 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [476]
Ferenci P. “Historical treatment of chronic hepatitis B and chronic hepatitis C.” Gut (1993). PMID: 8314494 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [477]
Schmilovitz-Weiss H, Levy M, Thompson N et al.. “Viral markers in the treatment of hepatitis B and C.” Gut (1993). PMID: 7686114 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [478]
Bizollon T, Ducerf C, Trepo C et al.. “Hepatitis C virus recurrence after liver transplantation.” Gut (1999). PMID: 10075968 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [479]
Irving WL. “Acute hepatitis C virus infection: a neglected disease?” Gut (2006). PMID: 16849345 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Prognosis & Natural History - [480]
Rosman AS, Waraich A, Galvin K et al.. “Alcoholism is associated with hepatitis C but not hepatitis B in an urban population.” The American journal of gastroenterology (1996). PMID: 8633498 ↗
L3REVIEW_NARRATIVECited in: History and Evolution of Treatment - [481]
Wu T, Kwok RM, Tran TT. “Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues.” The American journal of gastroenterology (2017). PMID: 29087395 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [482]
Bruno R, Sacchi P, Puoti M et al.. “HCV chronic hepatitis in patients with HIV: clinical management issues.” The American journal of gastroenterology (2002). PMID: 12135007 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [483]
Bain VG. “Effect of HCV viral dynamics on treatment design: lessons learned from HIV.” The American journal of gastroenterology (2001). PMID: 11693314 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [484]
Mindikoglu AL, Miller RR. “Hepatitis C in the elderly: epidemiology, natural history, and treatment.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2008). PMID: 19084480 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Special Populations & Pregnancy - [485]
Wong W, Terrault N. “Update on chronic hepatitis C.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2005). PMID: 15952092 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [486]
Kia L, Rinella ME. “Interpretation and management of hepatic abnormalities in pregnancy.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 23707777 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Special Populations & Pregnancy - [487]
Marotta P, Hueppe D, Zehnter E et al.. “Efficacy of chronic hepatitis C therapy in community-based trials.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2009). PMID: 19447199 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [488]
Goodnough LT, Shander A, Brecher ME. “Transfusion medicine: looking to the future.” Lancet (London, England) (2003). PMID: 12531595 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [489]
Persico M, Persico E, Suozzo R et al.. “Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.” Gastroenterology (2000). PMID: 10734027 ↗
L2OTHERCited in: History and Evolution of Treatment - [490]
Amadei B, Urbani S, Cazaly A et al.. “Activation of natural killer cells during acute infection with hepatitis C virus.” Gastroenterology (2010). PMID: 20080094 ↗
L2OTHERCited in: History and Evolution of Treatment - [491]
Ruhl M, Knuschke T, Schewior K et al.. “CD8+ T-cell response promotes evolution of hepatitis C virus nonstructural proteins.” Gastroenterology (2011). PMID: 21376049 ↗
L4OTHERCited in: History and Evolution of Treatment - [492]
Yano M, Yatsuhashi H, Inoue O et al.. “Epidemiology and long term prognosis of hepatitis C virus infection in Japan.” Gut (1993). PMID: 7686112 ↗
L5OTHERCited in: History and Evolution of Treatment - [493]
Gordon SC. “Occult viral hepatitis and noncirrhotic hepatocellular carcinoma.” The American journal of gastroenterology (2005). PMID: 16144125 ↗
L5OTHERCited in: History and Evolution of Treatment - [494]
Jakobsen JC, Nielsen EE, Feinberg J et al.. “Direct-acting antivirals for chronic hepatitis C.” The Cochrane database of systematic reviews (2017). PMID: 28585310 ↗
L1SR_OBSCited in: History and Evolution of Treatment, Complications, Prognosis & Natural History, Special Populations & Pregnancy - [495]
Alberti A, Vario A, Ferrari A et al.. “Review article: chronic hepatitis C--natural history and cofactors.” Alimentary pharmacology & therapeutics (2005). PMID: 16225479 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [496]
Ampuero J, Romero-Gómez M, Reddy KR. “Review article: HCV genotype 3 – the new treatment challenge.” Alimentary pharmacology & therapeutics (2014). PMID: 24612116 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [497]
Chen N, Chen Y, Liu Q et al.. “Incidence and risk factors of post-transplant diabetes mellitus after kidney transplantation: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 42267307 ↗
L2SR_OBSCited in: History and Evolution of Treatment - [498]
van Velsen LM, Krassenburg LAP, Hirode G et al.. “Association Between Sustained Virological Response and Adverse Liver-Related Events in Patients With Decompensated Hepatitis C Virus Cirrhosis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40962195 ↗
L2OTHERCited in: History and Evolution of Treatment - [499]
Tabatabavakili S, Aleyadeh W, Cerrocchi O et al.. “Incidence of Hepatitis C Virus Infections Among Users of Human Immunodeficiency Virus Pre-exposure Prophylaxis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 33737225 ↗
L2OTHERCited in: History and Evolution of Treatment, Prevention, Screening & Surveillance - [500]
Esteban JI, Esteban R, Viladomiu L et al.. “Hepatitis C virus antibodies among risk groups in Spain.” Lancet (London, England) (1989). PMID: 2569102 ↗
L4OTHERCited in: History and Evolution of Treatment - [501]
Akiyama MJ, Kaba-Diakite F, Dimaulaluan M et al.. “Mitigation of COVID-19 through onsite testing and education among formerly incarcerated individuals (the MOSAIC study): an open-label, single-centre, randomised controlled trial.” The Lancet. Public health (2026). PMID: 42335913 ↗
L1RCTCited in: History and Evolution of Treatment - [502]
. “[Chinese guideline for the chemotherapy of multidrug-resistant/rifampicin-resistant tuberculosis (2026 edition)].” Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases (2026). PMID: 42236454 ↗
L1GUIDELINECited in: History and Evolution of Treatment - [503]
Zhou XJ, Vo A, Morelli G et al.. “In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug-Metabolizing Enzymes.” Journal of clinical pharmacology (2026). PMID: 42053458 ↗
L2RCTCited in: History and Evolution of Treatment - [504]
Shi Y, Chien N, Fong A et al.. “Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology.” Alimentary pharmacology & therapeutics (2025). PMID: 40013475 ↗
L3OTHERCited in: History and Evolution of Treatment, Prognosis & Natural History - [505]
Kakizaki S, Ikegami T, Hatanaka T et al.. “Long-Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus-Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study.” Hepatology research : the official journal of the Japan Society of Hepatology (2026). PMID: 41918474 ↗
L3COHORTCited in: History and Evolution of Treatment - [506]
Jovanović-Ćupić S, Krajnović M, Todorović L et al.. “HCV-Induced Hepatocarcinogenesis: Molecular Mechanisms, Persistent Cancer Risk, and Future Perspectives.” Biomedicines (2026). PMID: 42351723 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [507]
Calderón-Villarreal A. “Considering water, sanitation, and hygiene as a valuable component of harm reduction.” Harm reduction journal (2026). PMID: 41965754 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [508]
Fernández-García OA, Co J, Suandork T et al.. “Trends in Increased Infection Risk Deceased Organ Donors. A Two-Centre Retrospective Study.” Canadian journal of kidney health and disease (2026). PMID: 42368892 ↗
L3COHORTCited in: History and Evolution of Treatment - [509]
Qin Y, Lu L, Huang X et al.. “De novo mutations in ANK1 and SPTB cause hereditary spherocytosis: three case reports and literature review.” Annals of hematology (2026). PMID: 41920367 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [510]
Yee HS, Currie SL, Darling JM et al.. “Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office.” The American journal of gastroenterology (2006). PMID: 17032203 ↗
L1GUIDELINECited in: Complications - [511]
Ghany MG, Lok AS, Everhart JE et al.. “Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.” Gastroenterology (2009). PMID: 19766643 ↗
L2RCTCited in: Complications - [512]
Gane EJ, Hyland RH, An D et al.. “Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.” Gastroenterology (2015). PMID: 26261007 ↗
L1RCTCited in: Complications - [513]
Lok AS, Everhart JE, Wright EC et al.. “Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.” Gastroenterology (2010). PMID: 21129375 ↗
L1RCTCited in: Complications - [514]
Lambrecht RW, Sterling RK, Naishadham D et al.. “Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C.” Gastroenterology (2011). PMID: 21335007 ↗
L2RCTCited in: Complications - [515]
Fontana RJ, Sanyal AJ, Ghany MG et al.. “Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C.” Gastroenterology (2010). PMID: 20211180 ↗
L2RCTCited in: Complications - [516]
Fontana RJ, Dienstag JL, Bonkovsky HL et al.. “Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.” Gut (2010). PMID: 20675691 ↗
L2RCTCited in: Complications - [517]
Fontana RJ, Bieliauskas LA, Back-Madruga C et al.. “Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C.” The American journal of gastroenterology (2010). PMID: 20104219 ↗
L1RCTCited in: Complications - [518]
Cholankeril G, Taylor T, Kramer JR et al.. “Inequalities in Developing Cirrhosis Complications Over Time: A Cohort Study.” The American journal of gastroenterology (2025). PMID: 39907257 ↗
L3COHORTCited in: Complications - [519]
Bruno S, Zuin M, Crosignani A et al.. “Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.” The American journal of gastroenterology (2009). PMID: 19352340 ↗
L2COHORTCited in: Complications - [520]
Singal AG, Volk ML, Jensen D et al.. “A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2009). PMID: 19948249 ↗
L2SR_OBSCited in: Complications - [521]
Konerman MA, Yapali S, Lok AS. “Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring--predictors and predictive models of disease progression.” Alimentary pharmacology & therapeutics (2014). PMID: 25164152 ↗
L2SR_OBSCited in: Complications - [522]
Tan RZH, Lockart I, Abdel Shaheed C et al.. “Systematic review with meta-analysis: The effects of non-steroidal anti-inflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma.” Alimentary pharmacology & therapeutics (2021). PMID: 34247393 ↗
L2SR_OBSCited in: Complications, Prevention, Screening & Surveillance - [523]
Alazawi W, Cunningham M, Dearden J et al.. “Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection.” Alimentary pharmacology & therapeutics (2010). PMID: 20497143 ↗
L2SR_OBSCited in: Complications - [524]
Scott N, McBryde ES, Thompson A et al.. “Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.” Gut (2016). PMID: 27196586 ↗
L2OTHERCited in: Complications - [525]
Aytaman A, McFarlane SI. “Uncovering glucose abnormalities in people with hepatitis C infection: should oral glucose tolerance test become a standard of care?” The American journal of gastroenterology (2008). PMID: 18796093 ↗
L5OTHERCited in: Complications - [526]
Fontana RJ, Sanyal AJ, Ghany MG et al.. “Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C.” The American journal of gastroenterology (2010). PMID: 21139575 ↗
L2OTHERCited in: Complications - [527]
Huang CF, Lai HC, Chen CY et al.. “Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH).” The American journal of gastroenterology (2020). PMID: 32221162 ↗
L2OTHERCited in: Complications - [528]
Jacobson IM, Davis GL, El-Serag H et al.. “Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2010). PMID: 20713178 ↗
L5REVIEW_NARRATIVECited in: Complications - [529]
Mendizabal M, Piñero F, Ridruejo E et al.. “Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2020). PMID: 32113892 ↗
L2OTHERCited in: Complications - [530]
Turco L, Taru MG, Vitale G et al.. “Beta-Blockers Lower First Decompensation in Patients With Cirrhosis and Enduring Portal Hypertension After Etiological Treatment.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 39209198 ↗
L2OTHERCited in: Complications - [531]
Pawa S, Ehrinpreis M, Mutchnick M et al.. “Percutaneous liver biopsy is safe in chronic hepatitis C patients with end-stage renal disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2007). PMID: 17904916 ↗
L3OTHERCited in: Complications - [532]
Patel K, Remlinger KS, Walker TG et al.. “Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2014). PMID: 24815325 ↗
L3OTHERCited in: Complications - [533]
Yasunaga H. “Risk of authoritarianism: fibrinogen-transmitted hepatitis C in Japan.” Lancet (London, England) (2007). PMID: 18083405 ↗
L5REVIEW_NARRATIVECited in: Complications, Special Populations & Pregnancy - [534]
Williams R, Alexander G, Aspinall R et al.. “Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK.” Lancet (London, England) (2018). PMID: 30473364 ↗
L5OTHERCited in: Complications - [535]
Yucuma D, Rakover A, Warsop ZI et al.. “Natural history of chronic hepatitis B in untreated adults without cirrhosis according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review and meta-analysis.” The lancet. Gastroenterology & hepatology (2026). PMID: 41839199 ↗
L2SR_OBSCited in: Complications, Prognosis & Natural History - [536]
Moon AM, Green PK, Rockey DC et al.. “Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding.” Alimentary pharmacology & therapeutics (2019). PMID: 31773763 ↗
L2OTHERCited in: Complications - [537]
Fouad Y, Lazarus JV, Negro F et al.. “MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective.” Alimentary pharmacology & therapeutics (2021). PMID: 33751604 ↗
L5REVIEW_NARRATIVECited in: Complications - [538]
Zeuzem S, Alberti A, Rosenberg W et al.. “Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity.” Alimentary pharmacology & therapeutics (2006). PMID: 17014573 ↗
L5REVIEW_NARRATIVECited in: Complications - [539]
Bjelakovic M, Nikolova D, Bjelakovic G et al.. “Vitamin D supplementation for chronic liver diseases in adults.” The Cochrane database of systematic reviews (2021). PMID: 34431511 ↗
L1SR_OBSCited in: Complications - [540]
Jeong O, Chu C, Kim J et al.. “Disease burden of chronic hepatitis B and C patients in South Korea: a population-based 16-year cohort study.” BMC infectious diseases (2025). PMID: 41331447 ↗
L2COHORTCited in: Complications - [541]
Stockdale AJ, Kreuels B, Shawa IT et al.. “Causes, associated exposures, and outcomes of cirrhosis and hepatocellular carcinoma in Malawi: an observational cohort and case-control study.” The Lancet. Global health (2025). PMID: 41109263 ↗
L3CASE_CONTROLCited in: Complications - [542]
Chang SS, Chen YC, Hu HY et al.. “Optimal surveillance intervals for hepatocellular carcinoma screening in cirrhotic patients with hepatitis C infection: a Taiwanese national cohort study.” BMC cancer (2025). PMID: 40615970 ↗
L2COHORTCited in: Complications - [543]
Jacobson IM, Gordon SC, Kowdley KV et al.. “Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.” The New England journal of medicine (2013). PMID: 23607593 ↗
L1RCTCited in: Prognosis & Natural History - [544]
McHutchison JG, Manns MP, Muir AJ et al.. “Telaprevir for previously treated chronic HCV infection.” The New England journal of medicine (2010). PMID: 20375406 ↗
L1RCTCited in: Prognosis & Natural History - [545]
Bacon BR, Gordon SC, Lawitz E et al.. “Boceprevir for previously treated chronic HCV genotype 1 infection.” The New England journal of medicine (2011). PMID: 21449784 ↗
L1RCTCited in: Prognosis & Natural History - [546]
Feld JJ, Kowdley KV, Coakley E et al.. “Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.” The New England journal of medicine (2014). PMID: 24720703 ↗
L1RCTCited in: Prognosis & Natural History - [547]
Raasikh T, Jamali T, Flores A et al.. “Systematic review: hepatitis C viraemic allografts to hepatitis C-negative recipients in solid organ transplantation.” Alimentary pharmacology & therapeutics (2021). PMID: 34265111 ↗
L2SR_OBSCited in: Prognosis & Natural History, Special Populations & Pregnancy - [548]
Asselah T, Bièche I, Sabbagh A et al.. “Gene expression and hepatitis C virus infection.” Gut (2008). PMID: 19074178 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History - [549]
Manns MP, Wedemeyer H, Cornberg M. “Treating viral hepatitis C: efficacy, side effects, and complications.” Gut (2006). PMID: 16905701 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History, Special Populations & Pregnancy - [550]
Zoulim F, Liang TJ, Gerbes AL et al.. “Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.” Gut (2015). PMID: 26449729 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History, Special Populations & Pregnancy - [551]
Mutimer DJ, Lok A. “Management of HBV- and HCV-induced end stage liver disease.” Gut (2012). PMID: 22504920 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History - [552]
Kotlyar DS, Campbell MS, Reddy KR. “Recurrence of diseases following orthotopic liver transplantation.” The American journal of gastroenterology (2006). PMID: 16771963 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History - [553]
Younossi ZM, Wong G, Anstee QM et al.. “The Global Burden of Liver Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 37121527 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History - [554]
Maheshwari A, Ray S, Thuluvath PJ. “Acute hepatitis C.” Lancet (London, England) (2008). PMID: 18657711 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History, Special Populations & Pregnancy, Prevention, Screening & Surveillance - [555]
Mao D, Nan W, Lin M et al.. “The impact of maternal chronic viral hepatitis infections on pregnancy and neonatal outcomes in in vitro fertilization: a systematic review and meta-analysis.” Journal of ovarian research (2026). PMID: 41840684 ↗
L2SR_OBSCited in: Prognosis & Natural History - [556]
Im YR, Chen SE, Jagdish R et al.. “Efficacy of antiviral therapy in adults with chronic hepatitis B according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review and meta-analysis.” The lancet. Gastroenterology & hepatology (2026). PMID: 41839198 ↗
L1SR_OBSCited in: Prognosis & Natural History - [557]
Clark PJ, Valery PC, Strasser SI et al.. “Surviving Hepatitis C-Understanding Death and Survival Beyond Cure.” Alimentary pharmacology & therapeutics (2025). PMID: 40536167 ↗
L2OTHERCited in: Prognosis & Natural History - [558]
Yang XY, Zhuo Q, Wu TX et al.. “Bicyclol for chronic hepatitis C.” The Cochrane database of systematic reviews (2007). PMID: 17253534 ↗
L1SR_OBSCited in: Prognosis & Natural History, Special Populations & Pregnancy - [559]
Nikolova K, Gluud C, Grevstad B et al.. “Nitazoxanide for chronic hepatitis C.” The Cochrane database of systematic reviews (2014). PMID: 24706397 ↗
L1SR_OBSCited in: Prognosis & Natural History, Special Populations & Pregnancy - [560]
Rambaldi A, Jacobs BP, Gluud C. “Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases.” The Cochrane database of systematic reviews (2007). PMID: 17943794 ↗
L1SR_OBSCited in: Prognosis & Natural History, Special Populations & Pregnancy - [561]
Brok J, Gluud LL, Gluud C. “Ribavirin monotherapy for chronic hepatitis C.” The Cochrane database of systematic reviews (2009). PMID: 19821346 ↗
L1SR_OBSCited in: Prognosis & Natural History - [562]
Rehermann B, Thimme R. “Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.” Gastroenterology (2018). PMID: 30267712 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy - [563]
Balagopal A, Thomas DL, Thio CL. “IL28B and the control of hepatitis C virus infection.” Gastroenterology (2010). PMID: 20950615 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy - [564]
Winkler F, Hipp AV, Ramirez C et al.. “Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8+ T cells.” Gut (2023). PMID: 37541771 ↗
L4OTHERCited in: Special Populations & Pregnancy - [565]
Cheent K, Khakoo SI. “Natural killer cells and hepatitis C: action and reaction.” Gut (2010). PMID: 20876777 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy - [566]
Harrison SA. “Small molecule and novel treatments for chronic hepatitis C virus infection.” The American journal of gastroenterology (2007). PMID: 17617208 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy - [567]
Awan AA, Jadoul M, Martin P. “Hepatitis C in Chronic Kidney Disease: An Overview of the KDIGO Guideline.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 31376491 ↗
L1REVIEW_NARRATIVECited in: Special Populations & Pregnancy - [568]
Martinello M, Solomon SS, Terrault NA et al.. “Hepatitis C.” Lancet (London, England) (2023). PMID: 37741678 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy, Prevention, Screening & Surveillance - [569]
Webster DP, Klenerman P, Dusheiko GM. “Hepatitis C.” Lancet (London, England) (2015). PMID: 25687730 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy - [570]
Pearlman BL, Hinds AE. “Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.” Alimentary pharmacology & therapeutics (2018). PMID: 30288771 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy - [571]
Gurusamy KS, Tsochatzis E, Xirouchakis E et al.. “Antiviral therapy for recurrent liver graft infection with hepatitis C virus.” The Cochrane database of systematic reviews (2010). PMID: 20091608 ↗
L1SR_OBSCited in: Special Populations & Pregnancy - [572]
Ananchuensook P, Treeprasertsuk S, Komolmit P et al.. “Liver stiffness by non-invasive tests predicts hepatocellular carcinoma and liver-related complications following viral eradication with direct-acting antivirals in chronic hepatitis C: a retrospective cohort study.” BMC gastroenterology (2026). PMID: 42135704 ↗
L2COHORTCited in: Special Populations & Pregnancy - [573]
Federico P, Canciello MA, Granata B et al.. “Dual Immune Checkpoint Blockade in Synchronous Hepatocellular and Renal Cell Carcinoma: A Real-World Case Report of Durable Dual Response.” Oncology research (2026). PMID: 42358813 ↗
L4CASE_REPORTCited in: Special Populations & Pregnancy - [574]
Ghandour F, Zein-Sabatto B, Lobo J et al.. “Exploring fibronodular hepatocellular carcinoma: a case series investigating histopathologic and clinical characteristics and its potential association with cirrhosis.” American journal of clinical pathology (2026). PMID: 42308143 ↗
L4CASE_REPORTCited in: Special Populations & Pregnancy - [575]
López C, Gispert MÀ, Picart E et al.. “Viral hepatitis detection through emergency hospital departments in a Spanish region with high immigration: implications for elimination strategies.” Infectious diseases of poverty (2026). PMID: 42410473 ↗
L2OTHERCited in: Special Populations & Pregnancy - [576]
Klade CS, Wedemeyer H, Berg T et al.. “Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.” Gastroenterology (2008). PMID: 18471515 ↗
L1RCTCited in: Prevention, Screening & Surveillance - [577]
Dahari H, Feinstone SM, Major ME. “Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.” Gastroenterology (2010). PMID: 20621699 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance - [578]
Shah HA, Abu-Amara M. “Education provides significant benefits to patients with hepatitis B virus or hepatitis C virus infection: a systematic review.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 23639601 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance - [579]
Cortesi PA, Barca R, Giudicatti G et al.. “Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.” Alimentary pharmacology & therapeutics (2019). PMID: 30843268 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance - [580]
Bailey JR, Barnes E, Cox AL. “Approaches, Progress, and Challenges to Hepatitis C Vaccine Development.” Gastroenterology (2018). PMID: 30268785 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance - [581]
Fauvelle C, Felmlee DJ, Crouchet E et al.. “Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies.” Gastroenterology (2015). PMID: 26404951 ↗
L5OTHERCited in: Prevention, Screening & Surveillance - [582]
Levander S, Holmström F, Frelin L et al.. “Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model.” Gut (2017). PMID: 28646094 ↗
L5OTHERCited in: Prevention, Screening & Surveillance - [583]
Roulot D, Costes JL, Buyck JF et al.. “Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years.” Gut (2010). PMID: 21068129 ↗
L4OTHERCited in: Prevention, Screening & Surveillance - [584]
Kanwal F, Hoang T, Kramer J et al.. “The performance of process measures in hepatitis C.” The American journal of gastroenterology (2012). PMID: 22777337 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [585]
Hu TH, Luh DL, Tsao YY et al.. “Using the Diabetes Care System for a County-Wide Hepatitis C Elimination: An Integrated Community-Based Shared Care Model in Taiwan.” The American journal of gastroenterology (2023). PMID: 38084857 ↗
L4OTHERCited in: Prevention, Screening & Surveillance - [586]
Bui H, Kumar NG, Singal AG et al.. “Implementation of a Hepatocellular Carcinoma Surveillance Program in a Community-Based Integrated Health System in Patients With Hepatitis C Cirrhosis.” The American journal of gastroenterology (2024). PMID: 38334275 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [587]
Mallette C, Flynn MA, Promrat K. “Outcome of screening for hepatitis C virus infection based on risk factors.” The American journal of gastroenterology (2007). PMID: 17894850 ↗
L4OTHERCited in: Prevention, Screening & Surveillance - [588]
Stramer SL, Wend U, Candotti D et al.. “Nucleic acid testing to detect HBV infection in blood donors.” The New England journal of medicine (2011). PMID: 21247314 ↗
L4OTHERCited in: Prevention, Screening & Surveillance - [589]
Llaneras J, Riveiro-Barciela M, Rando-Segura A et al.. “Etiologies and Features of Acute Viral Hepatitis in Spain.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2020). PMID: 32663522 ↗
L4OTHERCited in: Prevention, Screening & Surveillance - [590]
Abdulla R, Boxtha C, Courtney EP et al.. “Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening (MATCHES): Study protocol for a hybrid 1 stepped-wedge multibehavioral randomized trial.” Contemporary clinical trials (2026). PMID: 41692274 ↗
L5TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance - [591]
Lamadrid A, Leiva-Escobar I, Soza A et al.. “Impact of the COVID-19 pandemic on hepatitis C care across the cascade of care: a scoping review.” BMC infectious diseases (2026). PMID: 42288770 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance - [592]
Santo T, Hickman M, Altice FL et al.. “Global coverage of interventions for reduction of injecting drug use-related harm, HIV, viral hepatitis and tuberculosis in prisons and other carceral settings: A systematic review.” The International journal on drug policy (2026). PMID: 41651702 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance - [593]
Gisbert JP, Chaparro M, Esteve M. “Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease.” Alimentary pharmacology & therapeutics (2011). PMID: 21416659 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance - [594]
Ramos-Rincon JM, Pinargote-Celorio H, de Mendoza C et al.. “Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in Spain.” Alimentary pharmacology & therapeutics (2022). PMID: 36320189 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [595]
Liu CH, Peng CY, Kao WY et al.. “Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment.” Alimentary pharmacology & therapeutics (2021). PMID: 34773272 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [596]
Lee MK, Alfego D, Walworth C et al.. “Trends in Reflexive Hepatitis C Virus Testing in a National US Laboratory: A Retrospective Study From 2018 to 2024.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41964422 ↗
L4COHORTCited in: Prevention, Screening & Surveillance - [597]
Al-Shuaili HH, Al-Busafi SA, Al Busafi SS et al.. “Impact of Hepatitis B Exposure and/or HIV Co-Infection on Clinical Outcomes in Chronic Hepatitis C Patients in Oman: An Ambidirectional Cohort Study.” Journal of medical virology (2026). PMID: 41949324 ↗
L2COHORTCited in: Prevention, Screening & Surveillance